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ABSTRACT
Elevated levels of lipoprotein(a) (Lp(a)) are an independent, causal risk factor for
coronary heart disease. Lp(a) is structurally similar to low-density lipoprotein (LDL), but
is distinguished by the covalent addition of apolipoprotein(a) (apo(a)), which is a
polymorphic glycoprotein that shares homology with plasminogen. Genomewide
association studies (GWAS) identified that mutations in the vicinity of the SORT1 gene are
associated with a ~5.8 mg/dL decrease in LDL cholesterol, 18% decrease in coronary artery
disease risk, and 40% decrease myocardial infarction risk. Sortilin, the protein product of
SORT1, was found to directly associate with apoB-100, and regulate apoB-100/VLDL
secretion and LDL catabolism. The work in this thesis evaluates if sortilin plays a similar
role in regulating Lp(a)/apo(a) metabolism. Pulse-chase analysis demonstrated that sortilin
overexpression increased the accumulation of intracellular and secreted apo(a); the
opposite effect was observed with reduced sortilin expression. Critical roles in mediating
the ability of sortilin to increase apo(a) secretion were identified for the weak lysine
bindings sites (LBS) in kringle IV type 7 and type 8, but not the strong LBS in kringle IV
type 10, of apo(a). Sortilin overexpression also increased Lp(a) internalization, with data
suggesting that this pathway occurs independently of the LDL receptor. Treatment with a
lysine analog abolished the ability of sortilin to increase Lp(a) internalization. The effects
of sortilin overexpression on both apo(a) secretion and Lp(a) catabolism were dependent
upon the ability of sortilin to act as a trafficking receptor. Naturally occurring
polymorphisms of sortilin were found to be expressed in individuals with elevated levels
of Lp(a). Expression of these sortilin mutants resulted in altered apo(a) secretion and Lp(a)
internalization compared to wild-type sortilin. Taken together, our data suggest that sortilin
is involved in the regulation of Lp(a)/apo(a) metabolism.
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CHAPTER 1: GENERAL INTRODUCTION

1.1 Cardiovascular Disease and Atherosclerosis
Cardiovascular disease (CVD) is a broad classification for a variety of disease states
that affect the heart and associated blood vessels. It is recognized as the leading cause of
mortality in the world (1). CVD can be subdivided into numerous categories, with the most
common category known as coronary artery disease (CAD) (2). CAD is regulated by a
plethora of complex factors such as genetic heritance, environmental elements, and lifestyle
(3). CAD is a progressive disease, with atherosclerosis acting as the underlying, causal
mechanism. Atherosclerosis is an inflammatory disease that is defined by the accumulation
of lipids and other elements in the walls of the large arteries in the cardiovascular system
(Fig. 1.1) (4, 5). This accumulation leads to the formation of atherosclerotic lesions. High
density lipoprotein (HDL) does not accumulate in lesions, but rather acts as a scavenger
that prevents lipid oxidation and removes excess cholesterol from circulation (4).
In normal physiology, endothelial cells (ECs) lining the lumenal side of the artery
are bound together through tight junctions that function as a permeability barrier between
the arterial lumen and the extravascular tissue (4, 5). However, factors such as infection,
oxidation, and sheer stress can promote inflammation and induce EC injury. As a result,
the actin and tubulin cytoskeletons of ECs are reorganized, thus leading to an increase in
the permeability of this layer (6, 7). This process is called EC dysfunction, and it is
associated with the beginning stages of atherosclerotic development. Lipids and fibrous
materials diffuse passively from the blood into the intima through EC junctions, where they
are retained in the vessel wall through interactions with the extracellular matrix (ECM).
1

Lipids undergo various modifications once in the sub-endothelial space, such as oxidation
or lipolysis, which triggers an inflammatory response by ECs. Proinflammatory cytokines,
such as interleukins (ILs) and transforming growth factors (TGFs), are released by ECs,
and monocytes are recruited to the vessel wall by adhesion molecules, such as the
intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1
(VCAM-1), on the vascular surface (7). Monocytes are a type of white blood cell classified
as leukocytes. They subsequently differentiate into macrophages and form foam cells in the
arterial intima by ingesting modified lipids through various methods which include:
phagocytosis, micropinocytosis, and receptor-mediated endocytosis (4). Foam cell
accumulation leads to the formation of a lipid-rich core, which can become necrotic over
time as foam cells undergo apoptosis. Furthermore, necrotic foam cells release proinflammatory elements that amplify plaque inflammation and further promote the
recruitment of additional monocytes. Smooth muscle cells (SMCs) undergo migration and
proliferation from the tunica media into the intima as a response to cytokine and growth
factor release (4). This leads to the formation of a fibrous capsule that surrounds and
stabilizes the growing inflammatory plaque. However, the integrity of this cap becomes
compromised overtime through proteasomal degradation of ECM proteins by proteinases
such as matrix metalloproteinases (MMPs) (8). A weakened fibrous cap, growing necrotic
core, and the elevation of pro-inflammatory elements increases the risk of a ruptured
atheroma. Acute thrombosis and vascular occlusion are the immediate result of a ruptured
plaque, which can lead to ischemia, myocardial infarction (MI), and stroke (4). Individuals
that possess elevated levels of plasma lipoproteins, such as low density lipoprotein (LDL)
and lipoprotein(a) (Lp(a)), are associated with increased risk of developing CAD through
their ability to contribute to the development and progression of atherosclerotic lesions.
2

Figure 1.1: Progression of atherosclerosis. The initiation and progression of
atherosclerosis is a complex process that incorporates several stages. In normal physiology,
endothelial cells (ECs) act as a permeability layer on the lumenal side of the artery. EC
dysfunction brought about by EC injury leads to a reorganization of the cytoskeletons of
ECs, thus increasing the permeability of the EC layer. As a result, a persistent influx of
lipids and fibrous materials occurs through passive diffusion of EC junctions. These
materials are retained in the arterial wall, and undergo modification. This triggers an
activation response by ECs, which recruits monocytes to the arterial wall. Activated
monocytes differentiate into macrophages and engulf the modified materials, forming foam
cells. Foam cell apoptosis over time leads to the formation of a necrotic core. Cytokine
release by ECs stimulates the proliferation and migration of smooth muscle cells (SMCs),
leading to the formation of a fibrous cap that surrounds the growing atheroma. Proteosomal
degradation threatens the integrity of the cap over time, potentially leading to a rupture.
Plaque rupture is immediately followed by acute thrombosis and vascular occlusion.
Modified from reference 5.
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1.2 Lipoprotein(a) and Apolipoprotein(a)
1.2.1 Structure of Lp(a) and Apo(a)
Lipoprotein(a) (Lp(a)), first discovered in 1963 by Kåre Berg, is a unique
lipoprotein that is found only in humans, Old World primates, and hedgehogs (9-11). Lp(a)
is an atherogenic lipoprotein that is structurally similar to low-density lipoprotein (LDL) in
that it possesses a comparable lipid core associated with an apolipoprotein B-100 (apoB100) moiety (12). However, it is distinguished from LDL by the presence of the
polymorphic glycoprotein apolipoprotein(a) (apo(a)), which is covalently bound to apoB100 through a single disulfide linkage (Fig. 1.2) (13). Apo(a) is encoded by the LPA gene
located on chromosome 6q26-27 (14).
Structurally, apo(a) is composed of multiple triple-looped structures classified as
kringle domains; each kringle is stabilized by three conserved intramolecular disulfide
bonds (15). These domains are linked by short segments of serine/threonine- and prolinerich sequences called linker regions (16). Kringle domains are characteristic of many
proteins that are involved in the coagulation and fibrinolytic cascades, and generally play
a role in facilitating ligand binding (17). Analysis of the apo(a) cDNA sequence in 1987
revealed extensive homology between human apo(a) and the zymogen plasminogen, which
is the precursor form of plasmin (18). Plasmin is an important enzyme involved in the
process of fibrinolysis, and is composed of five distinct kringle domains followed by a
serine protease domain (18). Apo(a), on the other hand, contains multiple plasminogen-like
kringle IV (KIV) domains, followed by a kringle V (KV) and protease-like domains that
are also highly similar to the corresponding domains in plasminogen (Fig. 1.3) (19). The
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multiple copies of the KIV-like sequences in apo(a) can be further categorized into ten
subtypes (KIV1-10) based on amino acid sequence (18). Apo(a) contains only one copy of
each KIV subtype with the exception of KIV2, which can be present in 3 to >40 identically
repeated copies (20). The mutable number of KIV2 domains gives rise to the size
heterogeneity observed within Lp(a), which can vary over 1000-fold between individuals
(15), and can be attributed to allelic variation in the LPA gene (21, 22). The protease-like
domain in apo(a) is catalytically inactive (16, 23), unlike the corresponding domain in
plasminogen which can be activated through catalytic cleavage of the peptide bond between
R560 and V561 (23).
Lysine-binding sites (LBS), present in both apo(a) and plasminogen, are binding
pockets present within some of the kringles that bind lysine. The pocket is flanked by
oppositely charged residues at either end of the site (24, 25). The anionic residues within
the binding pocket interact with the ammonium groups of lysine residues, while the cationic
residues in the binding pocket interact with the carboxyl groups of lysine residues during
ligand binding. The trough of the pocket is lined by hydrophobic, aromatic residues that
stabilize the aliphatic backbone of lysine (24). KIV5-8 of apo(a) are classified as weak LBS,
while KIV10 is classified as a strong LBS (Fig. 1.3). The amino acid sequence of the LBS
in apo(a) KIV10 is the most similar to that found in KIV of plasminogen, with the only
difference being an arginine to lysine conversion at position 35 in KIV10 (18).
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Figure 1.2: Structural representation of an Lp(a) particle. Lipoprotein(a) (Lp(a)) is
composed of a lipid particle that is indistinguishable from low-density lipoprotein (LDL)
with respect to lipid composition and the presence of an apolipoproteinB-100 (apoB-100)
moiety. Lp(a) differs from LDL, however, by the covalent attachment of apolipoprotein(a).
The lipid particle is composed of triglycerides (TG) and cholesterol esters (CE) that are
contained by a layer of phospholipids (PL) and free cholesterol (FC) that surround the
centralized core. Apo(a) contains multiple plasminogen kringle IV (KIV)-like domains, a
single kringle V (KV)-like domain, and an inactive protease domain (P). The KIV domains
are subdivided into 10 subtypes classified as KIV1-10, and KIV2 can be present in a variable
number of tandemly repeated copies encoded by the LPA gene which gives rise to Lp(a)
isoform size variation. Weak lysine binding sites present in apo(a) KIV7 and KIV8 are
required to mediate a non-covalent interaction between apo(a) and apoB-100 (identified as
Lys in the apoB structure) that precedes disulfide linkage between a free cysteine residue
in apo(a) KIV9 and the C-terminal region of apoB. Adapted from reference 12.
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Figure 1.3: Apo(a) is homologous to plasminogen. The zymogen plasminogen is a
precursor of plasmin. It is composed of an N-terminal tail sequence, followed by five
distinct kringle domains classified as kringles I-V (KI-KV) and a serine protease domain.
Apo(a) is composed of multiple kringle domains that share homology with KIV of
plasminogen, as well as a single copy of a comparable KV domain and a protease-like
domain that is catalytically inactive. The multiple copies of plasminogen KIV-like domains
in apo(a) vary from each other with respect to their amino acid sequences. Therefore, they
are classified into subtypes KIV1-10. All of the KIV-like subtypes of apo(a) are present in
one copy with the exception of KIV2, where copy number can vary from 3 to greater than
40 tandemly repeated, identical copies. KIV5-8 each possess weak lysine binding sites
(LBS) whereas KIV10 contains a strong LBS. This kringle domain shares the most
homology with KIV of plasminogen. KIV9 contains a free cysteine residue that is critical
in forming a disulfide bond with apoB-100. Adapted from reference 20.
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1.2.2 Lipoprotein(a) Levels in Plasma
Varying levels of Lp(a) are present in the human population, with plasma
concentrations ranging from undetectable to greater than 100 mg/dL (26). The LPA gene
LPAaccounts for up to 90% of the variation observed in plasma Lp(a) levels in the
population (21). As mentioned above, the variable number of repeated KIV2 domains gives
rise to the size heterogeneity observed in Lp(a) (21, 22). A general inverse relationship
exists between the number of KIV2 copies present in apo(a) and plasma levels of the
corresponding Lp(a) (15, 27). Smaller apo(a) isoforms have a reduced residence time in the
endoplasmic reticulum (ER) (28) and, as such, are less susceptible to quality control
mechanisms resulting in intracellular degradation of misfolded proteins (29). Various
single nucleotide polymorphisms (SNPs) have also been found to greatly influence Lp(a)
levels. Two in particular, rs10455872 and rs3798220, were found to account for 60% of
the variability in plasma Lp(a) concentrations (30). These mutations were also associated
with a significantly increased risk for coronary heart disease (CHD) (30).
1.2.3 Lipoprotein(a) Pathophysiology
Lp(a) has been identified through multiple genetic and epidemiological, genetic
association, studies to be an independent, causal risk factor for CHD (30-35). A large metaanalysis indicated a continuous association between CHD risk and elevated levels of
plasma Lp(a). This increase in risk is associated with a potential increase in the occurrence
of coronary events (32). Lp(a) is now considered the strongest genetic risk factor for CHD
(36). Mendelian randomization studies confirmed this association by demonstrating a
strong correlation between Lp(a) isoform size and risk for MI (34). Lp(a) has also been
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suggested to be a risk factor for stroke, peripheral vascular disease, and aortic valve stenosis
(30, 32, 37-39).
1.2.4 Potential Mechanisms of Action
While the specific physiological role of Lp(a) remains enigmatic, it is generally
accepted that this atherogenic lipoprotein greatly promotes the development of
atherosclerosis. Numerous studies have revealed a variety of potential mechanisms by
which Lp(a) can contribute to atherosclerosis and CVD (Fig. 1.4) (40). Since LDL is
prominently related to increased risk of CVD and coronary events, it was postulated that
the LDL-like component of Lp(a) plays an important proatherogenic role. Possession of an
LDL-like component alludes to a similar mechanistic contribution for Lp(a) to that of LDL
with respect to atherogenesis. This includes mediating pro-inflammatory effects, activating
ECs, recruiting monocytes to the site of lipid retention and acceleration of foam cell
formation. However, it is the presence of the unique apo(a) component that separates Lp(a)
from LDL as a risk factor (13). Indeed, apo(a) provides distinction between Lp(a) and other
atherogenic lipoproteins through its unique contributions to both the proatherogenic and
prothrombotic properties of Lp(a) (Fig. 1.5) (13, 14, 40).
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Figure 1.4: Postulated mechanisms of action for Lp(a). Lp(a) has been identified as the
strongest genetic risk factor for coronary heart disease (CHD). Meta-analysis as well as
numerous genetic studies have confirmed its role as an independent and causal risk factor
for CHD. A role for Lp(a) in risk of myocardial infarction (MI), ischemic stroke, peripheral
vascular disease, and aortic valve stenosis has also been determined. The proposed
proatherogenic mechanisms of Lp(a) are listed on the left, while the prothrombotic
mechanisms are listed on the right. PL, phospholipids; SMC, smooth muscle cells; EC,
endothelial cells; TFPI, tissue factor pathway inhibitor; PAI-1, plasminogen activator
inhibitor-1. Modified from reference 39.
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Figure 1.5: Apo(a)-driven mechanisms behind the proatherogenic and prothrombotic
properties of Lp(a). Multiple mechanisms of action have been proposed for the
prothrombotic and proatherogenic properties of Lp(a). Both the lipid particle, and apo(a)
component, contribute to Lp(a) pathophysiology. The various proposed proatherogenic and
prothrombotic properties of Lp(a) mediated by the apo(a) component are indicated here.
The corresponding apo(a) kringle domains associated with these mechanisms are also
indicated. DANCE, developmental arteries and neural crest epidermal growth factor
(EGF)-like; SMC, smooth muscle cell; EC, endothelial cell; IL-8, interleukin-8. Modified
from reference 13.
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One of the major contributors to Lp(a) pathophysiology is the association between
Lp(a) and inflammation. A key component in the pro-inflammatory capabilities of Lp(a)
particles is the presence of an oxidized phospholipid (OxPL) modification. As previously
mentioned, an elevated inflammatory response can lead to endothelial dysfunction, thus
increasing arterial wall permeability (4). Interestingly, research conducted in human
patients indicated preferential binding of pro-inflammatory OxPLs to Lp(a) in comparison
to LDL (41). Previous research has implicated a role for apo(a) KV in facilitating covalent
OxPL modification; however, the presence of OxPLs were observed in apo(a) variants that
did not possess a KV domain (42, 43). Recent in vitro work indicates that the strong LBS
in KIV10 plays a critical role in facilitating the addition of covalent OxPL to Lp(a) (44).
Mutagenesis of an aspartic acid residue within the LBS led to the abolishment of the lysine
binding capabilities of apo(a) KIV10, and a concomitant inhibition of OxPL addition. This
study also demonstrated that oxidation of apo(a) is associated with increased stimulation of
interleukin-8 (IL-8), which is an important cytokine involved in the recruitment of
inflammatory cells (44). These data demonstrate a novel mechanism through which the
apo(a) component can stimulate atherogenesis. Interestingly, the aforementioned study is
not the first to identify a role for Lp(a) in the stimulation and activation of various proinflammatory signalling cascades and cytokines. Previous in vivo and in vitro studies found
that Lp(a) can stimulate monocyte chemoattractant protein-1 (Mac-1), which is a key
chemokine involved in regulating the migration and infiltration of inflammatory cells such
as monocytes (45, 46). This leads to an interesting role for Lp(a) as a chemoattractant and
regulator of the inflammatory response within the vasculature. It is tempting to speculate
that the covalent OxPL on apo(a) may be central in mediating many of the proinflammatory
effects of apo(a)/Lp(a) that have been reported.
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Homology between apo(a) and plasminogen led to the hypothesis that Lp(a) may
also act as a prothrombotic factor in humans (18). Indeed, previous studies found that Lp(a)
was able to compete with plasminogen for binding to endothelial cells and monocytes; this
function was mediated by the apo(a) component (47, 48). Furthermore, the apo(a)
component has also been shown to inhibit the activation of plasminogen. Generally,
plasminogen is activated to plasmin through proteolytic cleavage induced by tissue
plasminogen activator (tPA) or urokinase-type plasminogen activator (uPA) (49). Plasmin
actively degrades fibrin, thus promoting the break-down of blood clots. Lp(a) was found to
compete with both plasminogen and tPA in binding to fibrin (50, 51), thus leading to a
decrease in both plasminogen activation and clot lysis. Furthermore, apo(a) KIV5-9, as well
as KV, were found to substantially inhibit the conversion of Glu-plasminogen to Lysplasminogen, which is a reaction that enhances plasminogen activation (52). This was
supported by a subsequent study that demonstrated inhibition of tPA mediated plasminogen
activation in vitro in numerous cell types (53). Finally, Lp(a) was found to elevate the
expression of plasminogen activator inhibitor-1 (PAI-1)(54). Therefore, Lp(a) may
potentially contribute to the atherosclerosis through prothrombotic mechanisms, as well as
through proatherogenic mechanisms.
1.2.5 Lp(a) Assembly
It is generally accepted that rate of assembly, and not the rate of catabolism, is the
primary determinant of plasma Lp(a) levels (27, 55, 56). Both apo(a) and apoB are
produced by hepatocytes in the liver (57, 58). Previous research has shown that, in the
physiological setting, negligible amounts of free apo(a) exist as the majority of apo(a)
associates with apoB following secretion (59). The formation of an Lp(a) particle occurs as
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a two-step process, where an initial non-covalent association is subsequently followed by
the formation of a disulfide bond linkage between apo(a) and apoB (60). It was initially
determined that disruption of the weak LBS in apo(a) by lysine analogues led to a
significant decrease in Lp(a) particle assembly (61). It was therefore postulated that the
weak LBS in KIV5-8 were involved in mediating the initial non-covalent interaction
between apo(a) and apoB (60). However, a study utilizing 17K apo(a), which is a
physiologically relevant isoform of apo(a) that possesses eight KIV2 repeats, demonstrated
that only the weak LBS in apo(a) KIV7 and KIV8 are important for non-covalent assembly;
these sites are required to mediate the initial non-covalent interaction with Lys680 and Lys690
in the amino-terminus of apoB-100 (62). Interestingly, it is also possible that ligand binding
in the strong LBS of apo(a) KIV10 can induce a conformation change in apo(a), and
accelerate covalent linkage with apoB (63). Since non-covalent assembly precedes the
formation of the disulfide bond linkage, it has been postulated that this interaction may
properly orient apo(a) and apoB to facilitate efficient disulfide bond formation (64). The
covalent linkage has been reported to occur between Cys4057 of apo(a) in KIV9 and Cys4326
in the C-terminal region of apoB-100 (65, 66). However, other studies have suggested that
disulfide linkage occurs with Cys3734 in the C-terminal region of apoB (67-70).
Despite this generally accepted mechanism, the exact site of particle formation
remains controversial. The majority of evidence suggests that the formation of the covalent
bond between apo(a) and apoB-100 occurs extracellularly, or on the cell surface, of
hepatocytes (71-76). Specifically, in vitro analysis in hepatocellular carcinoma (HepG2)
cells utilizing r-apo(a) demonstrated that covalent Lp(a) particles were present in the
medium, but absent in cellular lysates (73). This observation was further supported in vitro
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through the discovery that extracellular disulfide bond formation occurs between apo(a)
and apoB; this was proposed to be facilitated by Lp(a) oxidases secreted from HepG2 cells
(74). Enzyme-linked immunosorbent assay (ELISA) analysis conducted with human liver
tissue also established the absence of covalent Lp(a) particles in human liver homogenates
(75). Conversely, multiple studies support an intracellular site of Lp(a) assembly (77-79);
this data is supported by kinetic data in humans (80, 81). However, intracellular assembly
of Lp(a) was only been observed in a previous study by Bonen et al.., where a very small,
non-physiologically relevant isoform of apo(a) was used (79). While the kinetic data
support the notion of intracellular assembly, it cannot exclude the possibility that the
disulfide linkage between newly synthesized apo(a) and apoB-100 containing lipoproteins
occurs extracellularly. It is possible that the non-covalent association between apo(a) and
apoB-100 occurs intracellularly, with the subsequent covalent complex forming upon
secretion of apo(a) and apoB from hepatocytes.
Interestingly, an association between the biosynthetic pathways of apo(a) and
triglycerides has also been proposed, thus creating an intriguing link between the synthesis
of apo(a) and apoB-100 containing lipids (77). Indeed, in vitro studies conducted in
hepatoma cells demonstrated that a hypo glycosylated, immature, non-secretable form of
apo(a) could associate with apoB-100, thus supporting the hypothesis that non-covalent
assembly can occur intracellularly (82). Furthermore, a clinical study involving targeted
therapy against the microsomal triglyceride transfer protein (MTP) further supports the
concept that the secretion of apo(a) and apoB are linked. MTP is directly involved in the
synthesis of apoB-containing lipoproteins (83). Inhibition of this protein leads to a
significant reduction in apoB and a concomitant reduction in Lp(a) (84). Individuals with
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abetalipoproteinemia, which involves a loss-of-function MTP, also possessed lowered
levels of both apoB and Lp(a) (85). Finally, a kinetic study conducted in humans indicated
that the production rate of apoB associated with Lp(a) particles was similar to apo(a), and
different from apoB found in LDL (80). In support of this finding, Su et al. demonstrated
that Lp(a) was composed of newly synthesized apo(a) and apoB moieties, and that the
production rates of were similar for both components (81). Taken together, the previous
studies suggest that the initial, non-covalent interaction between apo(a) and apoB may
occur intracellularly, with the covalent assembly subsequently occurring on the cell
membrane or in the extracellular milieu upon secretion of the complex.
Since the predominant mechanism dictating individual variation in Lp(a) levels is
due to genetic differences within the LPA gene, it is important to understand the role of
apo(a) biosynthesis in regulating Lp(a) production. Previous studies have established that
the production of apo(a) is dependent upon the correct folding and processing of the protein
in the ER, where small apo(a) isoforms are secreted more efficiently than large isoforms
(28, 29, 86). While a variety of chaperones have been identified as playing a role in apo(a)
maturation intracellularly, finding new players that are required for apo(a) maturation will
help to further understand a potential regulatory mechanism involved in dictating plasma
Lp(a) levels (76, 87, 88).
1.2.6 Production, Maturation, and Secretion of Apo(a)
The structure of apo(a), as well as the high levels of post-translational modifications
required for its maturation, results in a complex biosynthetic pathway for this protein. As
previously mentioned, apo(a) is synthesized in the liver, and it has been proposed that the
rate of apo(a) synthesis is a major determinant of plasma Lp(a) concentrations (58, 88). The
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production rate of the protein is dependent upon multiple factors. A previous study
provided evidence that mRNA stability, as well as the rate of LPA gene transcription can
alter the secretion rate of apo(a) (88). The isoform size of apo(a) also plays a role, with an
inverse correlation observed between size and efficiency of synthesis (27, 28, 89). Previous
studies have demonstrated that larger apo(a) isoforms are subject to increased ER retention
times (27). This corresponds to increased time required for protein folding and modification
of larger apo(a) isoforms (28). Pulse-chase studies conducted by White et al.. indicated that
two forms of apo(a) were detectable in cell lysates, a hypo-glycosylated, immature form
and a fully glycosylated, mature, secretable form. Furthermore, this study demonstrated
that detection of mature apo(a) did not occur until approximately 30-60 minutes of chase
time in baboon hepatocytes (28). This suggests that maturation of apo(a) is a rate-limiting
step in apo(a) secretion, and that apo(a) is subject to complex folding kinetics (76). The
general consensus is that small isoforms of apo(a) are more efficiently folded and secreted
compared to large isoforms, the latter of which exhibits increased folding demands
resulting in longer ER retention times, and thus, increased targeting to the endoplasmicreticulum-associated degradation (ERAD) pathway (29, 86, 89). Interestingly, White and
coworkers also found that 50% of apo(a) immunoprecipitated from the lysates of baboon
hepatocytes was in the mature form (76), therefore suggesting that the intracellular
transport of apo(a) through the biosynthetic pathway is another rate-limiting step in apo(a)
secretion.
The proper completion of post-translational modifications is also required for the
secretion of mature apo(a). Glycosylation is a post-translational modification that results in
the addition of complex carbohydrate moieties to nascent proteins (90). Glycosylation plays
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a role in the biosynthetic pathway of apo(a). Plasma-derived apo(a) possesses both N- and
O-linked glycans, with the carbohydrate modifications accounting for approximately 28%
of apo(a) by mass (91). Each individual apo(a) KIV domain contains at least one possible
site for N-linked carbohydrate addition, while the linker regions contain multiple sites for
O-linked glycosylation as the amino acid sequences in these regions are rich in
serine/threonine residues (91, 92). Studies involving the inhibition of N-linked
glycosylation in apo(a) resulted in aggregation of the protein in the ER, leading to increased
levels of degradation (76, 93); this arises in part due to altered interactions between apo(a)
and various chaperone proteins, thus increasing degradation rates of apo(a) (87-89).
Apo(a) has been found to directly interact with calnexin, BiP (immunoglobulin
heavy chain binding protein), and protein disulfide isomerase (PDI). In general, these
chaperone proteins act as regulators of quality control in the ER during protein synthesis,
and can either retain misfolded proteins in the ER to facilitate corrective measures or target
them to the ERAD pathway (94, 95). Furthermore, each of these chaperones have been
proposed to regulate the intracellular, presecretory degradation rates of apo(a) (87, 89).
Calnexin was found to transiently associate with apo(a) and facilitate movement of the
immature, hypo-glycosylated form from the ER to the pre-medial Golgi compartment (8789). Calnexin is an ER chaperone proteins that recognizes mono-glucosylated, N-linked
carbohydrates on proteins, and it is an important component of the ERAD pathway (94).
Generally, glucose molecules are sequentially cleaved from N-linked glycan precursors by
glucosidases I and II in a process known as glucose trimming. Once removed, a protein can
be shuttled to the Golgi for further modification and secretion (96). However, if a protein
is improperly folded, a glucose residue is added back to the N-linked glycan motifs by
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UDP-glucose:glycoprotein glucosyltransferase (UGGT) to re-establish an interaction with
calnexin (97). Folded proteins that possess properly trimmed glycans cannot be recognized
by UGGT, leading to secretion of the protein from the ER (97).
Studies conducted in baboon hepatocytes demonstrated that the presence of Nlinked mono-glucosylated carbohydrates, as well as glucose trimming, were required for
efficient secretion of apo(a) (89). Interaction with calnexin led to apo(a) retention in the
ER, and prevented the improperly processed immature form of apo(a) from being exported
to the Golgi or targeted to the ERAD pathway (89). Co-immunoprecipitation (co-IP) studies
also demonstrated an interaction between apo(a) and the ER chaperones PDI and BiP (89).
BiP targets improperly folded proteins to the ERAD pathway and retains misfolded proteins
in the ER, while PDI has a well characterized role in catalysing the formation of disulfide
bonds (89, 98). Upon completion of correct domain folding, apo(a) is transported out of the
ER to the pre-medial Golgi compartment, where it undergoes further modification through
the addition of O-linked glycans (91). Overall, the biosynthetic pathway of apo(a) is
complex, and secretion of the mature protein is dependent upon multiple factors. However,
further research is required to fully understand the biosynthetic pathway of apo(a),
particularly with respect to the mechanistic details of apo(a) transport between intracellular
compartments.
1.2.7 Lp(a) Catabolism
The catabolic pathways for Lp(a) removal from the circulation remains enigmatic
despite numerous studies focused on elucidating mechanisms for particle clearance
(reviewed in ref. 100). It is generally accepted that the liver is the predominant site of Lp(a)
clearance, with a small role postulated for the kidneys in catabolism (99). Specifically,
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individuals with impaired kidney function have been found to have higher levels of plasma
Lp(a), which is correlated in part to a decrease in Lp(a) catabolism (100). However, in
healthy individuals, the role of the kidneys in Lp(a) clearance was found to be minimal
(101).
Numerous receptors have been implicated in Lp(a) catabolism. Based on the
structural composition of Lp(a), it was initially postulated that the major catabolic pathway
would be driven by the LDL component of Lp(a). As such, the LDL receptor (LDLR) was
hypothesized to be the primary receptor in Lp(a) catabolism. However, evidence
demonstrates a controversial role for the LDLR, as several studies support a role in Lp(a)
catabolism (102-113), whereas multiple studies suggest that it does not mediate Lp(a)
clearance (101, 114-117). The majority of these studies utilize in vitro methods, with the
remainder using in vivo analysis in both mice and humans to analyze a potential role for
the LDLR in Lp(a) catabolism. Furthermore, some studies focus on Lp(a) clearance in the
context of Familial Hypercholesterolemia (FH) or proprotein convertase subtilisin kexin
type 9 (PCSK9) activity. FH is an autosomal autosomal dominant disorder that is
characterized by elevated levels of LDL cholesterol (LDL-C). It is caused by mutations in
multiple genes that are associated with the production and catabolism of apoB-100
containing particles (118). PCSK9, on the other hand, is a serine protease zymogen that
mediates the degradation of the LDLR (119).
In vitro analysis conducted in HepG2 and fibroblast cells demonstrates that Lp(a)
can bind to and be internalized by the LDLR (102-105, 108). Furthermore, Lp(a)
catabolism was found to be reduced in FH human fibroblasts (105, 109). This was
supported by research conducted by our group, which demonstrated that PCSK9 treatment
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led to a decrease in the amount of Lp(a) internalized in both HepG2 cells and human
fibroblasts (112). Furthermore, Lp(a) internalization was reduced in HepG2 cells incubated
with a monoclonal antibody that blocked LDLR activity, and in FH human fibroblasts
(112). With respect to in vivo analysis, experiments conducted by Hofmann et al..
demonstrated that overexpression of the LDLR in a mouse model led to a significant
increase in the clearance rate of injected Lp(a) when compared to control mice (110).
Studies conducted in human patients revealed that Lp(a) plasma levels were significantly
higher in individuals with FH as opposed to unaffected individuals (106, 107, 111).
Furthermore, clinical trials studying evolocumab, a monoclonal antibody directed at
PCSK9, showed reduced Lp(a) levels in treated patients compared to control patients.
Taken together, these data provide strong evidence for an association between the LDLR
and Lp(a) catabolism.
Conversely, in vivo studies conducted in a mouse model demonstrated that the
catabolic rate of Lp(a) in LDLR-/- mice was similar to control mice (101). This was
supported by a study conducted by Reblin et al.., which demonstrated no change in the
uptake of radiolabelled Lp(a) in mice with defective LDLR when compared to control mice
(117). Furthermore, in contrast to the aforementioned studies involving FH individuals, no
significant difference in Lp(a) levels were observed between FH patients when compared
to unaffected individuals (114-116). Studies conducted on statin therapy provide
contradictory evidence for the role of the LDLR in Lp(a) clearance as well. Specifically,
treatment with various statins was found to successfully lower LDL levels while
concomitantly increasing, or having no effect on, Lp(a) levels (120). Overall, it is clear that
further research is required to firmly establish if the LDLR plays a role in Lp(a) clearance.
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Other receptors have been implicated in facilitating the internalization and
degradation of Lp(a). These receptors include: the scavenger receptor class B type I (SRB1), various plasminogen receptors, low-density lipoprotein-related protein (LRP-1), the
very low density lipoprotein receptor (VLDLR), and megalin/glycoprotein 330 (gp330)
(102, 108, 121-123). In vitro studies suggest that the apo(a) component is required to
mediate an interaction with SR-B1, VLDL, LRP-1, and the plasminogen receptors, whereas
the apoB component predominantly mediated an interaction with gp330. However, further
research is required to characterize the exact mechanism of action for these receptors in
Lp(a) catabolism. Overall, these data suggests that the catabolism of Lp(a) is complex, with
the major pathway governing Lp(a) catabolism remaining enigmatic. Future work is
required to further characterize receptors implicated in Lp(a) clearance, and to determine
novel receptors that may play a role in mediating Lp(a) catabolism.
1.3 Sortilin: Defining Structure, Function, and Multi-Ligand Nature
Sortilin, also identified as neurotensin receptor-3, is a multi-ligand sorting receptor
belonging to the vacuolar protein sorting 10 (VPS10) domain family (124, 125). Other
members of this family include VPS10p, SorCS 1-3, and the LDLR-like SorLA (Fig. 1.6)
(126, 127). Sortilin is classified as a type-1 transmembrane receptor and is characterized
by the extracellular VPS10 domain. This domain, which constitutes the entire ectodomain
of the protein, is composed of a 700 amino acid section containing a VPS10p-cysteine rich
domain that binds ligands in the shape of a ten-bladed ß-propeller (128). The remaining
structure consists of a single transmembrane segment, and a short, cytoplasmic tail that
possesses multiple sorting/internalization motifs (129).
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Figure 1.6: Structural representation of VPS10 domain family. The mammalian VPS10
domain family is represented by five proteins. They are all type-1 transmembrane proteins
that are involved in cellular signaling and trafficking. Each receptor is initially synthesized
as a propeptide. Removal of the prosegment, and activation of the receptors, is achieved in
the Golgi through furin cleavage. Each receptor possess a unique VPS10 binding domain
that is homologous to the VPS10P sorting receptor found in yeast. The VPS10 domain
comprises the entire extracellular portion of sortilin, whereas the SORCS1-3 receptors
contain an additional leucine-rich domain, and SORLA contains a variation of extracellular
domains. The remaining structure is composed of a single transmembrane segment and
short, cytoplasmic domains that possess multiple canonical sorting motifs. Location of the
various sorting motifs of sortilin are indicated by asterisks, with red symbolizing the FXXX-Y motif, yellow symbolizing the tyrosine motif, and black symbolizing the acidic
dileucine motif. These motifs are also present in SORLA. Alternative splicing of SORCS13 leads to variation in the sorting motifs found in these domains. Image modified from
reference 128.
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Sortilin is initially synthesized as a propeptide, which is subsequently cleaved in
the late trans-Golgi network (TGN) by the proprotein convertase furin (126, 130). This
propeptide plays a crucial role in the early processing of sortilin by preventing premature
ligand binding, and facilitating transport through the biosynthetic pathway. Upon cleavage,
sortilin becomes an active protein receptor (126, 130). Research has demonstrated that
sortilin is a multi-functional protein that interacts with a variety of ligands. Direct
interactions have been documented with: neurotensin (131), the pro-form of nerve growth
factor-ß (NGF) (132), the pro-form of brain-derived neurotrophic factor (BDNF) (133),
tyrosine receptor kinases (Trk receptors) (134), amyloid precursor protein (APP) (135),
progranulin (136),prosaposin and Gm2 activator protein (Gm2AP) (137), apolipoprotein E
(apoE) (138), lipoprotein lipase (LPL) (139), apolipoprotein A-V (140), apolipoproteinB100 (141, 142), proprotein convertase subtilisin/kexin type 9 (PCSK9) (143) and receptorassociated protein (RAP) (124). Interestingly, the 44-amino acid propeptide that is
generated by furin cleavage also exhibits high-affinity binding with the mature sortilin
receptor. In general, these interacting partners compete for binding with the mature receptor
(128, 130). This was specifically demonstrated between neurotensin, RAP, and the
propeptide (130). This restriction in binding is attributed to restricted space within the 10bladed ß-propeller domain (128).
Sortilin is highly expressed in neuronal tissues such as the brain, spinal cord,
skeletal muscle, and thyroid; however, lower expression is also observed in the heart, liver,
and kidneys (124, 129, 144, 145). With respect to the subcellular localization of sortilin,
previous research found that the majority of sortilin localizes within the Golgi and
endosomal compartments; however, sortilin is also able to localize at the cell surface (134,
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135, 143, 146). With respect to physiological function, sortilin has been shown to play a
role in a variety of biological processes that include: glucose metabolism (147, 148),
regulation of neuronal cell proliferation (132, 140, 149), Golgi-to-lysosome trafficking
(135, 139, 150, 151), and cell signaling and endosomal trafficking (134, 136, 140-143, 146,
152, 153). Overall, this research demonstrates that sortilin predominantly functions as an
intracellular trafficking receptor.
Following activation by furin cleavage, the mature sortilin receptor facilitates
sorting and trafficking through three main biology pathways. One pathway involves
localization of sortilin to the cell surface through secretory vesicles, where it acts as an
internalization receptor for a variety of ligands; sortilin internalizes through clathrinmediated endocytosis (136, 139, 140, 142, 146, 150). A second pathway involves the
transport of sortilin and its cargo from the cell surface, or the Golgi complex, to endosomes.
Cargo either dissociates from sortilin in endosomal compartments, and is directed towards
lysosomes, or is recycled with sortilin to the TGN (135, 137, 142, 146, 150, 154-158). The
third pathway involves secretory conduits, where sortilin facilitates the trafficking of
ligands from the Golgi to endosomes or secretory vesicles (129, 134, 141, 143, 152, 158,
159). In all cases, sortilin is recycled back to the TGN through retrograde transport
mediated by the retromer adaptor complex (151, 160, 161). The retromer is a pentameric
complex that was first identified in Saccharomyces cerevisiae, and previous research found
that it played a role in recycling the VPS10p receptor, which is the bacterial orthologue of
sortilin (162, 163). In mammals, the retromer is comprised of five subdomains that function
in mediating the retrieval of several different cargo proteins from the endosome to the TGN
(151).
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Mechanistically, the functionality of sortilin is generally regulated by the
intracellular domain of the protein, with the sorting and internalization motifs playing a
major role. . This domain is involved in mediating receptor-cargo binding, degredation, and
both the anterograde and retrograde transport of sortilin. The majority of the functionality
of sortilin is dependent on interactions between the trafficking motifs of sortilin and various
cargo adaptor complexes (Fig. 1.7) (146, 149, 151). In general, these trafficking motifs
have been shown to be involved in adaptor protein binding, endocytosis, basolateral
targeting and Golgi-endosome sorting (146). The intracellular domain of sortilin contains
three canonical motifs: an acidic dileucine motif (HDDSDEDLLE), a tyrosine motif
(YXXL or YSVL) and the consensus hexapeptide internalization motif (F-XXX-Y) (124).
These motifs are also found in the cytoplasmic domain of the mannose-6-phoshpate
receptor (MPR), which is an established sorting receptor in the TGN (164). Interestingly,
the intracellular domain of sortilin is highly homologous to that of the MPRs, which
suggests that these trafficking receptors may share similar trafficking pathways.
Furthermore, immunogold labelling studies demonstrated that the subcellular distributions
of both sortilin and MPRs were nearly identical in HepG2 cells, thus indicating that these
receptors also share similar transport kinetics (161). This was further supported by colocalization studies, which demonstrated that sortilin and MPRs displayed strong colocalization, thus providing further evidence that these proteins function through similar
pathways (124, 165). Previous research by Nielsen et al. supports these notions, as chimeric
constructs consisting of the lumenal domain of MPR and the cytoplasmic domain of sortilin
were able to rescue trafficking defects observed in cells lacking function MPRs (146).
Overall, these studies indicate that sortilin and MPRs may act as redundant pathways for
intracellular trafficking.
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Figure 1.7: Intracellular interactions between the cytoplasmic domain of sortilin and
various cargo adaptor proteins. Trafficking between the trans-Golgi network (TGN) and
endosomal compartments is regulated by the interaction of sortilin with activator protein 1
(AP-1), Golgi-localizing, Gamma-adaptin -containing, ARF-binding proteins (GGAs), and
the retromer complex. Sortilin interacts with clathrin through AP-1 and GGAs, which
allows sortilin and its Golgi cargo to be internalized in clathrin-coated-cargo vesicles.
Anterograde transport traffics these vesicles to endosomal compartments, where both the
cargo and AP-1/GGAs are released. The exposed cytoplasmic domain interacts with the
retromer complex, facilitating the retrograde transport of sortilin back to the TGN.
Modified from reference 152.
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Sortilin interacts with three types of adapter proteins (Fig. 1.7). One complex, the
retromer, was mentioned previously. The remaining adaptor complexes include the
activator protein 1 (AP-1) complex (166), and the Golgi-localizing, Gamma-adaptin earcontaining, ARF-binding proteins (GGA1, GGA2, and GGA3) (146, 167). Both AP-1 and
the GGAs interact with clathrin, and mediate the trafficking capabilities of MPRs by
facilitating the incorporation of the MPR-ligand complex into clathrin-coated cargo
vesicles; this complex is subsequently transported to endosomes (151).
A similar mechanism is proposed for both AP-1 and the GGAs with respect to the
intracellular trafficking of sortilin (Fig 1.7). Similar to MPRs, the interaction between
sortilin and AP-1 is mediated through the tyrosine motif. Previous research involving the
inhibition of AP-1 activity led to the increased accumulation of sortilin within the TGN
(168). Multiple studies demonstrated that an intact tyrosine motif was required to mediate
an interaction between sortilin and the retromer complex (161, 168). After sortilin binds to
its ligand, it is proposed that this receptor-ligand complex is incorporated into clathrincoated cargo vesicles and transported to the endosomes. While in the endosomes, AP-1 is
released, thus exposing the cytoplasmic domain of sortilin, allowing the tyrosine motif to
interact with the retromer complex. Mutation of either the tyrosine or leucine residue in the
YXXL inhibited the interaction of the cytoplasmic domain of sortilin with the retromer.
Consequentially, an accumulation of sortilin in the endosomal system, with a concomitant
depletion in the Golgi complex, was observed as sortilin was unable to recycle back to the
TGN (168). Therefore, the interaction between AP-1 and sortilin plays an important role in
facilitating both the anterograde and retrograde transport of the sortilin and sortilin-ligand
complexes. The dileucine motif is responsible for mediating an interaction between sortilin
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and the GGAs. Similar to the studies on AP-1, mutation of the GGAs inhibited sortilin from
participating in anterograde transport, as an increased accumulation of sortilin was
observed in the perinuclear region (137, 146). Taken overall, sortilin functions as an
intracellular trafficking receptor, and is functionally dependent upon interaction with
various adaptor proteins.
Modification events of sortilin have also been implicated in regulating the
functionality of the receptor (169). Previous studies found that MPRs possessed a casein
kinase II phosphorylation motif, identified as ESEER, that was present immediately
upstream of the dileucine sorting motif (170, 171). Phosphorylation of the serine residue
within this motif increased binding affinity between GGAs and the cytoplasmic domain of
MPRs, thus enhancing anterograde transport of the receptor-cargo complex (170, 171). The
VPS29 subunit of the retromer was found to dephosphorylate this serine residue upon
interaction of MPRs with the recycling complex, thus enhancing the interaction between
the cytoplasmic domain of MPRs and the retromer (172, 173). These finding collectively
indicated that phosphorylation of this motif plays a role in mediating the intracellular
targeting of MPRs. Similar to MPRs, sortilin also contains a casein kinase II
phosphorylation motif, identified as SGY. The similar subcellular distributions (161), as
well as trafficking pathways (151), of sortilin and MPRs suggest that such a
phosphorylation event may likewise regulate the intracellular targeting of sortilin.
Palmitoylation, which is a reversible post-translationional modification involving the
addition of a saturated palmitic acid on cysteine residues, was found to mediate levels of
sortilin degradation. Previous studies found that a cysteine residue within the cytoplasmic
domain of sortilin was palmitoylated, and that this modification was involved in controlling
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the bioavailability of sortilin (169, 174). Removal of this modification led to the
ubiquitination of sortilin, and subsequent degradation of the receptor in the lysosomal
compartment (169). Taken together, these data demonstrate that both the bioavailability
and activity of sortilin may be highly regulated within the cell.
1.3.1 Putative Role of Sortilin in Human Disease
A putative association between sortilin and a variety of human diseases has been
suggested due to the multi-ligand and multi-functional nature of the trafficking receptor
(reviewed in reference 170). First purified in human brain tissue when studying lipoprotein
interactions, subsequent research led to the characterization of this receptor in various
neurological and neurodegenerative diseases (175). A role for sortilin in promoting proapoptotic signalling and neuronal cell death has been established through its interaction
with the proforms of various neurotrophin (NT) and neurological growth factors (NGF)
(132-134, 159). Elevated levels of neuronal apoptosis are associated with numerous
neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.
A putative role for sortilin in promoting the development of Alzheimer’s disease
has been postulated based on studies monitoring apoE and APP metabolism. Alzheimer’s
disease involves the accumulation of senile plaques within the hippocampus region of the
brain, with development of these plaques precluding neuronal apoptosis (176).
Experimental data demonstrate an ability for sortilin to act as a novel receptor for apoE in
the brain. ApoE interacts with the amyloid-beta peptide (AB-ß), a cellular component of
APP cleavage that is the main component of senile plaques in the brains of Alzheimer
patients. This interaction facilitates the cellular catabolism of the complex through
internalization by apoE receptors; thereby lowering the neurotoxic effects of AB-ß. Studies
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conducted in vivo have demonstrated that increased sortilin expression is associated with a
decrease in apoE/AB-ß accumulation, with sortilin promoting the lysosomal degradation
of the apoE/AB-ß complex (138). Furthermore, sortilin was found to regulate the retrograde
transport and activity of the ß-site ß-amyloid precursor protein (APP)-cleaving enzyme 1
(BACE1). This protein catalyzes the initial phase of APP cleavage (158). Recent in vitro
and in vivo work demonstrated that the intracellular domain of sortilin can directly interact
with and promote the lysosomal targeting of APP. A functional hexapeptide motif was
required for this interaction, as mutations in this domain led to a reduction in the ability of
sortilin to mediate the lysosomal degradation of APP (135).
Associations between sortilin activity and the development of Diabetes mellitus
have also been suggested through both in vivo and in vitro studies. Diabetes mellitus is a
group of metabolic disorders that are characterized by hyperglycemia. Multiple studies
have elucidated an association between sortilin and the intracellular trafficking of glucose
transporter type 4 (Glut4) (147, 148, 165, 177). Glut4 plays a critical role in the regulation
of blood glucose levels in adipose and muscle tissues. Elevated insulin levels lead to the
translocation of Glut4 to the cell membrane and a concomitant increase in glucose uptake
(148). Glut4 is contained and shuttled within Glut4 storage vesicles (GSVs) upon insulin
response. Work conducted in adipocytes demonstrated that sortilin is a major component
of GSVs (165, 177), and in vitro vesicle reconstitution assays indicated that the formation
of GSVs can be regulated by sortilin activity (148). Furthermore, the VPS10 domain was
found to facilitate translocation of GSVs to the cell surface upon response to elevated
insulin levels (147). Therefore, these studies demonstrate that an increase in sortilin activity
is associated with an increase in glucose uptake in adipocytes and muscle cells.
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1.3.2 GWAS Studies and Identification of SORT1 as a Risk Gene for
Cardiovascular Disease and Its Role in LDL Metabolism
With multiple studies elucidating well-characterized roles for sortilin in neuronal
cells, intriguing genome wide association studies (GWAS) led to an unexpected association
between the 1p13 region and CAD (178-182). This suggested a role for sortilin in
cardiovascular disease, particularly with respect to plasma cholesterol levels and risk of MI
(183). Specifically, GWAS of European subjects possessing polymorphisms in the region
near SORT1 were associated with a ~5-8 mg/dL decrease in LDL cholesterol (LDL-C) and
total cholesterol concentrations (153, 178). Furthermore, a 40% reduction in risk for
myocardial infarction, and a 13% reduction in risk for CVD, was also associated with SNPs
in the 1p13 region (153, 178). With respect to SORT1, these studies identified seven
chromosomal loci to be associated with CAD; however, the gene cluster located in the 1p13
region appeared to have the most prominent role in affecting plasma LDL levels and MI
risk (184).This locus contained a haplotype of three tightly linked genes in linkage
disequilibrium, classified as PSRC1, CELSR2, and SORT1, that encode for the
proline/serine-rich coiled-coil 1 (PSRC1) protein, the cadherin EGF LAG seven-pass Gtype receptor 2 (CELSR2) protein, and the sortilin protein (SORT1) respectively (183).
These SNPs occurring in the 1p13 region, which include rs646776, rs599839, and
rs12740374, were all found to alter the gene expression levels of PSRC1, CELSR2, and
SORT1. The minor allele for rs646776 was found to increase mRNA levels. The minor Gallele of rs599839 increased SORT1 gene expression without altering the expression of
PSRC1 and CELSR2 (153). Fine mapping of SNP region also led to the discovery of the
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minor T-allele at rs12740374, which was associated with increased SORT1 gene expression
and protein production (152, 185).
With the emergence of genetic analysis supporting a role for the 1p13 region in
CAD, multiple studies were performed to determine a causal mechanism behind the
association between this chromosomal region and CVD. Prior research demonstrated a role
for sortilin in regulating lipoprotein catabolism; therefore, a similar role for sortilin in
controlling LDL catabolism was postulated (124, 138-140). In a study monitoring the
rs599839 SNP, HEK 293 cells were transfected with sortilin cDNA to determine if
overexpression of the protein was related to increased LDL uptake. A significant increase
was observed in LDL and RAP uptake in cells overexpressing sortilin (153). Therefore, it
was proposed that individuals possessing the minor alleles for SORT1 at this locus could
lower plasma LDL levels by increasing the rate of LDL catabolism. This hypothesis was
further supported in a subsequent study, where it was postulated that sortilin could act as
an independent cell surface receptor for LDL. Indeed, an increase in the catabolic rate of
LDL was observed in vivo in mouse models overexpressing hepatic sortilin (142).
Furthermore, liver specific knockdown of sortilin expression in a mouse model was
associated with a decrease in the catabolic rate of LDL (142). Interestingly, mutations
involving the complete removal of the intracellular sorting domain, or mutagenesis of key
leucine residues present in the acidic dileucine sorting motif, did not demonstrate a
significant increase in LDL degradation. While the altered dileucine mutant had
comparable LDL association rates to wildtype sortilin, the inability of sortilin to traffic
from the cell membrane to endosomes inhibited this variant from mediating LDL
degradation. The sortilin variant containing a removed cytoplasmic domain was unable to
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associate with, or mediate the degradation of, LDL (142). In an attempt to determine if the
regulation of LDL catabolism through sortilin expression was independent of the LDLR,
knockout mice completely lacking the LDLR protein were studied the in setting of either
sortilin knockout or overexpressing sortilin mice. Indeed, an increase in catabolism was
also observed in mice lacking the LDLR, thus indicating an independent role for sortilin in
LDL catabolism (142). Conversely, in vivo studies demonstrated that no difference in LDL
catabolism was observed in a SORT-/- mouse model when compared to control mice (141).
In a study monitoring the rs12740374 SNP, humanized mouse models were utilized
to study the effects of sortilin overexpression and sortilin knockdown on apoB and VLDL
secretion (152). As previously mentioned, this study performed fine mapping of the 1p13
locus to determine the causal SNP variant involved in regulating LDL metabolism, as well
as the effects upon gene expression brought about by this mutation. The presence of the
minor T-allele, as opposed to the major G-allele, at this locus resulted in the generation of
a C/EBP consensus site. Interestingly, the occurrence of the minor protective allele at this
locus was found to be approximately 30% in European populations (152). Expression
quantitative trait loci (eQTL) data demonstrated that a 5-6 fold increase in gene expression
was observed with the PSRC1 and SORT1 genes for each copy of the minor allele (Fig.
1.8). (152). Interestingly, while sortilin is highly expressed in an abundance of human
tissues, the increased gene expression brought about by the minor allele was liver specific,
as no change in protein level was detected in adipose or lymphocyte tissues. This
phenomenon could be explained by C/EBP, which is a liver-specific transcription factor.
Generation of a consensus binding site would therefore lead to a hepatic-specific increase
in sortilin production (152). With this knowledge, researchers conducting this study utilized
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adeno-associated virus known to specifically alter gene expression in the liver to
overexpress sortilin in humanized mice. Increased expression of hepatic sortilin was found
to significantly reduce plasma LDL levels in these mice by 30-70%; this data agreed with
the previous findings of the GWAS studies in human patients. To compliment these
findings, siRNAs specific to the SORT1 gene were utilized to knockdown hepatic sortilin
production. Gene expression was reduced by 70-90% in humanized mice, and was
accompanied by a 20-125% significant increase in LDL-C and VLDL-C levels (152).
With SORT1 not implicated as the causal gene mediating the association between
the SNPs in the 1p13 region and LDL-C levels, an attempt to elucidate a mechanistic basis
for this association was performed through analysing the rate of VLDL secretion. Primary
hepatocytes from a humanized mouse model were harvested from animals either
overexpressing sortilin or siRNA directed against sortilin, and subjected to labelling
experiments to monitor the rate of apoB secretion. A significant increase in apoB secretion
was observed in hepatocytes that possessed siRNAs specific to SORT1. In support of this
finding, the opposite trend was observed in mice overexpressing the SORT1 gene, where
higher sortilin levels correlated with a significant decrease in apoB secretion from
hepatocytes. Since the gene expression of PSRC1 was also greatly increased by the minor
T-allele, identical overexpression analysis was performed to study the effects of altered
PSRC1 expression on LDL-C. However, no significant changes in LDL-C were observed,
thus implicating SORT1 as the sole causal variant associated with regulating LDL-C at the
1p13 locus. Therefore, it was proposed that individuals that were homozygous for the minor
allele at SNP rs12740374 would possess a significantly lower risk rate for CAD due to a
decreased rate of LDL production (152).
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Figure 1.8: Schematic representation of SNP variation in the 1p13 gene and its effects
on CAD. Various single nucleotide polymorphisms (SNPs) in the 1p13 gene region were
identified through genome-wide association studies (GWAS) that significantly altered risk
levels associated with coronary heart disease (CHD) and myocardial infarction (MI). The
major SNPs were found to occur in a non-coding region between the CELSR2 and PSRC1
alleles. Initial studies demonstrated an association between the rs599839 SNP and MI and
LDL cholesterol levels. Fine mapping of this intergenic region was conducted to identify a
mechanism behind this association. The rs12740374 SNP was found to introduce a novel
binding site for a liver-rich transcription factor identified as C/EBP. Increased binding of
this factor lead to a significant upregulation in SORT1 gene expression, as well as a
concomitant elevation of the receptor sortilin. Image modified from reference 177.
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With SORT1 not implicated as the causal gene mediating the association between
the SNPs in the 1p13 region and LDL-C levels, an attempt to elucidate a mechanistic basis
for this association was performed through analysing the rate of VLDL secretion. Primary
hepatocytes from a humanized mouse model were harvested from animals either
overexpressing sortilin or siRNA directed against sortilin, and subjected to labelling
experiments to monitor the rate of apoB secretion. A significant increase in apoB secretion
was observed in hepatocytes that possessed siRNAs specific to SORT1. In support of this
finding, the opposite trend was observed in mice overexpressing the SORT1 gene, where
higher sortilin levels correlated with a significant decrease in apoB secretion from
hepatocytes. Since the gene expression of PSRC1 was also greatly increased by the minor
T-allele, identical overexpression analysis was performed to study the effects of altered
PSRC1 expression on LDL-C. However, no significant changes in LDL-C were observed,
thus implicating SORT1 as the sole causal variant associated with regulating LDL-C at the
1p13 locus. Therefore, it was proposed that individuals that were homozygous for the minor
allele at SNP rs12740374 would possess a significantly lower risk rate for CAD due to a
decreased rate of LDL production (152).
A subsequent study provided further evidence regarding an association between
increased sortilin levels and a reduction in apoB secretion. In vivo studies in wild-type mice
demonstrated that increased sortilin expression was associated with a decrease in apoB
secretion. This association was replicated in LDLR knockout mice. Mechanistically, the
ability of sortilin to lower apoB secretion appeared to be dependent upon lysosomal
localization, as the introduction of an endolysosome inhibitor completely abolished this
effect. Furthermore, while wildtype sortilin displayed an ability to co-localize with
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lysosome markers, a sortilin mutant lacking the entire intracellular domain, as well as a
mutant containing a mutated tyrosine and dileucine sorting motifs, were unable to replicate
this localization with lysosomes. An inability to reduce apoB secretion was demonstrated
in LDLR knockout mice expressing these sortilin variants, therefore supporting the
hypothesis that sortilin reduced apoB secretion through facilitating the trafficking of the
lipoprotein to lysosomes for degradation (142).
Conversely, an opposing study released shortly after demonstrated that increased
sortilin expression was associated with an increase in LDL-C. This study demonstrated an
approximately 30% reduction in plasma LDL levels in mice that were deficient in sortilin
and LDLR, and was accompanied by a 48.2% reduction in apoB-100. To support this
finding, overexpression of sortilin performed in hepatocytes yielded the opposite
association, with an approximate 42% increase in total cholesterol as well as ~44% increase
in apoB-100 (141). Interestingly, these findings only altered the levels of apoB-100, with
apoB48 levels remaining consistent throughout, therefore implying a role for sortilin in
regulating the metabolism of apoB-100 containing particles. To complement this
hypothesis, interaction studies were performed to analyze a potential interaction between
sortilin

and

apoB-100.

Multiple

experimental

methods

which

included

co-

immunoprecipitation (co-IP), surface plasmon resonance, and Förster resonance energy
transfer (FRET) demonstrated that an interaction occurs between sortilin and aboB100,
with the highest association occurring in the Golgi compartments. The interaction between
apoB-100 and sortilin, as assessed through SPR analysis, was found to be abolished when
a sortilin mutant that was unable to undergo maturation by furin cleavage was used (141).
A direct interaction between apoB and sortilin was also replicated in another study using
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SPR analysis, where it was determined that the interaction between the two proteins was
dependent upon a specific pH range. The highest rate of association was observed at a pH
of 7.4, with dissociation rapidly occurring as the pH was lowered to 5 during analysis (142).
Similar to previous studies, an attempt to determine a mechanistic basis for the
regulation of LDL-C was achieved through examining a potential role for sortilin in
regulating apoB and VLDL secretion and LDL catabolism. However, in opposition to
previous findings, metabolic labelling of hepatocytes demonstrated an increase in apoB100 secretion with sortilin overexpression; sortilin knockout hepatocytes yielded an overall
decrease in hepatic apoB-100 secretion. This relationship was reciprocated with respect to
VLDL secretion. In support of these findings, experiments conducted by Strong et al..
further demonstrated that VLDL secretion rates were decreased in a SORT-/- mouse model
when compared to control mice (142).
These data indicate that the relationship between sortilin expression and LDL
metabolism is complex. However, it is clear that sortilin plays a role in regulating the
metabolism of apoB-100, VLDL, and LDL particles. The enigmatic role of sortilin in
regulating LDL-C levels may be dependent upon multiple conditions. The mechanism of
regulation may be dependent upon the bioavailability of apoB and apoB-100 containing
lipoproteins. Furthermore, the expression levels of sortilin may also play a role. Finally,
environmental factors and experimental conditions may also regulate how sortilin affects
LDL metabolism. Taken overall, it appears that the ability of sortilin to regulate LDL
metabolism is dependent upon the metabolic milieu (183).
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1.3.3 Potential Role of Sortilin in Atherosclerosis
It is universally accepted that LDL-C is involved in the development of
atherosclerosis (4). With GWAS identifying a strong association between the 1p13 locus
and LDL-C, and multiple mechanistic studies demonstrating SORT1 as the causal gene
responsible for this relationship, a role for sortilin was proposed in the process of
atherosclerosis. Using apoE knockout mice that were deficient in sortilin expression, it was
shown that reduced expression of sortilin protein did not alter plasma cholesterol levels,
but led to a reduction in the development of atherosclerotic lesions (186). This result
indicated a role for sortilin in promoting atherosclerosis through a mechanism independent
of LDL-C regulation. Immune cells, as well as the production and recruitment of cytokines
and proinflammatory molecules, play a crucial role in the development of atherosclerotic
lesions (4). Studies conducted in sortilin deficient macrophages demonstrated a significant
decrease in the secretion of the IL-6 and IFN-y cytokines. Furthermore, strong colocalization between the cytokines and sortilin was observed intracellularly in sortilin
positive macrophages. Taken together, these data demonstrated that, in the absence of
sortilin expression, an attenuation of the inflammatory response in immune cells was
achieved with a corresponding reduction in the development of atherosclerosis in apoE
knockout mice (186).
This association between sortilin expression and atherosclerosis was further
demonstrated in macrophages. However, the mechanistic basis relied on variation in LDL
internalization as opposed to cytokine regulation (187). In contrast to the previous study,
no difference was observed in macrophage cytokine levels between sortilin knockout
animals and control animals. However, sortilin deficiency was still shown to significantly
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reduce the development of atherosclerotic lesions (187). With respect to mechanism, this
study determined that sortilin overexpression led to a significant increase in the total
cholesterol content of macrophages, which ultimately led to an increased rate of foam cell
formation both in vitro and in vivo (187). This effect was significantly reduced by knocking
down sortilin in macrophages. Furthermore, macrophages that were subjected to high
concentrations of LDL demonstrated a significant increase in sortilin expression compared
to cells with reduced cholesterol content (187). These data indicated that sortilin may be
acting as a direct receptor for LDL clearance in macrophages. Since previous data indicated
an ability for sortilin to regulate LDL-C levels independently of the LDLR receptor, a
similar hypothesis was proposed for macrophage cholesterol uptake (141, 142). Indeed, in
vivo experiments utilizing an inhibitor of actin polymerization and micropinocytosis
demonstrated a significant reduction in LDL internalization in sortilin knock down
macrophages, therefore supporting an LDLR independent mechanism for promoting LDL
uptake and foam cell formation (187).
1.4 Proprotein Convertase Subtilin Kinexin 9
PCSK9 is a serine protease zymogen encoded by the PCSK9 gene found on
chromosome 1p32.3 (188). First discovered in 2003, it is classified as the ninth member of
the peptidase S8B family (189, 190). PCSK9 is ubiquitously expressed in a variety of
tissues, with the highest levels of expression observed in the liver, intestines, and kidneys
(190). Structurally, this enzyme is composed of a short, 30 amino acid signal peptide and a
121 amino acid pro-domain. These regions are followed by a catalytic domain possessing
the D-H-S catalytic triad motif typically of serine proteases, a hinge region, and a Cterminal cysteine-histidine-rich domain (191). PCSK9 is initially synthesized as a 69241

amino acid propeptide. Maturation of the zymogen occurs after the removal of the signal
peptide through autocatalytic cleavage of the prodomain between the amino acids Q152-S153
in the ER. Similar to sortilin, the removal of the propeptide is a necessary step required for
PCSK9 maturation (192). Furthermore, the newly formed propeptide can non-covalently
bind to the catalytic domain of PCSK9 through hydrogen bond formation, leading to the
catalytic inactivation of the mature enzyme (191). PCSK9 is ultimately secreted from the
Golgi while complexed with its pro-domain (191).
The physiological function of PCSK9 is strongly associated with cholesterol
homeostasis, as this enzyme directly binds to and promotes the degradation of the LDLR
(119). This is achieved at the cell surface through an interaction between the catalytic
domain of PCSK9 and the epidermal growth factor-like repeat homology domain (EGFA)
of the LDLR (119). Under normal conditions, LDL will bind to its corresponding receptor,
initializing clathrin-mediated endocytosis of the complex. Once in the acidic environment
of the endosome, the LDLR undergoes a conformational change from an open state to a
closed state and releases its LDL ligand. Unbound particles are transported to lysosomes
for degradation while the LDLR is recycled to the cell surface (193, 194). However, in the
presence of PCSK9, the LDLR is unable to adopt a closed state in endosomes. The
interaction between PCSK9 and the LDLR is strengthened by the acidic conditions of
endosomes. Salt bridge formation between the pro-domain of PCSK9 and the ß-propeller
domain of LDLR, as well as a proposed interaction between the C-terminal domain of
PCSK9 and the ligand-binding domain of LDLR, prevent the receptor from transitioning
into a closed formation (195). As a result, the receptor is shuttled in complex with LDL and
PCSK9 to the lysosome for degradation (196). Interestingly, a direct association between
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LDL and PCSK9 can occur, where the lipoprotein particle has been observed to bind to the
N-terminal region of PCSK9. This interaction prevents PCSK9 from binding to the LDLR,
therefore abolishing its ability to degrade the receptor (197).
1.4.1 Regulation of PCSK9 Activity
PCSK9 activity and expression can be regulated in a variety of ways (reviewed in
ref. 180). At the endogenous level, the secreted form of PCSK9 can undergo catalytic
cleavage at an arginine residue present in the 218 amino acid position to produce in inactive
protein product. Truncation of PCSK9 is achieved by other proprotein convertases,
specifically furin and PC5/6A (198). Numerous natural mutations in the population have
also been shown to moderate the functional ability of PCSK9 to degrade the LDLR. A wellstudied gain-of-function mutation, D374Y, has been shown to have a 25-fold increase in
affinity for the LDLR, which concomitantly leads to a significant increase in LDL-C levels
(199). Data indicate that the presence of a tyrosine residue at this position enhances binding
of PCSK9 to the extracellular domain (ECD) of the LDLR (191). Conversely, loss-offunction mutations have consistently demonstrated a negative correlation with LDL-C
levels. Specifically, the L253F missense mutation was found to inhibit autocatalytic
cleavage, leading to a significant reduction in circulating PCSK9 levels. A C679X nonsense
mutation in the C-terminal domain leads to atypical folding of PCSK9, resulting in
accumulation in the ER and an inhibition of secretion of the mature protein (200). Overall,
greater than fifty PCSK9 variants have been characterized with respect to plasma
cholesterol levels (199).
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1.4.2 Association of PCSK9 with Sortilin
PCSK9 is a soluble protein that is incapable of interacting with adaptor proteins in
cellular compartments, therefore indicating a role for chaperone proteins in facilitating its
secretion from the ER and Golgi organelles. A recent study has demonstrated an interesting
association between sortilin and PCSK9 secretion. SPR analysis demonstrated a pH
dependent interaction between sortilin and PCSK9, with high affinity binding observed at
pH 7.4 and an abolishment of this interaction observed at pH 5.5 (143). Co-IP studies in
hepatic cells further supported this interaction, and further demonstrated that sortilin can
bind the immature form of PCSK9 as well (143). Interestingly, a similar pH dependent
interaction was observed between LDL and sortilin in hepatic tissues (141, 142).
Mechanistically, the ability of sortilin to facilitate PCSK9 secretion was found to be
dependent upon an interaction occurring late in the secretory pathway. A significant extent
of co-localization was observed between the two proteins in the TGN (143). Experiments
conducted with sortilin knock-out mice also demonstrated a significant alteration in
subcellular localization for both the immature and mature forms of the zymogen, therefore
suggesting that sortilin acts as a molecular chaperone for PCSK9 through the secretory
pathway (143).
1.5 Rationale and Objectives
Elevated plasma levels of Lp(a) have been identified through recent meta-analyses
to be an independent, causal risk factor for CHD (15, 31). Therefore, it is important to
develop an understanding of factors that increase Lp(a) concentrations in humans.
However, the metabolism of Lp(a) remains enigmatic. Furthermore, factors involved in
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regulating the intracellular transport of apo(a) through its biosynthetic pathway remain
unknown.
Lp(a) assembly occurs as a two-step mechanism. The majority of studies suggest
that an intracellular, non-covalent interaction occurs between apo(a) and apoB, with
covalent assembly of Lp(a) occurring extracellularly. Furthermore, previous studies
indicate that the secretion of apoB and apo(a) with respect to Lp(a) particles are linked (8082, 85). As such, increasing the rates of either apoB or apo(a) biosynthesis could potentially
lead to a concomitant increase in plasma Lp(a). Previous studies suggest that apo(a)
maturation and intracellular trafficking are the rate-limiting steps in apo(a) production (76),
however, little is known about the intracellular transport of apo(a). The rate of Lp(a)
catabolism also regulates plasma Lp(a) levels. Multiple receptors have been implicated in
Lp(a) catabolism; however, the primary route of Lp(a) clearance remains undefined.
Previous research shows that sortilin can regulate lipoprotein metabolism (124,
138-140). In particular, studies have shown that sortilin is a novel regulator of apoB/VLDL
secretion and LDL catabolism (141, 142, 152, 153). Furthermore, multiple studies establish
sortilin as an intracellular trafficking receptor. Since Lp(a) is structurally similar to LDL,
it is possible that sortilin may likewise regulate Lp(a) catabolism in a manner similar to that
of LDL. Moreover, the possible association between apoB and apo(a) secretion indicates
that sortilin may likewise affect apo(a) secretion.
Therefore, we hypothesize that sortilin can mediate Lp(a) clearance by acting as a
novel cell surface receptor for Lp(a). Moreover, we hypothesize that sortilin may directly
bind to apo(a), and regulate its rate of secretion by facilitating the intracellular trafficking
of nascent apo(a). To address this hypothesis, the following specific aims were developed:
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1)

To assess if a direct interaction can be observed between sortilin and either
Lp(a) or apo(a);

2)

To define a role for hepatic sortilin in apo(a) secretion;

3)

To determine if sortilin can increase the rate of Lp(a) or apo(a)
internalization in hepatocytes

4)

To identify if sortilin displays subcellular co-localization with Lp(a) or
apo(a) in hepatocytes
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CHAPTER 2: MATERIALS AND METHODS
2.1 Cell Culture – Established Cell Lines
All cell lines used in experiments were grown and cultured at 37oC in humidified
incubators containing an air:CO2 ratio of 19:1. Human hepatocellular carcinoma (HepG2)
cells were obtained from the American Type Culture Collection (ATCC) and maintained
in minimum essential medium (MEM; Gibco) supplemented with 10% FBS (ATCC) and
1% antibiotic-antimycotic (10 units/mL penicillin G sodium, 10 μg/mL streptomycin
sulfate, and 25 ng/mL amphotericin B) (Gibco).
Human fibroblast cell lines established from patients with primary familial
hypercholesterolemia (FH) were obtained from the Coriell Institute (catalogue numbers
GM01386, GM01355, and GM00701) and maintained in MEM (Gibco) containing 10%
(v/v) FBS (ATCC). Experiments with FH fibroblasts were performed between passages 8
and 20.
Human Embryonic Kidney (HEK293) cells were cultured in 100 mm tissue culture
plates (Sarstedt) in MEM supplemented with 5% FBS (v/v) (Gibco) and 1% antibioticantimycotic.
HepG2 cells lines stably expressing a 17-kringle form (17K) of recombinant apo(a)
(r-apo(a)) were constructed as follows. HepG2 cells were seeded at a density of 75,000
cells/well and transfected using MegaTran 1.0 transfection reagent (Origene) with 1
μg/well of expression plasmid (201) and 0.2 μg/plate of a plasmid encoding a neomycin
resistance protein as per manufacturer’s protocol. The transfection mixture was left on the
cells for 24 hours, after which the cells were given fresh medium and allowed to recover
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for 24 hours. The cells were then incubated in complete medium containing 400 μg/mL
Geneticin® selective antibiotic (G418 sulfate; Thermo Scientific). Surviving colonies
emerged after 3 weeks of selection and individual cell lines were obtained by dilution
cloning.
2.2 Mouse Primary Hepatocyte Isolation and Culture
Wild-type mice of the background strain (C57BL/6) were obtained from Jackson
Laboratories. Primary hepatocytes from wild-type mice were prepared by a modified
collagenase perfusion method (202). Mice were subjected to deep anesthesia (pentobarbitol
sodium diluted in saline at a dose of 50 mg/kg); mice were determined to have met surgical
plane anesthesia when toe pinch reflex was absent. Following thoracotomy and
catheterization of the hepatic portal vein, the livers were perfused with 50 mL of HEPESbuffered saline (HBS; 20 mM HEPES pH 7.4 containing 150 mM NaCl and 0.5 mM
ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA) at a flow rate
of 8 mL/min, followed by 50 mL of HBS containing 5 mM calcium chloride (CaCl2) and
collagenase (from Clostridium histolyticum, 0.5 mg/mL) at a rate of 6 mL/min. After
isolation, viability of hepatocytes was assessed by trypan blue exclusion staining (viability
of >80% was considered acceptable) and the cells were plated at a density of 2.0 × 105
cells/well into gelatin-coated 24-well plates in Williams E media (GIBCO) supplemented
with 10% FBS (ATCC), 2 mL-glutamine (GIBCO), and 1% antibiotic-antimycotic
(GIBCO). Approximately two hours after seeding, non-adherent cells were aspirated from
the plate and fresh medium was added. The animal experiments described above were
specifically approved by the University of Windsor Animal Use and Care Committee
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(protocol #14-24) and mice were maintained following the Canadian Council on Animal
Care guidelines at the University of Windsor.
2.3 Expression and Purification of Recombinant Apo(a)
The construction of expression plasmids encoding the r-apo(a)variants employed in
this study (17K-pRK5, 17KΔLBS7,8-pRK5 -pRK5, or 17KΔLBS10-pRK5) was previously
described, as was creation of stably-expressing cell lines in Hek293 cells (23). Conditioned
medium was harvested from lines stably-expressing the respective variants, and was
supplemented with PMSF to a final concentration of 1mM. Lysine-Sepharose affinity
chromatography was utilized to purify apo(a) from the conditioned media as previously
described (23, 203). Protein concentrations were determined spectrophotometrically using
pre-determined molar extinction coefficients (204). The purity of r-apo(a) was assessed
through comparative analysis to a purified r-apo(a) standard. This was achieved using SDSPAGE followed by silver stain analysis, where 20 μL of a 25 ng/μL solution was loaded
for both the purified and standard samples. One band was detected for both samples at
approximately 270 kDa, indicating that the protein solution was pure.
2.4 Construction of Recombinant Sortilin Expression Plasmids
A pcDNA 3.1C/Myc-His expression vector encoding wild-type sortilin was
generously provided by Dr. Nabil Seidah. This vector contained the cDNA for human
sortilin as well as a Myc-His tag at the carboxyl terminus. The cDNA of full-length, wildtype sortilin was amplified by polymerase chain reaction and inserted into pcDNA4A/MycHis digested with EcoRV and XbaI sites. The sequences of the primer pairs are as follows:
sortilin sense, 5’- CGG TCG AGA TGG AGC GGC CCT GGG GAG CT -3’ (EcoRV site
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underlined), sortilin anti-sense, 5’- CCT CTA GAT TCC AAG AGG TCC TCA TCT GAG
TC -3’ (XbaI site underlined). The pcDNA 3.1C/Myc-His expression vector containing the
cDNA for human sortilin was used as the template.
Two different wild-type sortilin versions were constructed: a soluble wild-type
sortilin (without the transmembrane region and cytoplasmic domain), and a wild-type
sortilin including the transmembrane region but lacking the cytoplasmic domain
(sortilinΔCT) in the pcDNA 4A/Myc-His expression vector. The pcDNA 4A/Myc-His
expression vector containing the cDNA for human sortilin was used as the template. The
same primer was used for the amino-terminus of the protein while the primer for the
carboxyl terminal region differed. The sequences of the primer pairs are as follows: aminoterminus 5’- CGG TCG AGA TGG AGC GGC CCT GGG GAG CT -3’ (EcoRV site
underlined), soluble sortilin anti-sense, 5’- GGT CTA GAA TTT GAC TTG GAA TTC
TG -3’ (XbaI site underlined), sortilinΔCT anti-sense, 5’- ACT CTA GAC CTT CCC CCA
CAG ACA TAT TTC -3’ (XbaI site underlined). The resulting sequences were amplified
by polymerase chain reaction and inserted into the pcDNA 4A/Myc-His expression vector.
For the sortilin trafficking variants, mutagenesis was carried out using the Q5 SiteDirected Mutagenesis Kit (New England Biolabs) according to the manufacturer’s
protocol. The primers used are shown in Table 2.1. For the sortilin trafficking mutants, the
template for the mutagenesis was the full-length, wild-type sortilin in pcDNA 4A/Myc-His
expression vector. For the sortilin polymorphic variants, mutagenesis was carried out using
the Q5 Site-Directed Mutagenesis Kit according to the manufacturer’s protocol. The
primers used are shown in Table 2.2. For the sortilin polymorphic variants, the template for
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the mutagenesis was the sortilin wild-type-pcDNA 3.1C/Myc-His expression vector. The
presence of the mutations was verified by DNA sequence analysis.
Table 2.1 Primer sequences for construction of Sortilin Trafficking Mutantsa
Trafficking Mutants
Sortilin Y792A
Sortilin L829A/L830A

Primer Sequence
5’-GTT CCT GGT GCA TCG AGC CTC
TGT GCT GCA GCA G-3’
5’-GAT GAC TCA GAT GAG GAC GCC
GCG GAA CCT CGA GGT CAC CC-3’

Table 2.2 Primer sequences for construction of Sortilin Polymorphic Variantsa
Polymorphic Variant
SORT1-I124V

5’-CACTGGGGTCGTTCTAGTCTTG-3’

SORT1-K205N

5’-ATTTTGCGAATAATTTTGTGCAAAC-3’

SORT1-K302E

5’-TATTGGTGTGGAAATCTACTCATTTG-3’

SORT1-F404Y

5’-GAGACGGACTATACCAACGTG-3’

SORT1-E444Q

5’-GAGGAAGCCTCAAAACAGTGAATGTG3’
5’-GAAAACAGTGGATGTGATGCTACAGC3’
5’-CAAGTCATCCATGTGTCAGAATGG-3’

SORT1-E447G
SORT1-V650M

Primer Sequence

a

Sense strand sequences only are shown. Mutated codons are double underlined; mutated
nucleotides are in boldface type. The 5´ end of the antisense primer was designed at the
base next to the 5´ end of the sense primer, and preceded in the opposite direction on the
complementary strand. The antisense primer was complementary to the plasmid sequence.

2.5 Construction, Expression and Purification of Recombinant PCSK9
The construction and expression of PCSK9-pcDNA 4C in HEK293 is previously
described (112). Conditioned medium was harvested from cells stably-expressing PCSK9
and supplemented with PMSF to a final concentration of 1mM. Nickel-Sepharose excel
(GE Healthcare) affinity chromatography was utilized to purify PCSK9 from the
conditioned medium as previously described (112). The bicinchoninic acid assay (BCA
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assay; Pierce) was utilized to determine the concentrations of the purified protein samples.
The purity of PCSK9 was assessed through comparative analysis to a purified PCSK9
standard. This was achieved using SDS-PAGE followed by silver stain analysis, where 20
μL of a 25 ng/μL solution was loaded for both the purified and standard samples. One band
was detected for both samples at approximately 74 kDa, indicating that the protein solution
was pure.
2.6 Transient Transfections
For internalization experiments, HepG2 cells grown to 70% confluence in 6 well
tissue culture plates were transfected with 1μg of either pcDNA 4A/Myc-His empty vector
(Invitrogen), sortilin wildtype-pcDNA 3.1C/Myc-His, SortilinΔCT-pcDNA 4A/Myc-His,
sortilin Y792A-pcDNA 4A/Myc-His, sortilin L829A/L830A-pcDNA 4A/Myc-His, sortilin
I124V-pcDNA3. 1C/Myc-His, sortilin K205N-pcDNA3.1C/Myc-His, sortilin K302EpcDNA3.1C/Myc-His,

sortilin

F404Y-pcDNA3.1C/Myc-His,

sortilin

E444Q-

pcDNA3.1C/Myc-His, or sortilin V650M-pcDNA3.1C/Myc-His using linear PEI (Sigma)
as per the manufacturer’s protocol.
For pulse-chase experiments, HepG2 cells grown to 70% confluence in 100 mm
tissue culture plates were transfected with 5 μg of either 17K apo(a)-pRK5, 17KΔ7,8 apo(a)pRK5, or 17KΔLBS10 apo(a)-pRK5 and either pcDNA 4A/Myc-His empty vector, sortilin
wildtype-pcDNA 3.1C/Myc-His, SortilinΔCT-pcDNA 4A/Myc-His, sortilin Y792ApcDNA 4A/Myc-His, or sortilin L829A/L830A-pcDNA 4A/Myc-His using linear PEI.
HepG2 cells stably expressing 17K apo(a) grown to 70% confluence in 100 mm tissue
culture plates were transfected with 5μg of either pcDNA3.1C/Myc-His empty vector or
sortilin wildtype-pcDNA 3.1C/Myc-His with linear PEI.
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For siRNA knockdown internalization experiments, HepG2 cells grown to 50%
confluence in 6 well tissue culture plates were transfected with 80 pmol of either sortilin
siRNA or scrambled control siRNA (Santa Cruz Biotechnology) as per the manufacturer’s
protocol. For siRNA-mediated sortilin knockdown pulse-chase experiments, HepG2 cells
stably expressing 17K apo(a) cells grown to 50% confluence in 100 mm tissue culture
plates were transfected with 440 pmol of either sortilin siRNA or scrambled control siRNA.
Human fibroblast cells were plated in 24-well tissue culture plates at 200,000
cells/well and were transfected 1-2 hours with 1μg of either pcDNA3.1C/Myc-His empty
vector or sortilin wildtype-pcDNA 3.1C/Myc-His using Lipofectamine® 3000 (Invitrogen)
as per manufacturer’s protocol.
Primary mouse hepatocytes were grown to 90% confluence in 24-well tissue culture
plate. The medium was changed approximately 1-2 hours after seeding. Approximately 12 hours following medium change, the cells were transfected with 1μg of either
pcDNA3.1C/Myc-His

empty

vector,

sortilin

wildtype-pcDNA

3.1C/Myc-His,

SortilinΔCT-pcDNA 4A/Myc-His, sortilin Y792A-pcDNA 4A/Myc-His, or sortilin
L829A/L830A-pcDNA 4A/Myc-His using Lipofectamine® 3000.
2.7 Preparation of Lipoprotein-Deficient Serum
Lipoprotein-depleted serum (LPDS) was prepared by addition of 1.21 g/mL sodium
bromide (NaBr) to FBS (ATCC) followed by ultracentrifugation at 45,000 x g for 18 hours
at 4oC. The top layer was removed by needle aspiration, and the infranatant was extensively
dialyzed at 4oC against HBS (20 mM HEPES pH 7.4 containing 150 mM NaCl) twice for
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two hours, and once overnight. The dialyzed LPDS was sterilized by passing through a
0.22- µm filter prior to supplementation of cell culture medium.
2.8 Internalization Assays
HepG2 cells were seeded into 6-well tissue culture plates at 3 x 105 cells/well, and
were allowed to attach overnight prior to transfection. Following overnight transfection
with either pcDNA3.1C/Myc-His empty vector, sortilin wildtype-pcDNA 3.1C/Myc-His,
SortilinΔCT-pcDNA

4A/Myc-His,

sortilin

Y792A-pcDNA

4A/Myc-His,

sortilin

L829A/L830A-pcDNA 4A/Myc-His, sortilin I124V-pcDNA3. 1C/Myc-His, sortilin
K205N-pcDNA3.1C/Myc-His, sortilin K302E-pcDNA3.1C/Myc-His, sortilin F404YpcDNA3.1C/Myc-His, sortilin E444Q-pcDNA3.1C/Myc-His, or sortilin V650MpcDNA3.1C/Myc-His, cells were trypsinized and seeded into 24-well tissue culture plates
(pre-coated with 1 mg/mL gelatin type A) at 3 x 105 cells/well. The cells were grown in
MEM containing 10% (v/v) LPDS for 16 hours prior to treatments. Cells were washed
twice with Opti-MEM (Gibco) and subsequently treated with Lp(a) (10 µg/mL) or r-apo(a)
variants (200 nM) in the absence or presence of either purified recombinant PCSK9 (20
µg/mL) or storage buffer (20 µg/mL) in Opti-MEM for 4 hours at 37oC. For experiments
utilizing ε-aminocaproic acid (ε-ACA), cells were treated with Lp(a) (10 µg/mL) or rapo(a) variants (200 nM) in the absence or presence of 0.2M ε-ACA for 4 hours at 37oC.
For experiments involving siRNA-mediated sortilin knockdown, cells were seeded
into 6-well tissue culture plates at 2 x 105 cells/well, and were allowed to attach overnight
prior to transfection. Following transfection with 80 ρmols of either sortilin siRNA or
scrambled control siRNA, cells were trypsinized and seeded into 24-well tissue culture
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plates (pre-coated with 1mg/mL gelatin type A) at 3 x 105 cells/well. The cells were
sustained in MEM containing 10% (v/v) LPDS for 16 hours prior to treatments. Cells were
washed twice with Opti-MEM and subsequently treated with Lp(a) (10 µg/mL) or r-apo(a)
variants (200 nM) in the absence or presence of either purified recombinant PCSK9 (20
µg/mL) or storage buffer (20 µg/mL) in Opti-MEM for 4 hours at 37oC.
Lysates were prepared from the cells as follows: the cells were extensively washed
at 4oC in the following order: three times with phosphate-buffered saline (PBS; 137 mM
NaCl, 2.7mM KCl, 10mM Na2HPO4, KH2PO4 at pH 7.4) containing 0.8% (w/v) bovine
serum albumin (BSA; PBS-BSA), twice with PBS-BSA containing 0.2 M ε-ACA for 5
minutes each, once with acid wash (0.2 M acetic acid pH 2.5 containing 0.5 M NaCl) for
10 minutes, once more with PBS-BSA, once more with acid wash for 10 minutes, and
finally twice for 5 minutes with PBS. The cells were then subsequently lysed in lysis buffer
(50 mM Tris pH 8.0, 1% (v/v) NP-40, 0.5% (w/v) sodium deoxycholate, 150 mM NaCl, 1
mM ethylenediaminetetraacetic acid (EDTA), 0.1% (w/v) SDS, 1 mM PMSF). Lysates
were subsequently subjected to SDS-PAGE and western blot analysis as described below.
For internalization experiments in human fibroblasts, cells were seeded into a 24well tissue culture plate at 3 x 105 cells/well, and were allowed to attach for approximately
1-2 hours prior to transfection. Following overnight transfection with either
pcDNA3.1C/Myc-His empty vector or sortilin wildtype-pcDNA 3.1C/Myc-His, the cells
were grown in MEM containing 10% (v/v) LPDS for 16 hours prior to treatments. Cells
were washed twice with Opti-MEM and treated with Lp(a) (10 µg/mL) or apo(a) (200 nM)
in the absence or presence of either purified recombinant PCSK9 (20 µg/mL) or storage
buffer (20 µg/mL) in Opti-MEM for 4 hours at 37oC. Cells were extensively washed as
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described for HepG2 cells above, with some exceptions. Following the initial PBS-BSA
wash step, the cells were washed twice with PBS containing 10 µg/mL heparin for 10
minutes each, followed by a single wash with PBS-BSA containing 0.2M ε-ACA for 5
minutes. Additionally, only one acid wash step was performed, which was followed by a
neutralization wash (0.5 M HEPES pH 7.5 containing 100 mM NaCl) for 10 minutes and
a single wash with PBS for 5 minutes. Lysates were prepared as described above.
For internalization experiments in primary mouse hepatocytes, cells were seeded
into a 24-well tissue culture plate at 3 x 105 cells/well, and were allowed to attach for
approximately 1-2 hours. Medium was changed, and cells were transfected approximately
1-2 hours following medium change. Following transfection with either pcDNA3.1C/MycHis empty vector, sortilin wildtype-pcDNA 3.1C/Myc-His, SortilinΔCT-pcDNA 4A/MycHis, sortilin Y792A-pcDNA 4A/Myc-His, or sortilin L829A/L830A-pcDNA 4A/Myc-His,
the cells were grown in Williams’ Medium E containing 10% for 16 hours prior to
treatment. Cells were washed twice with Opti-MEM and treated with Lp(a) (10 µg/mL) in
Opti-MEM for 4 hours at 37oC. Cells were extensively washed as described for HepG2
cells above. Lysates were prepared as described above.
2.9 Secretion Studies
HepG2 cells stably expressing stably expressing 17K r-apo(a) were seeded into 6well tissue culture plates at 3 x 105 cells/well and were allowed to attach overnight prior to
transfection. Following overnight transfection with either pcDNA3.1C/Myc-His empty
vector, sortilin wildtype-pcDNA 3.1C/Myc-His, sortilin I124V-pcDNA3. 1C/Myc-His,
sortilin K205N-pcDNA3.1C/Myc-His, sortilin K302E-pcDNA3.1C/Myc-His, sortilin
F404Y-pcDNA3.1C/Myc-His, sortilin E444Q-pcDNA3.1C/Myc-His, or sortilin V650M56

pcDNA3.1C/Myc-His, the medium was changed and the cells recovered for 24 hours.
Following 24 hours, 200 µL samples of medium was harvested from each well, and lysates
were prepared from the cells as follows: the cells were washed twice with ice cold PBS and
subsequently lysed in lysis buffer (50mM Tris pH 8.0, 1% (v/v) NP-40, 0.5% (w/v) sodium
deoxycholate, 150 mM NaCl, 1 mM EDTA, 0.1% (w/v) SDS, 1 mM PMSF). Lysates were
subsequently subjected to SDS-PAGE and western blot analysis as described below.
2.10 Pulse-Chase Studies
For overexpression studies, HepG2 cells were seeded into 100 mm tissue culture
plates at 1.5 x 106 cells/plate, and were allowed to attach overnight prior to transfection.
Following transfection with either pcDNA3.1C/Myc-His empty vector, sortilin wildtypepcDNA 3.1C/Myc-His, SortilinΔCT-pcDNA 4A/Myc-His, sortilin Y792A-pcDNA
4A/Myc-His, or sortilin L829A/L830A-pcDNA 4A/Myc-His, the cells were trypsinized
and seeded into 6-well plates at 6 x 105 cells/well. The cells were grown in MEM containing
10% FBS (ATCC) overnight prior to labelling. For siRNA-mediated sortilin knockdown
studies, HepG2 cells stably expressing 17K apo(a) were seeded into 100 mm tissue culture
plates at 1.75 x 106 cells/plate, and were allowed to attach overnight prior to transfection.
Following transfection with either pcDNA3.1C/Myc-His empty vector, sortilin wildtypepcDNA 3.1C/Myc-His, sortilin siRNA or scrambled control siRNA, the cells were
trypsinized and seeded into 6-well plates at 6 x 105 cells/well. The cells were grown in
MEM containing 10% FBS overnight prior to labelling.
On the day of the experiment, the cells were washed once with 1 mL of PBS, preincubated for 1 hour in 1 mL of methionine- and cysteine-free Dulbecco’s Modified Eagle
Medium (DMEM; Gibco) without serum and subsequently pulse-labelled in the same
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medium containing 200 µCi/well of [35S]-cysteine/[35S]-methionine labeling solution
(Perkin Elmer Life Sciences) for 1 hour. Following labelling, the wells were washed once
with 1 mL of PBS, and chased in 1 mL of complete growth medium for 0, 30, 60, 120, 240,
or 480 minutes. At each of these chase times, conditioned medium was collected and stored
on ice, and the cells were washed once with ice-cold PBS and subsequently lysed in cold
lysis buffer (50mM Tris pH 8.0, 1% (w/v) NP-40, 0.5% (w/v) sodium deoxycholate, 150
mM NaCl, 1 mM EDTA, 0.1% (w/v) SDS, 1 mM PMSF). Media and lysates were clarified
by centrifugation at 15,000 rpm in a microcentrifuge for 6 minutes to remove cellular
debris, and the supernatants were subjected to immunoprecipitation as described below.
Both media and lysates (1 mL and 500µL respectively) were pre-cleared by
incubation with 30 µL of gelatin-agarose (Sigma) for 2-3 hours at 4oC while gently shaking.
Samples were then immunoprecipitated with saturating quantities (1 µL) of anti-apo(a)
antibody (a5) (205) overnight at 4oC while gently shaking. After overnight incubation, 30
µL of protein G-agarose beads (Novex) was added and the mixtures incubated for 2-3 hours
at 4oC while gently shaking. The resulting pellets were washed three times with 500 µL of
RIPA buffer (50 mM Tris pH 7.4, 150 mM NaCl, 20mM EDTA, 1% (w/v) sodium
deoxycholate, 0.1% (w/v) SDS), washed once with 500 µL of TE buffer (10 mM Tris pH
7.5, 1mM EDTA) and finally re-suspended in 2x SDS Sample Buffer (250 mM Tris pH
6.8, 4% (w/v) SDS, 0.001% (w/v) bromophenol blue, 40% (v/v) glycerol) supplemented
with 7 µL of 100 mM dithiothreitol (DTT). Samples were briefly centrifuged to pellet the
agarose, boiled for 7 minutes, and then pulse-centrifuged again.
Immunoprecipitates were subjected to SDS-PAGE on 7% polyacrylamide gels.
Following electrophoresis, the gels were incubated in 100 mL fixing solution
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(methanol:H2O:glacial acetic acid, 40:50:10) while gently shaking for 20 minutes, briefly
rinsed with milli-Q H2O, and then incubated in 100 mL of Amplify solution (Amersham
Biosciences) while gently shaking for 20 minutes. The gels were then incubated in 100 mL
of milli-Q H2O containing 5 drops of 100% glycerol while gently shaking for 10 minutes.
Following the various washing steps, the gels were dried using a gel dryer (BioRad Model
583) on cycle 2 at 80oC for 45 minutes. Finally, the gels were exposed to a phosphor K
screen (BioRad) at room temperature for 90 hours before screens were imaged using a
BioRad Molecular Imager FX phosphoimager. Densitometric quantification of resulting
bands was performed using Alpha View software (Alpha Innotech). Lysate samples were
determined by measuring the combined total density of the immature and mature forms of
intracellular r-apo(a), as the two bands could not be reliably resolved for quantitative
analysis.
2.11 Co-immunoprecipitation Assay Using Sortilin, Lp(a)/apo(a) and/or apoB PullDown
For co-immunoprecipitation (IP) studies involving sortilin, HepG2 cells were
seeded into 6-well tissue culture plates at 4 x 105 cells/well. For co-IP studies involving
Lp(a)/apoB, HepG2 cells were seeded into 100 mm tissue culture plates at 3 x 106
cells/plate. The cells were allowed to attach overnight, and were sustained in MEM
supplemented with 10% LPDS and 1% antibiotic-antimycotic. The cells were washed twice
with Opti-MEM, and treated with Lp(a) (10 µg/mL) in Opti-MEM for 4 hours at 37oC.
For co-IP studies involving apo(a)/apoB, HepG2 cells stably expressing 17K apo(a)
were seeded into 6-well tissue culture plates at 4.5 x 105 cells/well (sortilin pull-down) or
into 100 mm tissue culture plates at 3 x 106 cells/plate (apo(a) pulldown). The cells were
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allowed to attach overnight, and were sustained in MEM supplemented with 10% LPDS
and 1% antibiotic-antimycotic.
For co-IP studies involving sortilin, the cells were washed once with PBS, and
treated with 1mM of the reducible protein cross-linker dithiobis(succinimidylpropionate)
(DPS; Pierce) in Opti-MEM for 30 minutes at room temperature (sortilin pull-down
experiments only). The reaction was quenched through the addition of 1 mL of 100 mM
Tris for 15 minutes at 4oC. The cells were washed twice with PBS, and lysed with 1 mL of
IP lysis buffer (50 mM Tris pH 7.4 containing 150 mM NaCl, 1 mM EDTA, 1.5% (v/v)
NP-40, 0.4% (w/v) sodium deoxycholate, 5% (v/v) glycerol). Lysates (1 mL) were
subjected to centrifugation at 15,000 rpm in a microcentrifuge for 10 minutes to clear
cellular debris, and subsequently pre-cleared by incubation with 30 µL of gelatin-agarose
for 2-3 hours at 4oC while gently shaking. The lysates were divided into two tubes, each
receiving 450 µL, and were incubated with either no antibody or goat-anti-human sortilin
polyclonal antibody (R&D Systems) overnight at a final concentration of 2 µg/mL at 4oC
while gently shaking. The resulting pellets were washed three times with 500 µL of ice cold
IP wash buffer (50 mM Tris pH 7.4 containing 150 mM NaCl, 1 mM EDTA, 0.1% (v/v)
NP-40, 0.4% (w/v) sodium deoxycholate, 5% (v/v) glycerol). Samples were re-suspended
in 2X SDS Sample Buffer supplemented with 7 µL of 100 mM DTT, and briefly
centrifuged to pellet the beads. Samples were boiled for 7 minutes, and then pulsecentrifuged again before subjecting samples to SDS-PAGE and western blot analysis as
described below.
For co-IP studies involving Lp(a)/apo(a) and/or apoB, the lysates were incubated
with either 1 µL of an anti-apo(a) antibody (a5) (205) or 5 µL of rabbit-anti-human apoB
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polyclonal antisera (Abcam) overnight at 4oC while gently shaking. After overnight
incubation, 30 µL of protein G-agarose beads was added and incubated for 2-3 hours at 4oC
while gently shaking. The beads were collected by brief centrifugation. The resulting
pellets were washed three times with ice cold RIPA buffer (50 mM Tris pH 7.4, 150 mM
NaCl, 20mM EDTA, 1% (w/v) sodium deoxycholate, 0.1% (w/v) SDS) and once with TE
buffer (10 mM Tris pH 7.5, 1mM EDTA). Samples were prepared as described above.
2.12 Western Blotting
For internalization studies, as well as secretion studies, cell lysates were subjected
to SDS-PAGE on 5-15% (Lp(a)-treated cells) or 7-15% (apo(a) treated cells)
polyacrylamide gradient gels. For co-IP studies, supernatants were subjected to SDS-PAGE
on 5-12% polyacrylamide gradient gels. All samples were prepared as 50 µL aliquots, and
re-suspended in 12 µL 2X SDS Sample Buffer supplemented with 7 µL of 100 mM DTT.
Samples were boiled for 7 minutes, and then pulse-centrifuged again before subjecting
samples to SDS-PAGE. The gels were electrophoretically transferred in ice cold transfer
buffer (25mM Tris pH 7.8, 1.92 M glycine, 10% (v/v) Methanol) for 2 hours at 0.2
milliamps onto PVDF membranes (Millipore) and blocked in 15 mL of either 50 mM Tris
pH7.6 containing 150 mM NaCl, 0.2% (v/v) Tween-20 (TBST) supplemented with 5%
(w/v) powdered non-fat milk or 50 mM Tris pH 7.6 containing 6 mM EDTA, 150mM NaCl,
0.05% (v/v) TritonX-100 (NET; Lp(a)/apo(a) blots only) supplemented with 5% (w/v)
powdered non-fat milk for 1 hour at room temperature while gently shaking. Following
blocking, the membranes were incubated with either mouse-anti-human apo(a) a5 antibody
(205), mouse-anti-human β-actin (Sigma), mouse-anti-human c-Myc epitope tag (NEQKLISEEDL-C; Invitrogen), mouse-anti-human apoB-100 (Santa Cruz), or goat-anti61

human sortilin (R&D Systems) overnight in the same blocking buffer at 4oC while gently
shaking. After overnight incubation, the membranes were washed three times with 15 mL
of TBST or NET for 10 minutes each while gently shaking. The membranes were then
subsequently incubated with either sheep-anti-mouse secondary antibody (GE Healthcare)
or bovine-anti-goat secondary antibody (Santa Cruz Biotechnology) in blocking buffer for
45 minutes at room temperature while gently shaking. The membranes were washed again
three times with TBST or NET for 10 minutes each while gently shaking. Immunoreactive
bands were visualized with SuperSignal® West Femto Maximum Sensitivity Substrate
(Thermo Scientific) using a FluorChem Q Imager (Alpha Innotech) and densitometric
quantification of resulting bands was performed using Alpha View software (Alpha
Innotech).
2.13 Immunofluorescence Studies
For apo(a) co-localization studies, HepG2 cells stably expressing 17K apo(a) were
seeded at 1.5 x 105 cells/well onto coverslips (pre-coated with 1 mg/mL gelatin type A)
placed in 24-well tissue culture plates. The cells were allowed to attach overnight in MEM
supplemented with 10% LPDS. The cells were extensively washed at 4oC as follows: three
times in PBS-BSA, twice in PBS-BSA containing 0.2M ε-ACA for 5 minutes each, and
three times with PBS. The cells were subsequently fixed with 3.7% paraformaldehyde
(Sigma) for 20 minutes at room temperature. The cells were washed once with PBS, and
then permeabilized with 0.2% (v/v) Triton X-100 in PBS for 5 minutes, and blocked with
blocking buffer (PBS containing 5% (w/v) BSA and 0.1% (v/v) Triton X-100) for 30
minutes while gently shaking at room temperature. The cells were subsequently incubated
with mouse-anti-human apo(a) antibody (a5) (205) (1:50), goat-anti-human sortilin
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polyclonal antibody (R&D Systems) (1:100), and either rabbit-anti-human mannosidase II
polyclonal antibody (Millipore) (1:100), rabbit-anti-human calnexin polyclonal antibody
(Abcam) (1:100), rabbit-anti-human EEA1 polyclonal antibody (Abcam) (1:250), or rabbitanti-human M6PR polyclonal antibody (Abcam) (1:100) in blocking buffer for 45 minutes
at 37oC.
Following primary antibody incubation, cells were washed three times with PBS
for 5 minutes each at room temperature and then incubated with Alexa Fluor 488conjugated donkey-anti-goat IgG (Invitrogen) (1:500), Alexa Fluor 568-conjugated
donkey-anti-mouse IgG (Invitrogen) (1:500), and Alexa Fluor 647-conjugated donkeyanti-rabbit IgG (Invitrogen) (1:500) in blocking buffer for 30 minutes at 37oC. Following
secondary antibody incubation, the cells were washed 3x with PBS, with the second wash
containing 1 µL/mL 4',6-diamidino-2-phenylindole (DAPI; Sigma), for 5 minutes each and
mounted to glass slides using anti-fade fluorescence mounting medium (Dako).
Immunofluorescence microscopy was performed on an Olympus IX81 confocal
microscope (Olympus America) using a 40x water immersion lens. Images were projected
using Olympus software. Post-acquisition, brightness-contrast adjustments were made in
Microsoft PowerPoint 2013 and were applied equally to all panels.
2.14 Sortilin Binding Assays
Purified soluble sortilin was dialyzed against 0.1M Na2CO3 pH 8.6 containing 0.2M
NaCl. The protein was then incubated with a 5-fold molar excess of Alexa Fluor 488
carboxylic acid, succinimidyl ester mixed isomers dissolved in dimethyl sulfoxide at 10
mg/mL (Invitrogen). The reaction mixture was rocked at 4oC for 4 hours to facilitate protein
labelling. The reaction was quenched through addition of 0.01 volumes of 1 M Tris, pH 8.0
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for 30 minutes at 4oC. Unbound dye was removed through extensive dialysis against 25
mM HEPES, pH 7.5 containing 300 mM NaCl, 50 mM KH2PO4, 0.1 mM CaCl2, and 10%
(v/v) glycerol. Labeled sortilin was concentrated using an Amicon Ultra-4 centrifugal filter
with a 10 kDa membrane cut-off (Millipore). The concentration of labeled-sortilin as
determined spectrophotometrically as previously described (112).
Binding curves were generated by incubating LDL or Lp(a), at 0.5 mg/mL, with
increasing amounts of soluble sortilin-Alexa 488 (25-800 nM) in binding buffer (25 mM
HEPES pH 7.4 containing 150 mM NaCl, 2 mM CaCl2, and 1% (w/v) BSA) for one hour
at 37oC. Glycerol was added to the samples to a final concentration of 10% (v/v) and the
samples were subjected to electrophoresis on 0.9% agarose gels (UltraPure Agarose,
Invitrogen) for 2 hours at 40V in 90 mM Tris pH 8.0 containing 80 mM borate and 2 mM
calcium lactate. In-gel scanning and quantification of the amount of labeled sortilin bound
to Lp(a) or LDL was performed with a FluorChem Q imager (Alpha Innotech). Intensity of
bands corresponding to bound sortilin were plotted as a function total concentration of
sortilin and the data were fit to a single site saturation ligand binding equation by non-linear
regression analysis using SigmaPlot 11.
2.15 Statistical Methods
For all internalization experiments, secretion studies, and pulse-chase experiments
involving 17KΔLBS7,8 and 17KΔLBS10 apo(a), comparisons between data sets were
performed using two-tail Student’s t-test assuming unequal variances
For pulse-chase experiments involving 17K apo(a), statistical analyses were
performed with the use of GraphPad Prism software, version 7.0 (Graphpad Software, Inc.).

64

Comparisons between samples were performed by one-way ANOVA using a Tukey posthoc analysis. Statistical significance was assumed at p < 0.05.
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CHAPTER 3: RESULTS

3.1 Sortilin Overexpression Alters Wild-Type Apo(a) Secretion in HepG2 Cells.
Sortilin expression has previously demonstrated an ability to alter the hepatic
secretion of VLDL (152, 206), apoB-100-containing lipoproteins (141, 206), or apoB-100
itself (142). We hypothesized that sortilin may likewise influence the secretion of apo(a),
and therefore affect Lp(a) levels in plasma. A

35

S-Met/Cys pulse-chase protocol was

utilized with hepatocellular carcinoma (HepG2) cells transiently expressing a recombinant
17K variant of apo(a) (17K r-apo(a)), which is a physiologically relevant apo(a) variant
that possesses eight KIV2 repeat domains. These cells were also transiently transfected with
an expression vector encoding sortilin or the corresponding empty vector as a control to
analyze increased sortilin expression on apo(a) secretion (Fig. 3.2 A-C).
As demonstrated in Fig. 3.2 B, there was a significant difference in the intracellular
accumulation of 17K r-apo(a) in cells overexpressing sortilin between 0-120 minutes of
chase time when compared to control cells. A significant difference in the accumulation of
secreted 17K r-apo(a) in cells overexpressing sortilin was also observed between 30-480
minutes of chase time when compared to control cells (Fig. 3.2 C). The earliest appearance
of mature apo(a) secreted into the medium was observed at 30 minutes for both control and
sortilin expressing cells (Fig. 3.2 A,C). Qualitative analysis of the fluorograms indicated
that there does not appear to be a notable difference in the rate of conversion from the
immature to mature form of apo(a) between cells expressing sortilin and control cells. The
rate of accumulation both intracellularly and in the medium is therefore altered by sortilin
overexpression without an apparent effect in the dynamics of secretion. Apo(a) is initially
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synthesized as a hypo-glycosylated precursor in the ER, with final maturation occurring in
the medial- to trans-Golgi compartment (82). As a result, N-linked glycans are added to
nascent apo(a) post-translationally, while O-linked glycosylation occurs in the Golgi
compartment (92). As a result, two unique apo(a) species are detectable in
immunoprecipitated, radiolabelled lysates that represent mature (top band) and immature
(bottom band) apo(a) (28, 76). As demonstrated in the representative fluorographs (Fig. 3.2
A), two bands in the lysates representing 17K r-apo(a) are observed. The initial,
intracellular r-apo(a) detected at 0 minutes of chase time (Fig. 3.2 A) is a higher mobility
species that likely represents an immature, incompletely glycosylated form. Conversion of
immature r-apo(a) to the mature, fully glycosylated, secretable form that is identical in
mobility to the 17K r-apo(a) detected in the conditioned medium was observed over the
time course of the experiment (Fig. 3.2 A). Radiolabelled immature 17K apo(a) was not
detectable in the lysates after 120 minutes of chase, while mature apo(a) was first observed
at 30 minutes of chase time. Small amounts of labelled mature apo(a) were still detectable
by 480 minutes of chase. (Fig. 3.2 A, B). With respect to lysates, the intracellular r-apo(a)
densitometric values are a representation of the total densities of the immature and mature
forms depicted in Fig. 3.2 A. The two bands could not be reliably resolved for quantitative
analysis, and were therefore analyzed in combination.
Multiple studies have identified sortilin as a novel mammalian sorting receptor. A
previous study monitoring a relationship between sortilin expression and LDL metabolism
found that some regulatory abilities were dependent upon a fully functioning cytoplasmic
domain (142). Furthermore previous studies have found that mutation of the canonical
YXXΦ tyrosine and DXXLL dileucine motifs (where X is any amino acid and Φ is any
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bulky, hydrophobic amino acid) in sortilin inhibit its abilities to function as a trafficking
receptor (142, 146, 168). To determine if the observed increase in apo(a) accumulation
brought about by sortilin overexpression was dependent upon its ability to act as a
trafficking receptor, we employed variants of sortilin in which this function was disrupted
by site-directed mutagenesis. Three mutants of human sortilin were generated through sitedirected mutagenesis. The tyrosine residue in the YXXΦ motif was substituted with an
alanine residue, yielding Y792A. Likewise, the leucine residues present in the DXXLL
motif were also substituted with alanine residues in combination, yielding L829/830A.
Finally, a premature stop codon was introduced into the sequence subsequent to the
transmembrane domain, yielding a sortilin variant, recognized as sortilinΔCT, which
completely lacked a cytoplasmic domain (Fig. 3.1).
HepG2 cells were transiently transfected with 17K r-apo(a), as well as with an
expression vector encoding either sortilinΔCT, sortilin Y792A, or sortilin L829/830A (Fig.
3.2 A-C). The three sortilin mutants expressed at similar levels in cell lysates, as determined
through western blot analysis (data not shown). As demonstrated by asterisks in Fig. 3.2 B,
there was a significant difference in the intracellular accumulation of 17K r-apo(a) in cells
overexpressing sortilin Y792A between 30-120 minutes of chase time compared to control
cells. No significant difference in intracellular accumulation was observed between control
cells and cells expressing either sortilinΔCT or L829/830A. A significant difference in the
accumulation of secreted 17K r-apo(a) in cells overexpressing both sortilin Y792A or
L829/830A was only observed at 480 minutes of chase time when compared to control cells
(Fig. 3.2 C, asterisks).

68

The defect in the ability of sortilin to increase both secreted and intracellular apo(a)
was most profound in cells expressing the sortilinΔCT mutant. In fact, the amount of apo(a)
in cells expressing sortilinΔCT was indistinguishable from that found in control cells. A
significantly lower effect on secreted apo(a) was observed between 30-480 minutes of
chase time, and a significantly reduced amount of intracellular apo(a) was observed
between 30-120 minutes of chase time, in sortilinΔCT expressing cells when compared to
cells expressing wild-type sortilin (Fig. 3.2 C, daggers). Reduction of the increasing effect
on apo(a) secretion was not as prominent in cells expressing sortilin Y792A or L829/830A.
The expression of either mutation led to lowered levels of both intracellular and secreted
17K r-apo(a) accumulation; however, levels of intracellular r-apo(a) were not significantly
different from cells expressing wild-type sortilin (Fig. 3.2 B). This trend was also observed
with secreted r-apo(a) accumulation, with the exception at 30 minutes of chase time, where
a significantly lower amount of 17K r-apo(a) was secreted in cells expressing either sortilin
Y792A or L829/830A when compared to sortilin expressing cells (Fig. 3.2 C, daggers).
The earliest appearance of mature apo(a) secreted into the medium was again observed at
30 minutes for cells expressing both empty vector and sortilin (Fig. 3.2 A, C). Similar to
cells expressing wild-type sortilin, qualitative analysis of the fluorograms indicated that
there is no notable difference in the rate of conversion from the immature to mature form
of apo(a) in cells expressing the sortilin mutants. The rate of accumulation in cells
expressing the mutants is lowered both intracellularly and in the medium compared to cells
expressing wild-type sortilin without an apparent effect in the dynamics of secretion.
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Figure 3.1: Recombinant sortilin constructs utilized in study. Sortilin is a type-1
transmembrane protein that is composed of an extracellular VPS10 domain, a single
transmembrane domain, and a cytoplasmic tail containing multiple, canonical sorting
motifs. From left to right: wild-type sortilin, sortilinΔCT (lacking a carboxyl terminal
domain), sortilin Y792A (lacking a functional YXXΦ sorting motif), and sortilin
L829/830A (lacking a functional DXXLL sorting motif).
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Figure 3.2: Effect of sortilin overexpression on intracellular accumulation and secretion
of apo(a). Pulse-chase analysis of HepG2 cells transiently expressing either a recombinant
(A) 17K apo(a) as well as either sortilin, sortilinΔCT, sortilin Y792A, sortilin
L829A/L830A, or the corresponding empty vector control (pcDNA). Cells were starved in
–Cys/Met media for 60 minutes, pulse-labelled for 60 minutes with 35S-Met/Cys, and
subsequently chased in unlabelled media for 0-480 minutes. Cell lysates (left) and media
(right) were collected at the indicated times of chase, apo(a) was immunoprecipitated, and
analyzed by 7% SDS-PAGE and fluorography. Representative fluorograms are shown. The
lower band (~450 kDa) represents immature, hypoglycosylated apo(a) while the upper band
(~550 kDa) represents mature, secretable apo(a) (B) Resulting densities of intracellular
17K apo(a) accumulation (combination of immature and mature 17K apo(a) bands) at the
indicated chase times respectively. (C) Resulting densities of secreted 17K apo(a)
accumulation at the indicated chase times respectively. Densitometric analysis was
conducted using AlphaView software, normalized to the maximum density observed for
pcDNA vector, and plotted as a function of time. The data corresponds to the means ± SEM
of at least 3 independent experiments. Significance compared to pcDNA is indicated
through asterisks, where *p<0.05 and **p<0.01. Significance compared to wild-type
sortilin is indicated through daggers, where †p<0.05 and ††p<0.01. The colours correspond
to the legend.
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3.2 Sortilin Appears to Predominantly Co-Localize With Apo(a) in Endosomal
Compartments
Sortilin predominantly localizes within the TGN and endosomal compartments,
with <10% of the protein localizing at the cell surface (134, 135, 143, 146). Based on the
concept that sortilin predominantly functions as an intracellular sorting protein, and that
sortilin overexpression can alter apo(a) secretion (Fig. 3.2), we hypothesized that sortilin
may co-localize intracellularly with apo(a). To explore this possibility, we studied if
endogenous sortilin co-localized with apo(a) in HepG2 cells stably expressing 17K-rapo(a) using immunofluorescence microscopy. As observed in Fig. 3.3, co-localization of
apo(a) and sortilin was observed (yellow) in merge panels. Furthermore, Fig. 3.3 B-D
demonstrated co-localization of sortilin and a Golgi specific marker (mannosidase II), an
early endosome specific marker (EEA1), and a late endosome specific marker (M6P, teal).
Triple co-localization of apo(a) and sortilin in both early and late endosomal compartments
(white) is also observed in Fig. 3.3 C, D. Conversely, triple co-localization of apo(a) and
sortilin with an ER specific marker (calnexin) or mannosidase II was not observed (Fig. 3.3
A, B).
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Figure 3.3: Sortilin and apo(a) display co-localization within endosomal compartments.
HepG2 cells were extensively washed, fixed and immunostained with a mouse anti-apo(a),
goat anti-sortilin, and either a rabbit anti-calnexin, anti-mannosidase II, anti-EEA1, or antiM6P antibody. The cells were then incubated with the corresponding secondary antibodies
that were linked to different fluorophores. (A-D) Co-localization is observed between
sortilin, apo(a) and (C) an early endosome specific marker (EEA1) as well as (D) a late
endosome specific marker (M6P). Co-localization between apo(a) and sortilin is observed
as yellow. Co-localization between apo(a) and the various compartmental markers is
observed as magenta, whereas co-localization between sortilin and the various
compartmental markers is observed as teal. Triple co-localization between apo(a), sortilin,
and compartmental markers is observed as white in all merge panels.
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3.3 Sortilin Overexpression Does Not Alter Secretion of an Apo(a) Variant That
Possesses Mutations in the Weak LBS of KIV7, 8.
Since apoB-100 secretion is regulated by sortilin expression (142), and apo(a)
secretion has been suggested to couple with that of apoB (77, 82), a 17K apo(a) variant that
is unable to non-covalently associate with apoB-100 was utilized to determine if sortilin
overexpression could alter the secretion of this mutant in a manner similar to that of 17K
r-apo(a). Previous work has demonstrated that the weak LBS of KIV7, 8 are required for the
initial non-covalent interactions that occur between apo(a) and apoB-100 in Lp(a) assembly
(62). Therefore, a 35S-Met/Cys pulse-chase protocol was used with HepG2 cells transiently
expressing a recombinant 17KΔLBS7,8-pRK5 apo(a) variant (17KΔLBS7,8 r-apo(a)). These
cells were also transiently transfected with an expression vector encoding sortilin or the
corresponding empty vector to analyze the relationship between sortilin overexpression and
secretion of 17KΔLBS7,8 r-apo(a) that cannot participate in non-covalent interaction with
apoB-100 (Fig. 3.4 A-C). As demonstrated in Fig. 3.4 B, C, there was no significant
difference observed in the accumulation of both intracellular and secreted 17KΔLBS7,8 rapo(a) between cells overexpressing sortilin and control cells. The kinetics of intracellular
maturation and secretion of 17KΔLBS7,8 r-apo(a) were similar to those of wild-type 17K rapo(a) (Fig. 3.2):the earliest appearance of mature 17KΔLBS7,8 r-apo(a) was observed at
30 minutes for cells expressing sortilin and control cells (Fig. 3.4 A, C). Radiolabelled,
immature 17KΔLBS7,8 r-apo(a) was barely detectable in the lysates after 60 minutes of
chase, while mature apo(a) was first observed at 30 minutes of chase time. Small amounts
of labelled, mature apo(a) were still detectable by 480 minutes of chase (Fig. 3.4 A, B).
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However, the 17KΔLBS7,8 r-apo(a) was completely resistant to the effects of
overexpressing sortilin.
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Figure 3.4: Sortilin overexpression does not alter the secretion of 17KΔLBS7,8 apo(a).
Pulse-chase analysis of HepG2 cells transiently expressing either a recombinant (A)
17KΔLBS7,8 apo(a) as well as either sortilin or the corresponding empty vector control
(pcDNA). Cells were starved in –Cys/Met DMEM for 60 minutes, pulse-labelled for 60
minutes with 35S-Met/Cys, and subsequently chased in unlabelled media for 0-480 minutes.
Cell lysates (left) and media (right) were collected at the indicated times of chase, apo(a)
immunoprecipitated, and analyzed by 7% SDS-PAGE and fluorography. Representative
fluorograms are shown. The lower band (~450 kDa) represents immature,
hypoglycosylated apo(a) while the upper band (~550 kDa) represents mature, secretable
apo(a) (B) Resulting densities of intracellular 17KΔLBS7,8 apo(a) accumulation
(combination of immature and mature 17K apo(a) bands) at the indicated chase times
respectively. (C) Resulting densities of secreted 17KΔLBS7,8 apo(a) accumulation at the
indicated chase times respectively. Densitometric analysis was conducted as described in
the legend to Figure 3.2. Significance compared to pcDNA is indicated through asterisks,
where *p<0.05.
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3.4 The Secretion of an Apo(a) Variant Lacking the Strong Lysine Binding Site in
KIV10 is Increased by Sortilin Overexpression.
A variety of pathogenic mechanisms attributed to the apo(a) component of Lp(a)
are associated with the proper functionality of the strong LBS in KIV10, which mediates
non-covalent, lysine-dependent interactions between Lp(a) and protein substrates (13).
Therefore, a role for the LBS in KIV10 in facilitating the ability of sortilin to alter apo(a)
secretion was assessed. Pulse-chase analysis was performed in HepG2 cells transiently
transfected with a recombinant variant of apo(a) that lacked a functional LBS in KIV10,
identified as 17KΔLBS10 r-apo(a). These cells were also transiently transfected with an
expression vector encoding sortilin or the corresponding empty vector (Fig. 3.5 A-C).
Interestingly, a significant difference in the intracellular accumulation of 17KΔLBS10 rapo(a) in cells overexpressing sortilin was only observed at the initial point of chase time
when compared to control cells (Fig. 3.5 B). On the other hand, a significant difference in
the accumulation of secreted 17KΔLBS10 r-apo(a) in cells overexpressing sortilin was
observed between 120-480 minutes of chase time when compared to control cells (Fig. 3.5
C). Similar to previous results (Fig. 3.2, 3.4 A, C), the earliest appearance of mature apo(a)
secreted into the medium was observed at 30 minutes for both empty vector and sortilin
expressing cells (Fig. 3.5 A, C). Radiolabelled, immature 17KΔLBS10 r-apo(a) was
detectable throughout the chase period; however, the majority was converted to mature
apo(a) after 120 minutes of chase time. Mature 17KΔLBS10 r-apo(a) was first observed at
30 minutes of chase time, and small amounts of labelled mature apo(a) were still detectable
by 480 minutes of chase (Fig. 3.5 A).
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Figure 3.5: Sortilin overexpression increases the secretion of a 17KΔLBS10 apo(a)
variant. Pulse-chase analysis of HepG2 cells transiently expressing either a recombinant
(A) 17KΔLBS10 apo(a) as well as either sortilin or the corresponding empty vector control
(pcDNA). Cells were starved in –Cys/Met DMEM for 60 minutes, pulse-labelled for 60
minutes with 35S-Met/Cys, and subsequently chased in unlabelled media for 0-480 minutes.
Cell lysates (left) and media (right) were collected at the indicated times of chase, apo(a)
immunoprecipitated, and analyzed by 7% SDS-PAGE and fluorography. Representative
fluorograms are shown. The lower band (~450 kDa) represents immature,
hypoglycosylated apo(a) while the upper band (~550 kDa) represents mature, secretable
apo(a) (B) Resulting densities of intracellular 17KΔLBS10 r-apo(a) accumulation
(combination of immature and mature 17K apo(a) bands) at the indicated chase times
respectively. (C) Resulting densities of secreted 17KΔLBS10 r-apo(a) accumulation at the
indicated chase times respectively. Densitometric analysis was conducted as described in
the legend to Figure 3.2. Significance compared to pcDNA is indicated through asterisks,
where *p<0.05.
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3.5 Knockdown of Sortilin Expression in HepG2 Cells Reduces Apo(a) Secretion
To provide independent evidence that sortilin promotes apo(a) secretion, we
reduced sortilin expression through siRNA treatment directed towards SORT1 mRNA.
Knockdown treatment was conducted in HepG2 cells that were stably expressing a wildtype 17K apo(a) variant, thus providing a model that would better represent endogenous
expression of both apo(a) and sortilin in hepatocytes. Pulse-chase analysis was performed
as described above. Knockdown experiments utilized cells that were transiently transfected
with either a scrambled siRNA that acted as a negative control for knockdown or siRNA
directed towards SORT1. As demonstrated in Fig. 3.6 B, siRNA-mediated knockdown of
sortilin expression reduced the intracellular accumulation of 17K apo(a), with significant
differences observed at 30 and between 120-480 minutes of chase time when compared to
control cells. Knockdown of sortilin expression also led to a concomitant reduction in the
amount of 17K apo(a) secreted from cells, as a significant difference was observed between
120-480 minutes of chase time when compared to control cells (Fig. 3.6 C). No significant
differences were observed in the accumulation of both intracellular and secreted apo(a)
between cells transfected with the scrambled siRNA and control cells (Fig. 3.6 B, C).
In support of a role for sortilin in mediating apo(a) secretion, a significant increase
in the accumulation of both intracellular and secreted apo(a) is observed in cells
overexpressing wild-type sortilin compared to control cells. Specifically, a significant
increase is observed in intracellular 17K r-apo(a) accumulation between 0-240 minutes of
chase time, and between 60-480 minutes of chase time for secreted 17K r-apo(a). These
data provide valuable confirmation for the ability of sortilin overexpression to regulate
apo(a) secretion in the setting of hepatocytes that are stably expressing apo(a). In contrast
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to HepG2 cells transiently expressing apo(a), the majority of immature to mature
conversion of stably expressing apo(a) occurred at 60 minutes as opposed to 30 minutes of
chase time. Significant differences in apo(a) secretion are also observed between cells
expressing sortilin and cells transiently transfected with the scrambled siRNA or siRNA
directed against sortilin. Fig. 3.6 B demonstrated significantly lower amounts of
intracellular 17K r-apo(a) accumulation between 0-240 minutes of chase time, and between
120-480 minutes of chase time for secreted 17K r-apo(a) in cells transfected with the
scrambled siRNA when compared to wild-type sortilin. Cells treated with siRNA directed
against sortilin demonstrated significantly lower amounts of intracellular 17K apo(a)
accumulation for all time points, and between 60-480 minutes of chase time for secreted
17K r-apo(a) when compared to cells overexpressing wild-type sortilin. (Fig. 3.6 C).
Radiolabelled, immature 17K apo(a) was not detectable in the lysates after 240 minutes of
chase, while mature apo(a) was first detected after 30 minutes of chase time for all samples.
Small amounts of labelled, mature apo(a) were still detectable by 480 minutes of chase
(Fig. 3.6 A, B)
Western blot analysis was used to determine the extent of sortilin knockdown in
cells treated with siRNA compared to the scrambled control. SDS-PAGE analysis was
performed on whole cell lysates 48 hours following siRNA treatment (Fig. 3.6 D). After
correction using the expression of β-actin expression as an internal control, transfection
with sortilin siRNA reduced sortilin expression by 53.7% compared to transfection with
the scrambled siRNA.
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Figure 3.6: Sortilin overexpression increases the secretion of a stably expressed 17K
apo(a) variant, while knockdown of sortilin expression reduces levels of secreted 17K
apo(a). Pulse-chase analysis of HepG2 cells stably expressing a recombinant (A) 17K
apo(a) and transiently transfected with either a plasmid vector encoding sortilin, the
corresponding empty vector control (pcDNA), sortilin targeting siRNA, or a corresponding
scrambled siRNA that acts as a negative control (scramble). Cells were starved in –Cys/Met
DMEM for 60 minutes, pulse-labelled for 60 minutes with 35S-Met/Cys, and subsequently
chased in unlabelled media for 0-480 minutes. Cell lysates (left) and media (right) were
collected at the indicated times of chase, apo(a) immunoprecipitated, and analyzed by 7%
SDS-PAGE and fluorography. Representative fluorograms are shown. The lower band
(~450 kDa) represents immature, hypoglycosylated apo(a) while the upper band (~550
kDa) represents mature, secretable apo(a) (B) Resulting densities of intracellular 17K
apo(a) accumulation (combination of immature and mature 17K apo(a) bands) at the
indicated chase times respectively. (C) Resulting densities of secreted 17K apo(a)
accumulation at the indicated chase times respectively. Densitometric analysis was
conducted as described in the legend to Figure 3.2. (D) Western blot analysis of sortilin
expression in HepG2 cells ectopically expressing an empty vector control, wildtype sortilin,
siRNA against sortilin expression, or a scrambled control respectively. Band intensities
were corrected using the expression of β-actin, and knockdown percentage was determined
by comparing band intensities of the scrambled siRNA with that of siRNA directed against
sortilin. The data corresponds to the means ± SEM of at least 3 independent experiments.
Significance compared to pcDNA is indicated through asterisks, where *p<0.05 and
**p<0.01. Significance compared to sortilin is indicated through daggers, where †p<0.05
and ††p<0.01. The colours correspond to the legends.
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3.6 Sortilin Overexpression Alters Lp(a), but not Apo(a), Internalization by HepG2
Cells.
Sortilin can regulate the metabolism of LDL particles by acting as a bona fide
internalization receptor (142, 153). Furthermore, this ability is dependent upon the ability
of sortilin to act as an intracellular trafficking receptor (142). Previous research conducted
by our group has demonstrated that exposure to exogenous PCSK9 can significantly reduce
both Lp(a) and apo(a) internalization in HepG2 cells (112). We therefore evaluated the role
of sortilin in regulating Lp(a) and apo(a) catabolism in HepG2 cells. We also sought to
determine if the relationship between sortilin and PCSK9 was associated with regulating
Lp(a) and apo(a) catabolism. Overexpression of sortilin resulted in a significant increase in
the amount of Lp(a) internalized when compared to control cells (Fig. 3.7 A, asterisks). To
confirm this finding, we generated internalization data in primary hepatocytes harvested
from C57 BL/6 mice. Isolated primary hepatocytes from mice were transiently transfected
with either an expression vector encoding sortilin or the corresponding empty vector as a
control, and a similar increase in Lp(a) internalization was observed in cells overexpressing
sortilin when compared to control cells (Fig. 3.7 B, asterisks). Conversely, no significant
increase in internalization of 17K r-apo(a) was observed in HepG2 cells upon
overexpression of sortilin (Fig. 3.9). Treatment of HepG2 cells with purified, recombinant
PCSK9 resulted in a significant reduction in both Lp(a) and apo(a) internalization, either
in the presence or absence of sortilin overexpression. Notably, a significant difference in
Lp(a) internalization was seen between PCSK9-treated cells overexpressing sortilin
compared to PCSK9-treated control cells (Fig. 3.7 A, daggers). No significant difference
in apo(a) internalization was seen between PCSK9-treated cells either overexpressing
sortilin or not (Fig. 3.9 ).
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To determine if the effect of sortilin on Lp(a) internalization was dependent upon
the ability of sortilin to act as a trafficking receptor, HepG2 cells were transiently
transfected with the trafficking variants employed in section 3.1 (see above). While a
significant increase in Lp(a) internalization was observed in cells overexpressing the
Y792A mutant, no increase was observed in cells overexpression of the sortilinΔCT or
L829/830A mutants when compared to control cells (Fig. 3.7 A). These findings were
recapitulated in primary mouse hepatocytes transfected with expression plasmids encoding
these sortilin mutants; however, a significant increase in Lp(a) internalization by cells
overexpressing the Y792A mutant was not observed (Fig. 3.7 B, asterisks). The defect in
the ability of sortilin to increase Lp(a) internalization in HepG2 cells was most profound in
cells overexpressing either the sortilinΔCT or L829/830A mutants. Interestingly,
significantly lower amounts of Lp(a) were internalized in cells overexpressing the
sortilinΔCT or Y792A mutants when compared to cells overexpressing wild-type sortilin.
A moderation reduction in Lp(a) internalization was observed in cells overexpressing the
L829/830A mutant when compared to cells overexpressing wild-type, but the difference
did not reach statistical significance (Fig. 3.7 A, double daggers). For internalization
experiments in primary mouse hepatocytes, the defect in the ability of sortilin to increase
Lp(a) internalization was most profound in cells overexpressing the sortilinΔCT mutant.
No statistically significant difference in the amount of Lp(a) internalized was observed
between cells overexpressing the Y792A or L829/830A mutants and cells overexpressing
wild-type sortilin (Fig. 3.7 B, double daggers).
To determine if endogenous sortilin can regulate Lp(a) catabolism, sortilin
knockdown experiments were conducted in HepG2 cells. Knockdown of human sortilin
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did not significantly reduce the amount of Lp(a) internalized in comparison to a scrambled
control (Fig. 3.8). After correction using the expression of β-actin as an internal control,
transfection with sortilin siRNA reduced sortilin expression by 59.4% compared to
transfection with the scrambled siRNA. Cells treated with PCSK9 demonstrated a
significant reduction in the levels of internalized Lp(a) when compared to cells that were
not treated with PCSK9 (Fig. 3.8, daggers).
To gain further insights into the molecular mechanism by which sortilin affects
Lp(a) internalization, HepG2 cells were treated with a lysine analog, ε-ACA, to inhibit
Lp(a) and apo(a) internalization by lysine binding receptors such as the plasminogen
receptors. Addition of ε-ACA resulted in a significant reduction in Lp(a) internalization in
HepG2 cells overexpressing either an empty vector control or wild-type sortilin. A
significant difference between ε-ACA-treated cells expressing sortilin and an empty vector
control was not observed (Fig. 3.10 E). As before, a significant difference in the amount of
Lp(a) internalized was observed in untreated cells overexpressing sortilin when compared
to the empty vector control (Fig. 3.7 A, B, Fig. 3.10 A). Similarly, no significant difference
was observed in the amounts of 17K apo(a) internalized with sortilin overexpression;
however, ε-ACA treatment led to a significant reduction in the levels of apo(a)
internalization (Fig. 3.9, Fig. 3.10 B).
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Figure 3.7: Sortilin overexpression increases Lp(a) internalization in hepatocytes.
Internalization assays in (A) HepG2 cells and (B) primary mouse hepatocytes transiently
transfected with a plasmid vector encoding sortilin or various sortilin trafficking variants.
Control cells were transfected with the corresponding empty expression vector (pcDNA).
Cells were grown for 16 hours in LPDS media and subsequently incubated with 10 µg/mL
Lp(a) in Opti-MEM in the (A) presence or absence of 20 µg/mL PCSK9 for 4 hours. In all
cases, the cells were extensively washed to remove any cell bound Lp(a)/apo(a), lysed, and
subjected to western blot analysis to determine the amount of Lp(a)/apo(a) internalized.
Densitometric analysis was conducted using AlphaView software. Values for Lp(a)/apo(a)
were corrected using the signal for ß-actin, and normalized to the resulting density observed
for pcDNA vector or scrambled siRNA control. The data corresponds to the means ± SEM
of at least 3 independent experiments. Significance compared to pcDNA or scrambled
siRNA is indicated through asterisks, where *p<0.05 and **p<0.01. Significance between
cells treated with PCSK9 and non-treated cells is indicated through daggers, where †p<0.05
and ††p<0.01. Significance between cells overexpressing sortilin and cells overexpressing
the various sortilin trafficking mutants is indicated through double daggers, where ‡p<0.05
and ‡ ‡p<0.01.
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Figure 3.8: Knockdown of sortilin expression does not alter Lp(a) internalization in
HepG2 cells. Internalization assays in HepG2 cells transiently transfected with siRNA
directed towards sortilin or a negative control scrambled siRNA. Cell treatments and data
analysis were conducted as described in the legend to Figure 3.7. Significance between
cells treated with PCSK9 and non-treated cells is indicated through daggers, where
††p<0.01.
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Figure 3.9: Sortilin overexpression does not alter apo(a) internalization in HepG2 cells.
Internalization assays in HepG2 cells transiently transfected with a plasmid vector encoding
sortilin or the corresponding empty vector control (pcDNA). Cells were grown for 16 hours
in LPDS media and subsequently incubated with 200 nM apo(a) in Opti-MEM in the
presence or absence of 20 µg/mL PCSK9 for 4 hours. Data analysis was conducted as
described in the legend to Figure 3.7. Significance between cells treated with PCSK9 and
non-treated cells is indicated through daggers, where ††p<0.01.
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Figure 3.10: Treatment with ε-ACA inhibits the ability of sortilin overexpression to
increase Lp(a) internalization in HepG2 cells. Internalization assays in HepG2 cells
transiently transfected with a plasmid vector encoding sortilin or the corresponding empty
vector control (pcDNA). Cells were grown for 16 housr in LPDS media and subsequently
incubated with (A) 10 µg/mL Lp(a) or (B) 200 nM 17K r-apo(a) in Opti-MEM in the
presence or absence of 200 mM ε-ACA for 4 hours. Data analysis was conducted as
described in the legend to Figure 3.7. Significance between cells treated with PCSK9 and
non-treated cells is indicated through daggers, where †p<0.05 and ††p<0.01.
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3.7 Sortilin Overexpression Can Increase Lp(a), but not Apo(a) Internalization in
Human Fibroblasts Lacking a Functional LDLR
Research has demonstrated that sortilin can increase the catabolic rate of LDL in
LDLR-/- mice, therefore identifying a novel LDLR-independent pathway for LDL
catabolism (142). While controversial, evidence for a role for the LDLR in regulating Lp(a)
catabolism has been previously demonstrated (102, 104, 110, 112). Therefore, we sought
to determine if there was an association between LDLR activity and the increase in Lp(a)
internalization mediated by sortilin overexpression. This was achieved through the
utilization of primary human fibroblasts that were isolated from individuals with familial
hypercholesterolemia (FH) or an unaffected control individual. The three cell lines used
were GM01386, which was isolated from the control individual that possessed a fully
functional LDLR; GM01355, which was isolated from an individual with severe
hypercholesterolemia and partially negative LDLR activity; and GM00701, which was
isolated from an individual that possessed <1% LDLR activity. Sortilin overexpression led
to a significant increase in the amount of Lp(a) internalized in all three cell lines when
compared to control cells transfected with the corresponding empty vector (Fig. 3.11 A).
Conversely, sortilin overexpression did not significantly increase the amount of 17K rapo(a) internalized by any of the cell lines (Fig. 3.11 B). These results are consistent with
the findings obtained in HepG2 cells, where sortilin overexpression significantly altered
Lp(a), but not apo(a), internalization (Fig. 3.7 A, B, Fig. 3.9).
A reduction in Lp(a) internalization was observed in the FH cell lines when
compared to the non-FH cell line, thus agreeing with previous research that demonstrated
a role for the LDLR in Lp(a) catabolism (102, 104, 112). Treatment of HepG2 cells with
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PCSK9 resulted in a significant reduction in Lp(a) internalization in the GM01386 cell line
only (Fig. 3.11 A). This is in agreement with the general accepted physiological function
of PCSK9, which is to facilitate the degradation of the LDLR (188). With respect to apo(a)
internalization, exogenous PCSK9 treatment did not significantly reduce internalization
levels (Fig. 3.11 B). This matches our previous study, in which the same primary human
fibroblast cell lines were utilized to study apo(a) internalization (112).
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Figure 3.11: Sortilin overexpression increases the internalization of Lp(a) in primary
human fibroblasts lacking functional LDL receptors. Non-FH and FH fibroblasts used
were: GM01386 (normal LDLR function); GM01355 (partially negative LDLR activity);
and GM00701 (<1% LDLR activity). Cells were transiently transfected with an expression
vector encoding sortilin or the corresponding empty vector (pcDNA) were grown for 16
hours in LPDS. They were subsequently incubated with (A) 10 µg/mL Lp(a) or (B) 200
nM 17K in the presence or absence of 20 µg/mL PCSK9. The cells were extensively
washed to remove any cell bound Lp(a) or apo(a) and subjected to western blot analysis to
determine the amount of Lp(a)/apo(a) internalized. Data analysis was conducted as
described in the legend to Figure 3.7. Significance compared to pcDNA is indicated through
asterisks, where *p<0.05 and **p<0.01. Significance between cells treated with PCSK9
and non-treated cells is indicated through daggers, where ††p<0.01.
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3.8 Sortilin Does Not Bind to Lp(a) or Apo(a) in vitro
Previous research has demonstrated that sortilin can directly bind to the apoB-100
component of LDL in hepatocytes (141, 142). This association allows for sortilin to act as
a novel cell surface receptor for apoB-100 containing lipoproteins. Since Lp(a) contains an
apoB-100 moiety, we investigated whether Lp(a), or 17K r-apo(a), could bind to sortilin in
vitro. An expression plasmid encoding a soluble variant of sortilin was generated through
the introduction of a premature stop codon prior to the transmembrane domain. The soluble
variant was purified and then fluorescently labelled in order to perform in vitro binding
analysis with Lp(a). LDL was utilized as a positive control. Band corresponding to LDL
bound to sortilin were quantified and fit to a one site saturation ligand binding equation by
non-linear regression analysis. We found that Lp(a) did not bind to sortilin in vitro (Fig.
3.12 A, C); however, sortilin was able to bind LDL with a KD of ~ 435 nM (Fig. 3.12 B,
C).
To further substantiate the inability of sortilin to physically interact with Lp(a), we
performed co-immunoprecipitation of endogenous sortilin present in lysates of HepG2 cells
with Lp(a), using an anti-apo(a) antibody. Co-immunoprecipitation of endogenous sortilin
and apoB, with anti-apoB antiserum, was performed as a positive control. In these studies,
a band of the appropriate size for sortilin was detectable in western blot analysis of fractions
immunoprecipitated using the anti-apoB antibody following immunoblotting with an antisortilin antibody, indicating that an interaction occurred between apoB and sortilin in
solution (Fig. 3.12 D). However, no observable sortilin band was present in HepG2 cell
lysates containing added Lp(a). Furthermore, immunoprecipitates of HepG2 cell lysates
stably expressing 17K r-apo(a) also lacked an immunoreactive band corresponding to
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sortilin (Fig. 3.12 D). Similar co-immunoprecipitation experiments were conducted with
an anti-sortilin antibody. However, neither Lp(a) nor apo(a) co-immunoprecipitated with
sortilin present in HepG2 cell lysates (Fig. 3.12 E).
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Fig 3.12: Sortilin binds to LDL in vitro but not to Lp(a) or apo(a). Various concentrations
of sortilin-Alexa 488 were incubated with 0.5 mg/mL of purified LDL or Lp(a) for one
hour at 37oC. Samples containing soluble sortilin and either Lp(a) (A) or LDL (B) were
resolved on 0.9% agarose gels. (C) Bands corresponding to either LDL-bound sortilin were
quantified and fit to a one site saturation binding equation by non-linear regression analysis
using SigmaPlot 11. KD of LDL ~ 435 nM (n=2). (D) Lysates prepared from HepG2 cells
either stably expressing 17K r-apo(a) or incubated with 10 µg/mL of Lp(a) were subjected
to immunoprecipitation with either anti-apo(a) or anti-apoB antibodies, as indicated.
Immunoprecipitates were analyzed by SDS-PAGE on 7-12% gradient polyacrylamide gels,
followed by immunoblotting for apoB, apo(a), and sortilin (n=3). (E) Lysates from HepG2
cells either stably expressing 17K r-apo(a) or incubated with 10 µg/mL of Lp(a) were
subjected to immunoprecipitation with an anti-sortilin antibody. Immunoprecipitates were
analyzed by SDS-PAGE on 7-15% gradient polyacrylamide gels, followed by
immunoblotting for apo(a), sortilin, or a no antibody control (n=3).
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3.9 Naturally Occurring Sortilin Polymorphisms May Be Associated With Elevated
Levels of Lp(a) in Human Patients
Deep sequencing of the SORT1 locus was performed in a cohort of patients
possessing elevated Lp(a) levels in an attempt to identify novel, common SNPs within the
gene that might influence the role of sortilin in Lp(a) synthesis or catabolism. The resulting
analysis led to the discovery of 19 rare, heterozygous missense or splicing variants within
SORT1. Interestingly, 9 individuals possessed Lp(a) within the top 5th percentile for the
general population. The seven polymorphisms in these 9 individuals were: I124V, K205N,
K302E, K404Y, E444Q, E447G, and V650M (Fig. 3.13).
To explore a potential relationship between these polymorphisms and elevated
levels of plasma Lp(a), site-directed mutagenesis was performed to generate the variants of
interest. Internalization assays were performed to determine if the SNPs could promote
Lp(a) catabolism in a manner similar to sortilin overexpression. Any notable reduction in
the amount of Lp(a) internalized could be suggestive of a possible mechanism contributing
to elevated plasma Lp(a) levels. Therefore, HepG2 cells were transfected with expression
vectors encoding either sortilin, or the various polymorphic variants, or the corresponding
empty vector as a control. As demonstrated in Fig. 3.14 A, differences are observed in the
amount of Lp(a) internalized in cells expressing the polymorphic SORT1 variants when
compared to either control cells or cells overexpressing sortilin. The amount of Lp(a)
internalized in cells overexpressing the I124V and E444Q variants was comparable to cells
overexpressing sortilin. A moderate decrease in the amount of Lp(a) internalized was
observed in cells overexpressing the K205N and K302E variants when compared to cells
overexpressing sortilin. A defect in the ability of sortilin to increase Lp(a) internalization
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was most profound in cells overexpressing the F404Y and V650M variants (Fig. 3.14 A).
The amount of Lp(a) internalized in cells overexpressing F404Y was comparable to control
cells, while a modest reduction in Lp(a) internalization was observed in cells
overexpressing V650M when compared to control cells. Overall, the data indicate that
F404Y and V650M are possible loss-of-function sortilin variants with respect to Lp(a)
internalization.
Since the data in this thesis have demonstrated the effect of sortilin expression and
apo(a) secretion, we postulated that the SORT1 polymorphisms may contribute to elevated
Lp(a) levels by giving rise to an increased rate of apo(a) production and secretion.
Overexpression of the sortilin variants in HepG2 cells had differential effects with respect
to apo(a) secreted in the medium when compared to cells overexpressing sortilin (Fig. 3.14
B). The amount of apo(a) secreted into the media by cells overexpressing the I124V variant
was comparable to cells overexpressing sortilin. A modest decrease in the amount of apo(a)
secreted was observed in cells overexpressing the K205N and V650M variants when
compared to cells overexpressing sortilin. Interestingly, large increase in apo(a) secretion
was observed in cells overexpressing the F404Y variant when compared to cells
overexpressing sortilin. Conversely, the amount of apo(a) secreted in cells overexpressing
the K302E variant was comparable to control cells, while a reduction in apo(a) secretion
was observed in cells overexpressing E444Q when compared to control cells (Fig. 3.14 B).
We have documented that sortilin overexpression not only increases apo(a)
secretion, but the accumulation of intracellular apo(a) as well (Fig. 3.2). Therefore, HepG2
cells transiently transfected with expression vectors encoding either sortilin, or the various
polymorphic variants, or the corresponding empty vector as a control were lysed to
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simultaneously analyze intracellular apo(a) accumulation (Fig. 3.14 C). All of the
polymorphic variants led to an increase in the intracellular accumulation of apo(a). Cells
overexpressing K205N had the most robust increase in intracellular apo(a) accumulation
when compared to control cells. Cells expressing I124V and F404Y demonstrated
comparable levels of intracellular apo(a) accumulation to cells overexpressing sortilin (Fig.
3.14 C). A modest decrease in intracellular apo(a) accumulation was observed in cells
overexpressing V650M when compared to cells overexpressing sortilin. Cells
overexpressing K302E and E444Q demonstrated only a modest increase in the amount of
intracellular apo(a) accumulated when compared to control cells (Fig. 3.14 C). Overall, the
data indicate that certain variants show an altered function of sortilin with respect to apo(a)
secretion. Western blot analysis of the expression of these plasmids demonstrated that the
E447G variant was not expressed (data not shown). Data on this variant are therefore not
available.
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Figure 3.13: Polymorphisms within the VPS10 domain of sortilin. The crystal structure
of the VPS10 domain of sortilin is rendered based on PDB #4PO7 (207) using Polyview
(http://polyview.cchmc.org/polyview3d.html). Two views of the structure are shown,
rotated 180° relative to each other along the vertical axis. The 10-bladed beta propeller is
in silver, the 10CC-a subdomain is in blue, and the 10CC-b subdomain is in green. The
conserved cysteine residues within the VPS10 domain are shown in red. Side chains of
residues that were mutated are labelled and shown in cyan (Ile124, Lys204, Lys302,
Phe404, Glu444, Glu447, Val*650). The residue in the 650 position is a methionine in the
crystal structure; this mutation was noted in the corresponding PDB file. The allele
frequency encoding either a valine or methionine at this position is not known.
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Figure 3.14: Sortilin polymorphisms may promote elevated levels of Lp(a) in human
patients. Internalization assays in (A) HepG2 cells transiently transfected with a plasmid
vector encoding sortilin or various polymorphic variants. Control cells were transfected
with the corresponding empty expression vector (pcDNA). Cells were grown for 16 hours
in LPDS media and subsequently incubated with 10 µg/mL of Lp(a) in Opti-MEM for 4
hours. the cells were extensively washed to remove any cell bound Lp(a), lysed, and
subjected to western blot analysis to determine the amount of Lp(a) internalized. Secretion
assays in (B)(C) HepG2 cells transiently transfected with a plasmid vector encoding
sortilin, the various polymorphic variants, or pcDNA were grown for 24 hours in MEM
media. Media was collected after 24 hours, and the cells were subsequently lysed and
subjected to western blot analysis to determine the amount of both (B) secreted and (C)
intracellular apo(a) accumulation. Values for Lp(a) internalization or apo(a) accumulation
are corrected for cell number and sortilin overexpression, and are expressed relative to that
observed when wild-type sortilin was overexpressed. Densitometric analysis was
conducted using Image Lab software. The data corresponds to the means ± SEM of at least
3 independent experiments.

108

CHAPTER 4: DISCUSSION

GWAS studies have identified various SNPs at the 1p13.3 locus that are associated
with total LDL cholesterol levels and risk for CAD and MI (183). While this locus
incorporates a haplotype block of three genes, namely SORT1, PSRC1, and CELSR2,
numerous mechanistic studies have identified a role for sortilin, encoded by SORT1, in
regulating LDL-C levels (141, 142, 152, 153). However, these studies yielded disparate
results with respect to the relationship between sortilin and LDL metabolism. Regarding
LDL catabolism, Strong et al. found through in vivo studies in a wild-type mouse model
that an increase in the catabolic rate of LDL is observed in animals overexpressing hepatic
sortilin when compared to control animals (142). Furthermore, sortilin expression was
found to increase LDL catabolism in an LDLR-/- mouse model, suggesting that sortilin can
mediate LDL clearance independently of the LDLR (142). These findings are in agreement
with previous in vitro studies conducted by Linsel-Nitschke et al. which demonstrate that
sortilin overexpression in Hek293 cells leads to an increase in the catabolic rate of LDL
(153). Conversely, in vitro studies conducted in primary mouse hepatocytes found no
difference in the endocytic uptake of LDL between control cells or sortilin-deficient cells
(141).
Conflicting findings are also observed in the relationship between sortilin and apoB
secretion. In vivo studies conducted by Musunuru et al. monitoring hepatic sortilin
overexpression and knockdown found that overexpression of sortilin leads to a decrease in
VLDL secretion, whereas knockdown of sortilin expression leads to an increase in VLDL
secretion (152). These studies were conducted in Apobec-/-; APOB TG mouse models,
which possess a humanized lipoprotein profile. The lipoproteome of wild-type mice is
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centered on higher circulating levels of HDL, whereas the lipoprotein distribution in
humans is centered on LDL and VLDL. Therefore, Apobec-/-; APOB TG mouse background
is a more physiologically relevant model for human metabolism (183). These findings are
in agreement with in vivo studies conducted by Strong et al.., which demonstrate that
sortilin directly binds to apoB-containing lipoproteins and promotes their pre-secretory
lysosomal degradation, thus inhibiting VLDL secretion (142). Furthermore, work
conducted by Ai. et al. also support a role for sortilin in promoting VLDL degradation, as
in vivo studies demonstrate that SORT1 expression is associated with reduced VLDL
secretion (208). In opposition to these findings, cell fractionation and pulse-chase
experiments conducted by Kjolby et al.. in a SORT1-/- mouse model demonstrated a
decrease in VLDL secretion when compared to control mice (141). Interestingly, studies
conducted by Strong et al. in SORT1-/- mice of both the wild-type and Apobec1-/-; hAPOB
Tg background support this finding, as a reduction in VLDL secretion was observed in the
absence of SORT1 expression (142).
Overall, these disparate findings indicate that both sortilin deficiency and
overexpression reduce VLDL secretion. Furthermore, some studies indicate that sortilin
can regulate LDL catabolism, while another study demonstrates no role for sortilin no
mediating LDL clearance. These data suggest that the hepatic functions of sortilin may
depend on the metabolic milieu. Indeed, multiple hypotheses have been proposed to
provide possible explanations for the contrasting results. One hypothesis suggests that
sortilin may promote lysosomal degradation of VLDL in conditions of elevated
intracellular apoB-100 levels, such as those observed in Apobec1-/- mouse models.
Conversely, sortilin may facilitate VLDL biosynthesis and secretion in conditions of
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reduced intracellular apoB-100 levels, such as those observed in a wild-type mouse model
(183). Another hypothesis suggests that the regulation of VLDL biosynthesis through
sortilin may be dependent upon the bioavailability of sortilin itself. This is reflected in the
various mouse models utilized to study the effects of sortilin on LDL metabolism. A total
body knockout of sortilin was associated with an increase in VLDL secretion (141, 142),
whereas the specific knockdown of hepatic sortilin was associated with decreased VLDL
secretion (142, 152, 208). In the latter studies, total expression of sortilin was unaffected
with the exception of the liver. Finally, environmental factors may also influence the effects
of sortilin on LDL metabolism, as the animals in the aforementioned studies were subjected
to different diets (183). Indeed, future work is required to reconcile these disparate
mechanisms. However, the overall consensus indicates that sortilin plays a role in
regulating both VLDL and apoB-100 secretion as well as LDL catabolism.
Despite the novel association between sortilin, apoB-100 containing lipoproteins,
and CAD, a role for this trafficking receptor in regulating Lp(a) metabolism has not been
explored. Since Lp(a) is structurally homologous to LDL with the presence of a similar
apoB-100 containing particle, it is plausible that sortilin may likewise regulate Lp(a)
metabolism in a manner similar to LDL. In this thesis, we provide evidence in cultured
hepatoma cells that increased sortilin expression is associated with an increase in the rate
of apo(a) secretion, while decreased sortilin expression is associated with a decreased rate
of apo(a) secretion; this effect is dependent upon functional LBS in apo(a) KIV7 and KIV8,
but not KIV10. We further demonstrated that sortilin overexpression increased the amount
of Lp(a) internalized in hepatocytes and primary human fibroblasts either expressing or
lacking functional LDLR activity. Interestingly, addition of ε-ACA, a lysine analog,
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eliminated the ability of sortilin to increase Lp(a) internalization. We further demonstrated
that both consequences of increased sortilin expression, namely increased apo(a) secretion
and increased Lp(a) catabolism, required the functional activity of various sorting motifs
in the cytoplasmic domain of sortilin. Regulation of Lp(a) catabolism and apo(a) secretion
appears to be of an indirect nature, as no direct binding was observed between sortilin and
either Lp(a) or apo(a). However, we demonstrated that sortilin co-localized with apo(a) in
early and late endosomal compartments of the cell, which is suggestive of a role for sortilin
in facilitating the intracellular trafficking of apo(a). Finally, deep sequencing of the SORT1
gene identified 19 novel mutations that produce different polymorphic variants of sortilin.
Seven of these mutations were found to occur in individuals that possessed extremely
elevated levels of Lp(a). In an attempt to determine a potential mechanistic basis behind
this association, we identified certain polymorphisms that altered Lp(a) catabolism and/or
apo(a) secretion in hepatocytes when compared to wild-type sortilin.
4.1 Sortilin Enhances Apo(a) Secretion in HepG2 Cells
The rate of hepatic apo(a) production is an important determinant of plasma Lp(a)
levels in humans (55, 56, 58). Previous research has demonstrated that the secretion of
apo(a) is a complex process that is influenced by a variety of factors. Significant retention
time of apo(a) both in the ER and Golgi compartments has been reported (76, 87). A direct
relationship has been reported between isoform size and relative intracellular retention
times (29). Studies conducted by White et al.. indicate that the observed variation in apo(a)
secretion efficiency may be associated with the correct trimming of N-linked glycans,
which occurs subsequent to folding events (28). Smaller isoforms of apo(a) are found to
have increased rates of secretion compared to larger isoforms (27); therefore, smaller
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isoforms may be more efficiently secreted through a reduced demand in N-linked glycan
processing. Apo(a) is initially synthesized as a hypo-glycosylated precursor, with N-linked
glycosylation occurring concomitantly to protein translation (82). The addition of O-linked
glycans, as well as the completion of maturation of apo(a), occurs upon movement of the
protein from the ER to the medial- to trans-Golgi compartments (91).
Overexpression of wild-type sortilin led to a significant increase in intracellular
apo(a) accumulation in, and a significant increase in the rate of secretion of apo(a) from,
HepG2 cells (Fig. 3.2). Furthermore, sortilin overexpression increased apo(a) secretion in
HepG2 cells stably expressing 17K r-apo(a) (Fig. 3.6). HepG2 cells transiently transfected
with siRNA directed towards SORT1 expression demonstrated an average knockdown
percentage of 53.7% in sortilin protein expression (Fig. 3.6 D). This reduction in sortilin
expression is associated with a significant decline in the amount of apo(a) secreted from
HepG2 cells stably expressing 17K r-apo(a) (Fig. 3.6 A, C). A significant difference in the
intracellular accumulation of 17K r-apo(a) was also observed in cells transfected with
sortilin directed siRNA (Fig. 3.6 B, C). Limits to the resolution of the bands meant that
quantitative analysis could not be made about the rate of conversation from a hypoglycoslyated to fully glycosylated form of apo(a); however, inspection of the fluorographs
(Fig. 3.2, 3.4, 3.5, 3.6) demonstrates that there does not appear to be a notable difference.
Mature apo(a) was first detectable in both the lysates and conditioned media at 30 minutes
of chase time in both control cells and cells overexpressing the various forms of sortilin.
Maturation of apo(a) has been identified to be a rate-limiting step in the biosynthesis
of the protein. However, it has also been postulated that the regulation of movement
between intracellular compartments acts a second rate-limiting step in apo(a) production
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(87). Our work indicates that sortilin may either prevent the presecretory degradation of
apo(a), or potentially function in mediating the intracellular transport of apo(a), and that
this effect is dependent upon the trafficking capabilities of sortilin. Analysis of the effect
of various sortilin mutants supports this notion, as a reduced effect on apo(a) secretion
compared to wild-type sortilin is observed for sortilin variants that possess mutations in
canonical sorting motifs found in the cytoplasmic domain of the receptor (Fig. 3.1). Sitedirected mutagenesis of key residues in the tyrosine and dileucine sorting motifs leads to a
reduced effect for sortilin in increasing the intracellular accumulation and secretion of
apo(a) (Fig. 3.2). Immunofluorescence data produced in this study further supports a
trafficking role for sortilin in enhancing apo(a) secretion, as qualitative co-localization is
observed between sortilin and apo(a) within endosomal compartments (Fig. 3.3 C, D).
However, the co-localization observed with the endosomal compartments can reflect both
the secretory and internalization pathways. Therefore, future work is required to optimize
the immunofluorescence studies for quantitative analysis, and to explore the possibility that
a sortilin-mediated regulation of apo(a) secretion is solely a representation of the secretory
pathway. Maneuvers that inhibit apo(a) catabolism, such as ε-ACA addition, can be utilized
to study this hypothesis.
Previous studies have demonstrated that the tyrosine and dileucine sorting motifs
found in the cytoplasmic domain of sortilin are involved in mediating the intracellular
targeting of the receptor (146, 160-162, 168, 209). Functionally, the tyrosine motif mediates
sortilin trafficking through an interaction with adaptor protein-1 (AP-1), which is a member
of the multimeric adaptor protein family. Inhibition of AP-1 activity leads to increased
accumulation of sortilin within the TGN, suggesting that the tyrosine motif is involved in
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the anterograde transport of sortilin and its cargo to other cellular compartments, as well as
the cell surface (168). Our results support this notion, as a reduced effect on 17K r-apo(a)
secreted compared to wild-type sortilin is observed for cells overexpressing the Y792A
variant (Fig. 3.2 A, C). Interestingly, an increase in the intracellular accumulation of apo(a)
is observed in cells overexpressing Y792A when compared to control cells (Fig. 3.2 A, B).
Therefore, the increase in 17K r-apo(a) intracellular accumulation observed in cells
overexpressing the Y792A variant is not reflected by an increase in secreted apo(a).
A possible explanation for the increase in intracellular apo(a) accumulation
observed in cells overexpressing the Y792A variant may be attributed to the homology
observed between the cytoplasmic domains of sortilin and mannose-6-phosphate receptors
(MPRs). MPRs are well characterized sorting receptors involved in trafficking ligands to
and from the trans-Golgi and endosomal compartments (151). Previous research has found
that the cytoplasmic domain of sortilin is highly homologous to that of MPRs, with both
domains possessing multiple, conserved sorting motifs that are involved in Golgi and
endosomal trafficking (146, 168, 209). As a result, both receptors may share a conserved
trafficking mechanism that exhibits functional dependence on interactions with adaptor
proteins (151). Previous work conducted by Hirst et al. in fibroblasts demonstrated that,
despite disrupting an interaction with AP-1, MPRs could still bind ligands, and participate
in anterograde transport while complexed with cargo to endosomal compartments (210).
This finding, as well as the homology between the cytoplasmic domains of sortilin and
MPRs suggests that the Y792A variant of sortilin, which is unable to interact with AP-1,
may be able to traffic to endosomal compartments in a manner similar to MPR. Indeed,
previous research found that MPRs interact with Golgi-localizing, Gamma-adaptin Ear-
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containing, ARF-binding proteins (GGAs), which mediate the anterograde transport of
MPR and its cargo (211). Likewise, the dileucine motif mediates sortilin trafficking through
an interaction with GGAs (146). Similar to the AP-1 studies, mutation of GGAs, which
abolished their ability to interact with the dileucine sorting motif, inhibited the anterograde
trafficking of sortilin resulting in the accumulation of the receptor in the perinuclear region
(137, 146). Therefore, an intact and functional dileucine sorting motif in the cytoplasmic
domain of sortilin is essential in facilitating the anterograde transport of the receptor and
its cargo from the TGN to endosomes.
Similar to the results obtained for the Y792A variant, a reduced effect on 17K rapo(a) secretion compared to wild-type sortilin is observed for cells overexpressing the
L829/830A variant (Fig. 3.2 A, C). Moreover, no significant differences in intracellular
apo(a) accumulation was observed between L829/830A and control cells (Fig. 3.2 A, B).
This suggests that the dileucine motif may play a more essential in mediating the increase
in the intracellular accumulation of apo(a) brought about through sortilin overexpression.
Taken together, the pulse-chase data indicate that the tyrosine and dileucine motifs within
the cytoplasmic domain of sortilin work in a coordinated manner to increase apo(a)
secretion. Indeed, removal of the entire cytoplasmic domain yielded the greatest reduction
in both intracellular and secreted apo(a) accumulation when compared to wild-type sortilin
(Fig. 3.2). The individual mutation of these domains did not completely abolish an increase
in apo(a) secretion brought about by sortilin overexpression, therefore, both motifs are
essential in mediating this effect. This is in agreement with previous research, which
indicated that the dileucine motif plays a bigger role in facilitating the intracellular
trafficking of sortilin (146).

116

However, the tyrosine motif in sortilin is essential in binding the Vps35 subunit of
the retromer complex, which is largely responsible for mediating the recycling of
trafficking receptors from endosomes to the TGN (151, 168). Mutation of essential residues
within this motif inhibits the interaction between sortilin and the retromer complex, thus
leading to an accumulation of sortilin in the endosomal system along with a concomitant
depletion in the Golgi complex (168). Therefore, the Y792A mutant receptors may be
capable of trafficking nascent apo(a) from the TGN to endosomal compartments, thus
leading to elevated levels of intracellular apo(a). However, this variant will become trapped
in the endosomal compartments, therefore inhibiting its ability to continuously promote the
secretion of newly synthesized apo(a). This may explain why cells overexpressing the
Y792A yielded an increase in intracellular apo(a) without a concomitant increase in apo(a)
secretion.
The overexpression of both the Y792A and L829/830A variants in HepG2 cells
displayed a significant increase in the amount of apo(a) secreted after 480 minutes of chase.
The homology with MPRs may again provide a possible explanation for this observation.
A previous study by Nielsen et al. demonstrated that chimeric constructs consisting of the
lumenal domain of MPR and the cytoplasmic domain of sortilin are able to rescue
trafficking defects observed in cells lacking functional MPRs (146). These data suggest
that sortilin and MPR may act as complimentary sorting receptors. Indeed, previous studies
found that extensive co-localization is observed between sortilin and MPRs, which suggests
that these proteins function in similar pathways (124, 165). Furthermore, immunogold
labelling studies conducted by Mari et al. demonstrated that the relative subcellular
distributions of sortilin and MPRs were nearly identical, demonstrating that these receptors
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may not only share similar transport pathways, but similar transport kinetics as well (161).
Taken together, these data suggest that the sorting pathways MPRs and sortilin may display
redundancy. Future work is required to determine if MPRs are upregulated in cells
overexpressing the sortilin trafficking mutants employed in this thesis, and if this
upregulation is associated with an ability to rescue the impaired trafficking capabilities of
sortilin.
Previous studies demonstrate that sortilin mediates apoB movement through the
biosynthetic pathway through its ability to act as a trafficking receptor (142). Furthermore,
sortilin was found to bind to apoB-100 with high-affinity, thus indicated that sortilin
directly regulates apoB secretion (141, 142). As such, we conducted in vitro experiments
to determine if sortilin can bind to apo(a) and directly facilitate transport of apo(a) through
the biosynthetic pathway. We found, through the use of two different methods, that
endogenous sortilin can bind to apoB-100, but not apo(a) in vitro (Fig. 3.12). This indicates
that sortilin is indirectly enhancing apo(a) secretion as opposed to directly binding to and
mediating apo(a) transport through intracellular compartments. The identification of colocalization in this thesis between apo(a) and sortilin (Fig. 3.3) indicates that sortilin may
enhance apo(a) secretion as part of a complex. It is possible that increased sortilin
expression may upregulate the expression, enhance the function, or alter the localization of
other trafficking proteins that act to mediate apo(a) movement through the biosynthetic
pathway.
Interestingly, pulse-chase analysis demonstrates that sortilin overexpression was
unable to influence the secretion of 17KΔLBS7,8, which is an apo(a) variant that lacks lysine
binding capabilities in the weak LBS of KIV7,8 (Fig. 3.4). The 17KΔLBS7,8 apo(a) variant
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possesses a glycine residue instead of an aspartate residue at position 56 in both KIV7 and
KIV8, thus altering the charged environment of the lysine binding pocket. As a result, these
kringle domains can no longer participate in lysine binding (62). Previous research of
17KΔLBS7,8 apo(a) demonstrates that intact, functional LBS in these KIV subtypes are
required for Lp(a) assembly. Specifically, lysine residues within the amino-terminal
segment of apoB-100 associate with the weak LBS of KIV7,8, thus mediating the noncovalent interaction between apo(a) and apoB that is the initial step involved in Lp(a)
particle assembly (212, 213).
The overall site of noncovalent, as well as final covalent, assembly remains
controversial. Multiple studies suggest that an Lp(a) particle is formed extracellularly
following the secretion of apo(a) and apoB from hepatocytes (73-76). However, research
has also demonstrated that Lp(a) formation can occur intracellularly (77-79); this is
supported by kinetic data in humans (80, 81). Interestingly, a study has found an association
between triglyceride synthesis and apo(a) production in in hepatocytes (77). Furthermore,
kinetic labelling studies in humans discovered that the production rates of both
apolipoprotein moieties of Lp(a) are identical, and that particle formation incorporates
newly-synthesized apo(a) and apoB as opposed to newly synthesized apo(a) associating
with circulating LDL particles (81). In vitro studies in hepatoma cells also demonstrate that
the hypo-glycosylated precursor of mature apo(a) can associate intracellularly with apoB100 (82). Taken together, these data support the concept that a non-covalent association
between apo(a) and apoB can occur intracellularly.
If apoB and apo(a) associate intracellularly as the evidence suggests, and previous
evidence indicates that the secretion of these apolipoproteins are linked, it is therefore
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possible that the increase in apo(a) secretion through sortilin overexpressing may be
mediated by a “piggyback” effect with apoB. Sortilin overexpression may enhance the
secretion of apoB, which indirectly promotes apo(a) secretion through the non-covalent
association of the two lipoproteins. The data in this thesis are in agreement with this
concept, as sortilin overexpression was unable to increase the secretion of 17KΔLBS7,8
apo(a).
However, this conclusion is complicated by the disparate results obtained in studies
monitoring the effects of sortilin expression on the secretion of apoB and apoB-100
containing lipoproteins. As explained previously, multiple studies found that increased
sortilin expression is associated with a concomitant reduction in apoB and VLDL secretion
(142, 152, 208). Conversely, a study conducted by Kjolby et al. found that increased sortilin
expression leads to enhanced apoB and VLDL secretion (141). Furthermore, multiple
studies found that a reduction in apoB secretion is observed in SORT1-/- mice (141, 142).
The pulse-chase analysis conducted in this thesis supports the latter findingsIf the ability
of sortilin to regulate apo(a) secretion is dependent upon a non-covalent interaction with
apoB, as well as its ability to directly regulate apoB biosynthesis, the observed increase in
apo(a) secretion with sortilin overexpression would have to be accompanied with a
concomitant increase in apoB secretion. The opposite effect would be observed in cells
with reduced sortilin expression. Therefore, future work is required to examine the
regulatory effects of sortilin expression on apoB secretion in the pulse-chase model utilized
in this study. Overexpression and knockdown of sortilin can be studied in the context of
apoB-100 secretion from HepG2 cells. The pulse-chase studies of apo(a) secretion can be
repeated in the context of HepG2 cells that are treated with siRNA directed against the
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apoB gene. It cannot be excluded that apo(a) KIV7,8 are mediating interactions not with
apoB, but instead with some other protein whose secretion is regulated by sortilin.
Pulse-chase analysis of 17KΔLBS10, which is an apo(a) variant that lacks lysine
binding capabilities in the strong LBS of KIV10, demonstrated that overexpression of
sortilin is able to significantly increase the intracellular accumulation and secretion of
apo(a) in a manner similar to that observed for wild-type apo(a) (Fig. 3.5). The 17KΔLBS10
variant possesses an alanine residue at position 57 in KIV10 as opposed to an aspartic acid
residue, thus altering the charged environment required for lysine recruitment and binding
(214). A functional LBS in KIV10 is important for the lysine-dependent association of
apo(a) with various protein substrates (13). It is possible that such interactions modulate
apo(a) secretion. Since the secretion of this variant was upregulated by sortilin in a manner
not dissimilar to wild-type apo(a), such interactions are not relevant to the effects of sortilin.
Notably, the non-covalent interaction of apo(a) with apoB is not influenced at all by the
KIV10 LBS. Taken together, the pulse-chase analysis (Fig. 3.2, 3.4, 3.5, 3.6), in
combination with the in vitro binding analysis (Fig. 3.12), suggests that an intracellular
association between apo(a) and apoB may be required to facilitate apo(a) secretion with
sortilin overexpression.
4.2 Sortilin Increases Internalization of Lp(a), But Not Apo(a)
The rate of clearance also plays a role in dictating the plasma concentrations of
Lp(a) (99). The main pathways of Lp(a) clearance remain controversial, as multiple studies
implicate the involvement of a variety of receptors, such as plasminogen receptors, LDLRs,
and VLDLRs, in facilitating the internalization and degradation of Lp(a) (99). The
discovery of a novel association between sortilin and LDL cholesterol levels provides an
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interesting insight into a potential role for sortilin in regulating LDL metabolism. As such,
both in vivo and in vitro indicate that sortilin can affect plasma LDL-C levels by promoting
the uptake and catabolism of LDL (142, 153), although a study by Kjolby and coworkers
refutes this concept (141). The specific mechanisms by which sortilin regulates LDL
catabolism appear to be dependent upon an interaction with the apoB component of LDL.
Since Lp(a) possesses a similar apoB component, we hypothesized that Lp(a) catabolism
may be regulated in a similar manner. As we report for the first time, overexpression of
sortilin results in a significant increase in the amount of Lp(a) internalized in HepG2 cells,
primary mouse hepatocytes, and primary human fibroblasts (Fig. 3.7, Fig. 3.11).
Recent evidence indicates that elevated levels of plasma Lp(a) can be significant
reduced with the use of monoclonal antibodies directed against PCSK9 (120). Furthermore,
previous data generated by our group demonstrates that treating HepG2 cells with wildtype, exogenous PCSK9 leads to a significant decrease in the amount of both Lp(a) and
apo(a) internalized (112). Interestingly, work conducted by Gustafsen and coworkers
provides evidence for a novel association between PCSK9 and sortilin (143). SPR analysis
and co-immunoprecipitation studies indicate that PCSK9 can bind to sortilin in a pH
dependent manner, and that this interaction was necessary for sortilin to act as a molecular
chaperone for, and promote the secretion of, PCSK9 late in the secretory pathway (143).
Based on this study, sortilin overexpression should lead to a concomitant increase in
PCSK9 bioavailability. Furthermore, numerous studies support a role for the LDLR a role
for the LDLR in in Lp(a) catabolism (102-113). However, this concept is controversial, as
multiple studies indicate that the LDLR does not mediate Lp(a) catabolism (101, 114-117).
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Previous work conducted by our group supports a role for the LDLR in mediating
Lp(a) catabolism, as PCSK9-treated HepG2 cells demonstrated a significant decrease in
the amount of Lp(a) internalized when compared to non-treated cells (112). In light of this
evidence, we hypothesized that increased PCSK9 bioavailability may counter the increased
rate in Lp(a) internalization brought about by sortilin overexpression. As observed in Fig.
3.7 A, PCSK9-treated HepG2 cells overexpressing wild-type sortilin demonstrate a
significant increase in the amount of Lp(a) internalized compared to PCSK9-treated control
cells. Therefore, sortilin overexpression is still able to promote Lp(a) internalization in
HepG2 cells in the presence of elevated levels of PCSK9. Work conducted by Strong and
coworkers found that sortilin expression in LDLR-/- mice led to a significant increase in the
catabolic rate of LDL when compared to control mice, therefore suggesting that sortilin
mediates LDL degradation through a pathway that is independent of the LDLR (142). As
demonstrated in Fig. 3.11 A, sortilin overexpression significantly increases the amount of
Lp(a) internalized in both FH and non FH human fibroblasts. This suggests that, similar to
the effects on LDL catabolism, sortilin can increase Lp(a) internalization through an
LDLR-independent pathway. This is supported by the results in PCSK9-treated HepG2
cells (Fig. 3.7 A). A similar result for PCSK9 treatment was not obtained in fibroblast cells
(Fig. 3.11 A), however, this could be due to variation in LDLR availability. Fibroblasts do
not produce apoB endogenously, and may therefore have reduced bioavailability of LDLR.
The ability of sortilin to increase LDL catabolism is dependent upon the proper
trafficking capabilities of the receptor (142). Therefore, to determine if the increase in Lp(a)
internalization brought about by sortilin overexpression is dependent upon the ability of
sortilin to act as a trafficking receptor, we monitored the levels of Lp(a) internalization
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occurring in HepG2 cells and primary mouse hepatocytes overexpressing the Y792A,
L829/830A, and sortilinΔCT trafficking mutants of sortilin. The defect in the ability of
sortilin to increase Lp(a) internalization in HepG2 cells was most profound in cells
overexpressing either the sortilinΔCT or Y792A mutants, as a significant reduction in the
amount of Lp(a) internalized is observed in cells overexpressing these variants when
compared to cells overexpressing wild-type sortilin. Such a difference is not observed in
cells overexpressing the L829/830A variant. However, as observed in Fig. 3.7, the amount
of Lp(a) internalized is comparable in cells overexpressing either the L829/830A or Y792A
variants. The SEM for the L829A/830A mutant is larger than the SEM of the Y792A or
sortilinΔCT mutants. This may have skewed the statistical analysis, resulting in a lack of
statistical significance observed between either control cells or cells overexpressing
sortilin. Therefore, more trials are required for the L829/830A variant to confirm if
impairment of the dileucine sorting motif leads to a reduced effect in Lp(a) internalization
in HepG2 cells.
Interestingly, no significant difference in Lp(a) internalization is observed between
primary mouse hepatocytes overexpressing either the Y792A or L829/830A mutant when
compared to hepatocytes overexpressing wild-type sortilin. Only the sortilinΔCT mutant to
demonstrated a defect in the ability of sortilin to increase Lp(a) internalization, as
hepatocytes overexpressing this variant demonstrated a significant reduction in the amount
of Lp(a) internalized when compared to cells overexpressing wild-type sortilin (Fig. 3.7 B).
Overall, the results obtained for Lp(a) internalization (Fig. 3.7 A, B) demonstrate
some similarities with those obtained for LDL catabolism by Strong and coworkers (142).
Mice expressing a sortilin variant similar to sortilinΔCT found that the absence of a
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cytoplasmic domain completely abolishes the ability of sortilin to increase LDL catabolism
(142). This is in agreement with the results obtained for HepG2 cells and mouse
hepatocytes overexpressing sortilinΔCT (Fig. 3.7 A, B). The comparable amount of Lp(a)
internalized between the control and the sortilinΔCT variant in both cell lines (Fig. 3.7 A,
B) suggests that the effect of sortilin overexpression on Lp(a) internalization is dependent
upon the ability of sortilin to act as a trafficking receptor, and that a fully intact cytoplasmic
domain is required to mediate this effect. Interestingly, Strong et al. found that a sortilin
variant that possessed mutations of conserved residues within the tyrosine and dileucine
motifs was still able to increase the rate of LDL clearance from plasma. The internalization
assays performed in primary mouse hepatocytes (Fig. 3.7 B) reflects this finding for Lp(a)
internalization, as only a moderate reduction in the amount of Lp(a) internalized is observed
in hepatocytes overexpressing both Y792A and L829/830A compared to wild-type sortilin.
When taken together, these data indicate that the tyrosine and dileucine motifs within the
cytoplasmic domain of sortilin may work in a coordinated manner to facilitate Lp(a)
internalization in HepG2 cells.
Previous research found that sortilin directly trafficks LDL to the lysosome
subsequent to internalization (142). Strong et al. found that the variant possessing
mutagenized tyrosine and dileucine motifs was unable to effectively promote the lysosomal
degradation of LDL in a manner similar to wild-type sortilin (142). LDL internalization by
the LDLR occurs through clathrin-mediated endocytosis, where LDL is shuttled to the
lysosome for degradation subsequent to internalization at the cell surface (215). Work
conducted by our group demonstrates that Lp(a) is likewise internalized through clathrinmediated endocytosis, and that Lp(a) is targeted to lysosomes following internalization

125

(112). Sortilin is able to bind a variety of ligands and traffic them from the Golgi apparatus
to the lysosome. This ability is dependent upon the formation of clathrin-coated-cargo
vesicles (151). Clathrin interacts with the multimeric and monomeric adaptor protein
families which include AP-1 and GGAs. As previously mentioned, the tyrosine motif is
responsible for binding AP-1, while the dileucine motif mediates interaction with the GGAs
(137, 146, 168). Disrupting these motifs through mutation can inhibit their ability to interact
with adaptor proteins, and thus clathrin. This may impair the ability of sortilin and its cargo
to localize in clathrin-coated-cargo vesicles, leading to a concomitant reduction in the
ability of sortilin to participate in lysosomal trafficking. This could lead to a reduction in
the clathrin-mediated endocytosis of, and concomitant reduction in the lysosomal targeting
of, LDL as observed by Strong et al. (142). Likewise, this disruption in clathrin interaction
can providing a possible explanation for the decrease in Lp(a) internalization observed in
HepG2 cells overexpressing the sortilin trafficking variants. Therefore, future work is
required to determine if cells overexpressing the Y792A or L829/830A sortilin variants are
unable to traffic Lp(a) to the lysosome for degradation, and if inhibiting localization within
clathrin-coated vesicles is associated with decreased Lp(a) internalization in HepG2 cells.
This can be achieved by studying the effects of lysosomal inhibitors on Lp(a)
internalization in the context of sortilin overexpression. Likewise, co-localization studies
between sortilin, Lp(a), and a lysosmal marker may also provide interesting insight with
respect to this hypothesis.
To determine if sortilin could mediate Lp(a) internalization at the endogenous level,
we reduced sortilin expression in HepG2 cells through siRNA-mediated targeting of the
SORT1 gene to determine if a reduction in sortilin expression would be associated with a
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decrease in Lp(a) internalization. However, despite an average knockdown percentage of
59.36%, a significance decrease in Lp(a) internalization is not observed in cells treated with
sortilin siRNA when compared to control cells (Fig. 3.8). These data indicate that sortilin
may only play a role in regulating the catabolism of Lp(a) when it is expressed at elevated
levels. GWAS studies identified an association between SNPs near the SORT1 gene and
LDL-C levels (178, 182). Fine mapping of this region demonstrates that a minor allele SNP,
rs12740374, occurring in a non-coding region between PSRC1 and CELSR2 generates a
novel binding site for C/EBP, which is a liver-specific transcription factor (152). Each copy
of the minor allele is found to be associated with a 6-fold increase in SORT1 expression.
Therefore, individuals with copies of the minor allele would possess significantly elevated
levels of sortilin. It is possible that Lp(a) catabolism is enhanced in such individuals,
although this possibility has not been examined.
To gain further insights into the molecular mechanism by which sortilin expression
regulates Lp(a) internalization, we conducted interaction studies to determine if sortilin is
mediating Lp(a) internalization by acting as a cell surface receptor. We found, through the
use of two different methods, that endogenous sortilin can bind apoB-100, but not Lp(a)
(Fig. 3.12). Previous work conducted by Kjolby et al. found that sortilin can interact with
apoB-100, but not apoB-48 (141). This suggests that sortilin interacts with the C-terminal
region of apoB. Several studies suggest that Cys4326 in apoB-100 is involved in disulfide
bond formation with apo(a) (65, 66). Conversely, other studies have implicated that the
disulfide linkage occurs between apo(a) and Cys3734 ine apoB (67-70). Both of these
cysteine residues are present in the C-terminal portion of apoB-100 (216, 217). Therefore,
it is possible that the covalent attachment of apo(a) to apoB may impair the ability of apoB
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to bind to sortilin. The interaction studies support this concept, as endogenous sortilin is
able to interact with apoB-100, but not the apoB component of Lp(a) (Fig. 3.12). The lack
of a direct interaction suggests that sortilin is not acting as a cell surface receptor for Lp(a).
It is possible that sortilin may affect the abundance of clearance receptors that
require interaction with both apo(a) (in a lysine dependent fashion) and apoB. The reduced
amounts of Lp(a) internalized in HepG2 cells overexpressing various trafficking mutants
of sortilin supports this hypothesis (Fig. 3.7 A, B). Both the tyrosine and dileucine sorting
motifs facilitate the anterograde transport of sortilin and its ligands, therefore indicating
that disruption of these motifs can inhibit sortilin from trafficking potential Lp(a) clearance
receptors to the cell surface. Interestingly, treatment with a lysine analogue, ε-ACA, leads
to a significant reduction in the amount of both Lp(a) and apo(a) internalized in both control
cells and cells overexpressing wild-type sortilin (Fig. 3.10 A, B). Indeed, the amount of
Lp(a) internalized in ε-ACA-treated cells overexpressing sortilin is comparable to ε-ACAtreated control cells. This suggests that the ability of sortilin to increase Lp(a)
internalization is dependent on lysine binding interactions, which implicates an important
role for the apo(a) component of Lp(a) in mediating this effect.
The structural homology between apo(a) and plasminogen may be the potential
driving force behind this effect, as plasminogen receptors contain carboxyl-terminal lysine
residues that can interact with the LBS of apo(a) (102). Competitive binding between
apo(a) and Lp(a) with plasminogen for plasminogen receptors supports this concept, as
evidence suggests that Lp(a) can bind to and be internalized by these receptors (47, 48).
This suggests that receptors with carboxyl terminal lysine residues, such as the plasminogen
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receptors, may play a role in mediating the observed increase in Lp(a) internalization with
sortilin overexpression.
Previous work demonstrates that the apo(a) component is necessary for Lp(a) to
interact with the plasminogen receptor αMß2 (46). Furthermore, a study by Tam and
coworkers indicate that the apo(a) component is responsible for binding to low affinity
plasminogen receptors on the surface of HepG2 cells. Treatment with ε-ACA reduced the
ability of plasminogen receptors to internalize apo(a), which are capable of binding and
internalizing both free and LDL-complexed apo(a) (102). However, the apparent role of
apo(a) is complicated by our results for apo(a) internalization, which demonstrate no
significant change in the amount of apo(a) internalized with sortilin overexpression when
compared to an empty vector control. (Fig. 3.9, Fig. 3.11 B). This may be reconciled by the
methodology chosen to study the internalization of apo(a). These studies monitored the
internalization of a free, recombinant apo(a). It is possible that sortilin is only capable of
increasing the internalization of apo(a) when it is in a complex with apoB. In the
physiological setting, negligible amounts of free apo(a) exists, as the majority of apo(a)
associates with apoB in Lp(a) particles following secretion (59). A second possible
explanation may involve the multiple pathways of apo(a) clearance. A greater amount of
routes are available for the clearance of free apo(a) as opposed to apo(a) in the context of
the Lp(a) particle. Indeed, a previous in vivo study demonstrated that apo(a) injected into
mice was cleared by the liver greater than twice as fast as Lp(a), thus indicating that the
lipid moiety may lower the affinity of Lp(a) for various apo(a) receptors (27). Therefore,
future work is required to determine if an association exists between sortilin expression and
various plasminogen receptors, as well as other receptors dependent upon lysine
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interactions, on the cell surface of hepatic cells, and if this is relevant to the increase in
Lp(a) internalization observed with sortilin overexpression. Measuring both the mRNA and
protein levels of various plasminogen receptors under the context of sortilin overexpression
may provide some interesting insight into this hypothesis.
It is also possible that sortilin is increasing the abundance of other receptors
implicated in Lp(a) catabolism such as LRP-1, VLDL, gp330, and SR-BI, which are
receptors implicated in Lp(a) catabolism (108, 121-123). The apo(a) component appears to
mediate the abilities of VLDL, LRP-1 and SR-BI to internalize Lp(a); however, the exact
mechanism of action remains unclear. Taken overall, our data indicate that sortilin is
indirectly facilitating Lp(a) catabolism by potentially increasing the concentration of cell
surface receptors responsible for binding to and internalizing circulating Lp(a). Future work
is required to determine if sortilin overexpression leads to a concomitant increase is
observed in the mRNA and protein levels of thesepotential Lp(a) receptors.
4.3 Naturally Occurring Polymorphisms Within the VPS10 Domain May Alter the
Ability of Sortilin to Increase Apo(a) Secretion and Lp(a) Catabolism
Data presented in this study demonstrate that sortilin overexpression can promote
Lp(a) catabolism and apo(a) secretion in hepatoma cells (Fig. 3.2, Fig. 3.7). Since nascent
apo(a) appears to immediately associate with apoB upon secretion from hepatocytes (59),
this suggests that an increase in apo(a) production should be associated with a concomitant
increase in Lp(a) particle assembly. Therefore, our data suggest that sortilin expression may
elevate Lp(a) plasma levels by increasing the synthesis of Lp(a). However, our findings
with respect to Lp(a) catabolism indicate that an increase in Lp(a) internalization brought
about by sortilin overexpression may likewise lower plasma levels of Lp(a). Indeed, it is
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possible that both mechanisms are occurring simultaneously in vivo, and that the effects of
sortilin on apo(a) secretion are cancelled out by the effects on Lp(a) internalization.
Therefore, in an attempt further understand how sortilin may contribute to Lp(a)
levels, deep sequencing of SORT1 was performed in patients possessing elevated levels of
Lp(a). Sequencing analysis led to the identification of 19 rare, heterozygous missense or
splicing variants within the SORT1 gene. Interestingly, 9 individuals within the cohort of
patients studied are found to possess plasma Lp(a) levels within the 5th percentile for the
general population. These individuals were found to be heterozygous for seven novel,
polymorphic variants of sortilin lead to amino acid substitions, all of which occur within
the VPS10 binding domain. In the interest of determining if an association can be made
between the expression of these sortilin variants and elevated Lp(a) levels, site-directed
mutagenesis was performed to generate plasmids for these variants, identified as I124V,
K205N, K302E, K404Y, E444Q, E447G, and V650M (Fig. 3.13).
The VPS10 domain, which is representative of the entire lumenal section of sortilin,
is a large domain composed of 716 amino acids (126, 128). This domain is present in all
members of the VPS10 mammalian protein family. Modest sequence similarity is observed
between the VPS10 domains for the VPS10 family members with the exception of the Nterminal propeptide and a ~120 amino acid sequence that contains ten conserved cysteine
residues (126). This region, which is found closest to the transmembrane domain, is
composed of amino acids 577-716 and is classified as the 10CC module. This segment can
be further subdivided into two small subdomains categorized as 10CC-A and 10CC-B
(residue 577-633 and 634-716 respectively) (128). Crystal structure analysis of the VPS10
domain found it to be oriented in the shape of a ten-bladed ß-propeller, with ligand binding
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occurring in the centralized tunnel of the structure (Fig. 3.13) (128). The 10CC domains
interact extensively with the ß-propeller, and the ten conserved cysteine residues were all
found to participate in disulfide binding, thus resulting in the formation of five, highly
conserved disulfide bond linkages within the 10CC module (Fig. 3.13) (126, 128).
Interestingly, previous research found that the 10CC domains could also participate in
ligand binding (126).
The I124V, K205N, K302E, F404Y, E444Q, and E447G polymorphisms all occur
within the ß-propeller region of the VPS10 domain (residues 46-576). The V650M
polymorphism is the only mutation that occurs within the highly conserved 10CC module,
specifically occurring between two cysteine residues in the 10CC-B subdomain that are
linked through a disulfide bond (Fig. 3.13). Overall, these mutations may contribute to
ligand binding variability within the VPS10 domain through variable folding dynamics.
This may consequentially lead to variation in the ability of sortilin to traffic cargo through
the biosynthetic pathway, thus leading to variations in Lp(a) levels. Since these
polymorphisms were found to occur in individuals that possessed elevated levels of Lp(a),
understanding the effect of these variants on apo(a) secretion and Lp(a) metabolism might
resolve whether sortilin has a greater impact on Lp(a) synthesis or catabolism. We
overexpressed the various polymorphic variants in HepG2 cells to study the effects of these
variants on apo(a) secretion and Lp(a) internalization. Varying trends are observed in
HepG2 cells overexpressing the polymorphic variants (Fig. 3.14), that do not provide a
definitive answer to this question.
The I124V variant appears to function in a manner similar to wild-type sortilin (Fig.
3.14), thus suggesting that the I124V variant may contribute to Lp(a)/apo(a) metabolism in
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a manner similar to that observed for wild-type sortilin. A modest reduction in both apo(a)
secretion and Lp(a) internalization is observed in cells expressing the K205N variant (Fig.
3.14 A, B). A large increase is observed in the intracellular accumulation of apo(a) for
K205N expressing cells (Fig. 3.14 C). It is possible that this mutation may promote apo(a)
biosynthesis or prevent the presecretory degradation of apo(a), yet be defective in its ability
to promote apo(a) secretion. Overall, it appears that this variant may contribute to elevated
Lp(a) levels through a modest reduction in catabolic rate accompanied with an increase in
apo(a) biosynthesis. Similar to the K205N variant, a modest reduction in the amount of
Lp(a) internalized in cells overexpressing the K302E variant compared to cells
overexpressing wild-type sortilin (Fig 3.14 A). Conversely, a decrease in the accumulation
of both intracellular and secreted apo(a) is observed in cells expressing this variant as well
(Fig. 3.14 B, C). Therefore, K302E may only play a minor role in contributing to elevated
Lp(a) levels, with this effect occurring at the level of catabolism as opposed to assembly.
The F404Y variant also displays a reduction in Lp(a) catabolism (Fig. 3.14 A) when
compared to cells overexpressing wild-type sortilin. Indeed, the amount of Lp(a)
internalized in cells overexpressing this variant are comparable to control cells. The
intracellular accumulation of apo(a) in cells overexpressing the F404Y variant is
comparable to cells overexpressing wild-type sortilin. However, the amount of apo(a)
secreted from cells overexpressing this variant is greater than that observed in cells
overexpressing wild-type sortilin (Fig. 3.14 B, C). Unlike the previous three
polymorphisms, the amount of Lp(a) internalized in cells expressing the E444Q mutant is
comparable to that observed in cells expressing wild-type sortilin (Fig. 3.14 A). A reduction
in both apo(a) secretion and intracellular accumulation is observed in cells overexpressing
this variant when compared to cells overexpressing wild-type sortilin (Fig. 3.14 B, C).
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These data suggest that this variant may not contribute to elevated Lp(a) levels. A reduction
in the amount of Lp(a) internalized is observed in cells expressing the V650M variant when
compared to cells expressing wild-type sortilin and control cells (Fig. 3.14 A). A moderate
decrease in both apo(a) secretion and intracellular accumulation is observed when
compared to cells overexpressing wild-type sortilin. However, the amount of both
intracellular and secreted apo(a) in cells overexpressing V650M is increased compared to
control cells, indicating that this variant can still promote apo(a) secretion (Fig. 3.14 B, C).
Taken together, these data suggest that the V650M variant may contribute to elevated Lp(a)
levels at the level of both catabolism and assembly.
The amino acid substitutions encompass conservative substitutions (e.g. I124V,
where one aliphatic side chain is substituted for another); charge substitutions (e.g. K302E,
where a positively charged side chain is substituted for a negatively charged one); and loss
of a charged residue (e.g. E444Q). These substititons could alter the folding and thus
tertiary structure of sortilin, or could result in changes to charged patches on the surface of
the protein. Either of these changes could affect the ability of sortilin to bind to gargets
through which it algers apo(a)/Lp(a) metabolism. The absence of overexpression for the
E447G variant led to the exclusion of this SNP from the data. It is possible that an error
occurred during the creation of the expression vector encoding this variant. Likewise, it is
also possible that this SNP may lead to a non-functional sortilin protein, which would be a
novel discovery. Therefore, future studies are required to characterize the E447G
polymorphic variant.
A particularly interesting case is theV650M mutation, as it is the only SNP that
occurs within the highly conserved 10CC module (Fig. 3.13). This region possesses 10
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cysteine residues that are conserved in both location and spacing, and are involved in the
formation of disulfide bonds. The 650 position is situated in the middle of two invariant
cysteine residues that are linked through a disulfide bond (residues C642 and C655
respectively) (126). Both valine and methionine possess nonpolar, aliphatic side chains.
However, the side chain of methionine is unique in that it possesses a sulfur atom. This
evokes evokes the possibility of the methionine becoming oxidized to a sulfoxide, which
would have a particularly notable effect on the structure of sortilin. Indeed, a previous study
indicates that oxidized methione residues can lead to misfolded or dysfunctional proteins
(218). Furthermore, a conserved disulfide bond occurs between C642 and C655; a sulfoxide
modification could potentially destabilize or inhibit this linkage. Since the 10CC module is
shown to extensively interact with and stabilize the ß-propeller (128), disruption within this
conserved region may destabilize the ß-propeller and alter its ligand binding potential.
Furthermore, the 10CC module can also participate in ligand binding (126). Therefore,
variation in folding can not only affect ligand binding potential in the tunnel of the ßpropeller, but in the 10CC module itself. Our data suggest that sortilin may promote Lp(a)
internalization by increasing the abundance of receptors involved in the clearance of Lp(a).
The reduction in the amount of Lp(a) internalized in cells overexpressing the V650M
variant suggests that this mutation impairs the ability of sortilin to increase the
concentration of these receptors at the cell surface. Conversely, the methionine substitution
in this region of the VPS10 domain does not appear affect the processing involved in
mediating apo(a) secretion.
Previous data demonstrate that neurotensin binds in the tunnel of the ß-propeller
domain. The C-terminal carboxylate group of neurotensin was found to be the major
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contributor to this association, as it forms salt bridges with the guanidinium group of
Arg292, as well as hydrogen bonds with the R groups of Ser283 and the aliphatic backbone
of Tyr318 (128). An additional salt bridge occurs between Glu667 in the 10CC-B domain
and Arg293 in the ß-propeller domain, suggesting that the 10CC-B domain is involved in
mediating the binding of neurotensin (128). Interestingly, previously reported interacting
partners of sortilin all demonstrate competitive binding, indicating that they share a similar
binding site (126). Since treatment with ε-ACA abolished the ability of sortilin to increase
Lp(a) internalization (Fig. 3.10), it is tempting to speculate that receptors with carboxylterminal lysine residues, such as plasminogen receptors, may bind to sortilin in a manner
similar to that of neurotensin. This would allow sortilin to directly bind to and mediate the
intracellular trafficking of these receptors, thus leading to a potential increase in cell surface
concentrations and a concomitant increase in Lp(a) internalization. Taken together, our
findings are consistent with the notion that some, but not all, variants may contribute to
elevated Lp(a) levels by either increasing the rate of particle assembly or decreasing the
rate of Lp(a) internalization.
4.4 Association Between Sortilin Expression and Plasma Lp(a) Levels
GWAS studies looking for biomarkers related to cardiovascular disease
demonstrated an association between SORT1 and a reduction in LDL-C, as well as risk for
MI and CAD. Elevated levels of plasma Lp(a) is recognized as an independent, causal risk
factor for CHD (15, 31). The association between CHD and Lp(a) as an independent risk
factor, as well as the previous studies demonstrating an association between SORT1
expression and LDL metabolism, led to our hypothesis that sortilin may play a role in
regulating Lp(a) metabolism. Our data indicate that the effects of sortilin expression on
136

regulating Lp(a) levels is multifaceted. Certainly, there is precedence for a complex
relationship between sortilin and aspects of Lp(a) metabolism, as evidenced by the ongoing
controversy regarding the role of sortilin in apoB/VLDL secretion and LDL catabolism that
was previously discussed. An additional layer of complexity is added by the significant size
heterogeneity in Lp(a). It is possible that the effects on apo(a) secretion and Lp(a)
metabolism vary depending on Lp(a) levels, which can differ up to 1000-fold between
individuals (15), on the isoform size of apo(a), which also exhibits a high degree of
variability between individuals (13), or on the expression levels of sortilin itself, as levels
differ based on cell type (129, 144, 145). Fig. 4.1 provides an overall model depicting how
sortilin may regulate Lp(a)/apo(a) metabolism based on the data in this thesis.

137

A

B

138

Figure 4.1: Model of sortilin action in apo(a) secretion and Lp(a) catabolism. (A)
Nascent apo(a) and apoB-100 are translated in the ER, where apoB undergoes lipidation by
microsomal triglyceride transfer protein (MTP). Immature apo(a) and lipidated apoB-100
are transported to the Golgi, where they associate non-covalently. Sortilin is activated by
furin cleavage in the trans-Golgi, where it might interact with, and facilitate the secretion
of, the apo(a)-apoB complex. Upon secretion into the extracellular space, the final covalent
attachment of apo(a) to apoB-100 occurs through the catalysis of a disulfide linkage. (B)
Sortilin mediates the intracellular trafficking of receptors involved in Lp(a) clearance, thus
increasing their bioavailability. Lp(a) is internalized through clathrin-mediated
endocytosis, and incorporated into early endosomes. It may then be transported to the
lysosome for degradation.
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Ultimately, further research is required to elucidate if the effects of sortilin
expression, or sequence variation within the protein, can lead to either an elevation or
reduction in plasma Lp(a) levels. Data in this thesis indicates that overexpression of sortilin
can regulate the pathways of both apo(a) secretion and Lp(a) catabolism. However, sortilin
siRNA experiments suggest that sortilin may play a more important role in the secretion of
apo(a). The discovery of the sortilin polymorphic variants in individuals with elevated
Lp(a) levels provides the potential to further elucidate if sortilin promotes both Lp(a)
assembly and catabolism in an equal manner. The available data on the polymorphic
variants is not enough to validate the effects of sortilin on these two parameters as further
repeats are required. However, the phenotypes of some variants, notably F404Y and
V650M, indicate the potential for linkage analysis between sortilin expression and elevated
levels of Lp(a). Analysis of individuals expressing these mutations may be the key to
determining if sortilin polymorphisms are direcly linked withthe elevated Lp(a) phenotype.
Furthermore, the polymorphism data demonstrate that some mutations only affect one of
the parameters that contribute to plasma Lp(a) levels. Therefore, future work involving the
analysis of structure vs. activity can be pursued to examine the mechanisms through which
sortilin mediates apo(a) secretion and Lp(a) catabolism, and thus determine the major
pathway in which sortilin regulates Lp(a) levels.
The GWAS studies may also be revisited to explore how sortilin affects Lp(a)
metabolism. The discovered SNPs in the 1p13 locus can be studied in the context of Lp(a)
levels. While LDL-C levels were studied, it would be interesting to determine differences
in the plasma Lp(a) levels between individuals that are homozygous for the major and
minor alleles in the 1p13 region. In particular, studying the Lp(a) levels in individuals that
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are homozygous recessive (homozygous for the protective “T” allele) would be of great
interest, as these individuals possess 10-12 fold higher hepatic sortilin levels compared to
individuals that are homozygous dominant. Experiments conducted in animal models may
also provide interesting insight into the effects of sortilin on Lp(a) levels in vivo. Purified
Lp(a) could be infused into either wild-type or SORT-/- mice, therefore allowing for the
comparison of Lp(a) clearance between the two murine models. Mice transgenic for the
LPA gene (219) could also provide an interesting model to pursue, as these mice produce
apo(a) in vivo. Therefore, a cross between LPA transgenic mice and SORT-/- mice could be
used to determine if apo(a) levels are altered, or if differences in secretion can be observed
in isolated primary hepatocytes. Finally, incorporating a mice that is transgenic for the
APOB and LPA genes will allow for the production of Lp(a) in vivo. A comparison of
Lp(a)/apo(a) levels could be determined between transgenic, wild-type mice and
transgenic, SORT-/- mice. Therefore, the effects of sortilin on apo(a) secretion and Lp(a)
clearance could be studied in vivo to determine if the effects are comparable to our in vitro
models.
4.5 Conclusion
Multiple genetic and epidemiological studies have identified Lp(a) as an
independent, causal risk factor for CHD. Lp(a) was first discovered in 1963, yet many
characteristics of this lipoprotein remain enigmatic. The primary catabolic pathway of
Lp(a) remains controversial. Furthermore, the synthesis and secretion of apo(a) remains a
complex process with many unknowns, particularly with respect to the mechanisms
involved in the intracellular trafficking of nascent apo(a). Although differences in
synthesis, not catabolism, have been shown to explain the inverse correlation between
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Lp(a) levels and apo(a) isoform sizes (27), the relative importance of control of synthesis
or catabolism in dictating Lp(a) levels in general is not clear.
With the recent discovery of an association between sortilin, LDL-C, and risk for
CAD, numerous groups worked to identify the mechanistic basis of this association.
Sortilin was found to be a novel regulator of apoB/VLDL synthesis and LDL catabolism.
Structural similarities between Lp(a) and LDL suggested that sortilin may likewise mediate
a regulatory pathway for both Lp(a) and apo(a). The present study explored this possibility.
We demonstrate that sortilin overexpression leads to a significant increase in the secretion
of a recombinant 17K apo(a) variant in hepatocytes, and that this effect is dependent upon
the ability of sortilin to act as a trafficking receptor. Moreover, siRNA-mediated
knockdown of sortilin led to a significant decrease in the amount of apo(a) secreted from
hepatocytes. Qualitative analysis of immunofluorescence studies indicated co-localization
between sortilin and apo(a), with triple staining occurring with early and late endosomal
markers. We indicate that certain kringle domains play a role in mediating this effect, as a
decreased effect of sortilin on apo(a) secretion was observed in a variant that contained
mutations in the weak LBS in KIV7,8, rendering them inactive. This variant is unable to
interact with apoB, suggesting that sortilin may increase apo(a) secretion in a manner that
is affiliated with its effects on the secretion of apoB from hepatocytes. We further
demonstrate that sortilin does not directly interact with apo(a) in vitro, thus indicating that
sortilin expression indirectly affects apo(a) secretion.
This study also establishes that sortilin overexpression can significantly increase the
amount of Lp(a), but not apo(a), internalized in hepatocytes and primary human fibroblasts.
Similar to the effects observed for apo(a) secretion, this effect on internalization appears to
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be dependent upon the ability of sortilin to act as a trafficking receptor. Knockdown of
sortilin expression did not significantly influence Lp(a) internalization, suggesting that this
effect is only relevant in individuals with elevated levels of sortilin expression. Treatment
with ε-ACA significantly reduced Lp(a) internalization with sortilin overexpression,
indicating that the increase in Lp(a) internalization brought about by sortilin overexpression
may involve the apo(a) component of Lp(a), in addition to being dependent on the presence
of apoB. Internalization assays conducted in human FH fibroblasts demonstrated that
sortilin overexpression led to a significant increase in Lp(a) internalization in cells that
lacked functional LDL receptors, suggesting that sortilin increase Lp(a) internalization
through an LDLR-independent pathway. Since sortilin does not bind to Lp(a); therefore,
sortilin expression acts to upregulate the intracellular trafficking and availability of cell
surface receptors that bind to and internalize Lp(a).
Deep sequencing of SORT1 in human patients with elevated Lp(a) levels identified
seven novel polymorphisms, I124V, K205N, K302E, F404Y, E444Q, E447G,

and

V650M, occurring in the VPS10 domain of sortilin. These mutants displayed varying trends
in their ability to regulate apo(a) secretion and Lp(a) metabolism. Of note are F404Y and
V650M, which demonstrated a reduced ability to increase Lp(a) internalization and an
enhanced or comparable ability to increase apo(a) secretion when compared to wild-type
sortilin. Overall, these data implicate sortilin as a novel regulator of Lp(a) metabolism.
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